{"questions": [{"id": "58ec6eb5eda5a5767200000c", "body": "Is Enlimomab effective for stroke treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11673584", "http://www.ncbi.nlm.nih.gov/pubmed/9693236", "http://www.ncbi.nlm.nih.gov/pubmed/11692032", "http://www.ncbi.nlm.nih.gov/pubmed/19849665", "http://www.ncbi.nlm.nih.gov/pubmed/2271790", "http://www.ncbi.nlm.nih.gov/pubmed/25415546", "http://www.ncbi.nlm.nih.gov/pubmed/9744839", "http://www.ncbi.nlm.nih.gov/pubmed/34488117", "http://www.ncbi.nlm.nih.gov/pubmed/12777909", "http://www.ncbi.nlm.nih.gov/pubmed/19558342"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584", "text": "CONCLUSIONS The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.", "offsetInBeginSection": 1440, "offsetInEndSection": 1635, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584", "text": "Enlimomab, a murine intercellular adhesion molecule-1 (ICAM-1) antibody, reduces leukocyte adhesion and infarct size in experimental stroke studies.", "offsetInBeginSection": 134, "offsetInEndSection": 282, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19849665", "text": "Treatment with a murine anti-ICAM-1 antibody (enlimomab) has been investigated in patients with acute ischemic stroke in the Enlimomab Acute Stroke Trial (EAST).", "offsetInBeginSection": 1772, "offsetInEndSection": 1933, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19849665", "text": "Several drugs, especially hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), have been demonstrated to reduce hsCRP levels independently of their effects on plasma cholesterol.", "offsetInBeginSection": 575, "offsetInEndSection": 765, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032", "text": "BACKGROUND AND PURPOSE Enlimomab, a murine monoclonal anti-human intercellular adhesion molecule (ICAM)-1 antibody, had a negative outcome in a multicenter acute-stroke trial.", "offsetInBeginSection": 0, "offsetInEndSection": 175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9744839", "text": "However, this treatment failed to show benefit in the Enlimomab Acute Stroke Trial.", "offsetInBeginSection": 1441, "offsetInEndSection": 1524, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10096530", "text": "CONCLUSION Short term enlimomab induction therapy after renal transplantation did not reduce the rate of acute rejection or DGF.", "offsetInBeginSection": 1621, "offsetInEndSection": 1749, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10096530", "text": "In animal studies using mouse monoclonal antibodies against ICAM-1 (enlimomab), renal allograft survival has been improved and reperfusion damage from ischemia reduced.", "offsetInBeginSection": 244, "offsetInEndSection": 412, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12038658", "text": "They included calcium channel antagonists, NMDA receptor antagonists, lubeluzole, CDP-choline, the free radical scavenger tirilazad and ebselen, enlimomab, GABA agonist clomethiazole, the sodium channel antagonist fosphenytoin, magnesium, glycine site antagonist GV150526 and piracetam.", "offsetInBeginSection": 409, "offsetInEndSection": 695, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9973515", "text": "R6.5 (BIRR-1, Enlimomab), a murine IgG2a mAb to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury.", "offsetInBeginSection": 0, "offsetInEndSection": 197, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a885add61bb38fb24000017", "body": "What is the H4S47C cleavage mapping method used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25491770", "http://www.ncbi.nlm.nih.gov/pubmed/24737863", "http://www.ncbi.nlm.nih.gov/pubmed/26275423", "http://www.ncbi.nlm.nih.gov/pubmed/8054978", "http://www.ncbi.nlm.nih.gov/pubmed/8621067", "http://www.ncbi.nlm.nih.gov/pubmed/24510259", "http://www.ncbi.nlm.nih.gov/pubmed/2987505", "http://www.ncbi.nlm.nih.gov/pubmed/10079758", "http://www.ncbi.nlm.nih.gov/pubmed/2413446", "http://www.ncbi.nlm.nih.gov/pubmed/34417616"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24737863", "text": "To resolve this controversy, we have applied H4S47C-anchored cleavage mapping, which reveals the precise position of histone H4 in every nucleosome in the genome.", "offsetInBeginSection": 172, "offsetInEndSection": 334, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25491770", "text": "To identify nucleosomes with alternative structures genome-wide, we used H4S47C-anchored cleavage mapping, which revealed that 5% of budding yeast (Saccharomyces cerevisiae) nucleosome positions have asymmetric histone-DNA interactions.", "offsetInBeginSection": 113, "offsetInEndSection": 349, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26275423", "text": "To map fission yeast centromeres, we applied H4S47C-anchored cleavage mapping and native and cross-linked chromatin immunoprecipitation with paired-end sequencing.", "offsetInBeginSection": 164, "offsetInEndSection": 327, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2413446", "text": "The peptide antibody method used, called cleavage mapping, should be a convenient technique for mapping residues and ligand binding sites in proteins.", "offsetInBeginSection": 616, "offsetInEndSection": 766, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2413446", "text": "Gel overlays of the partial cleavage fragments with 125I-labeled actin identified a calcium-dependent actin-binding region located within the amino-terminal peptide of Mr 32,000 of villin.", "offsetInBeginSection": 427, "offsetInEndSection": 615, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8054978", "text": "RecA-assisted restriction endonuclease (RARE) cleavage is a method to perform sequence-specific cleavage of genomic DNA, and is useful in physical mapping studies.", "offsetInBeginSection": 0, "offsetInEndSection": 163, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10079758", "text": "A method for mass spectrometric peptide mapping was developed, based on hydrolysis of a solid protein by acid vapor followed by mass spectrometric analysis of the cleavage products.", "offsetInBeginSection": 0, "offsetInEndSection": 181, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25352141", "text": "Heavy metal cleavage mapping analysis of both assembling and fully mature ribonucleoprotein (RNP) complexes are informative techniques for assessing the intermolecular base pairing between small non-coding RNAs and their interacting target RNAs.", "offsetInBeginSection": 0, "offsetInEndSection": 245, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8502555", "text": "The approach of using the lambda-terminase cleavage reaction is a simple one-step procedure with a high specificity which is particularly suitable for mapping very large genomes of eucaryotes.", "offsetInBeginSection": 1260, "offsetInEndSection": 1452, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19596816", "text": "We report a facile method that identifies single-stranded regions in RNA using short, randomized DNA oligonucleotides and RNase H cleavage.", "offsetInBeginSection": 247, "offsetInEndSection": 386, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac725250340b9f058000006", "body": "Which miRNA is associated with the circular RNA ciRS-7?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30072582", "http://www.ncbi.nlm.nih.gov/pubmed/33390857", "http://www.ncbi.nlm.nih.gov/pubmed/29635069", "http://www.ncbi.nlm.nih.gov/pubmed/24014594", "http://www.ncbi.nlm.nih.gov/pubmed/35667198", "http://www.ncbi.nlm.nih.gov/pubmed/30182381", "http://www.ncbi.nlm.nih.gov/pubmed/30711014", "http://www.ncbi.nlm.nih.gov/pubmed/30022841", "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "http://www.ncbi.nlm.nih.gov/pubmed/27614453"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24014594", "text": "Particularly, the recently identified circular RNA, ciRS-7, which acts as a designated miR-7 inhibitor/sponge, has conceptually changed the mechanistic understanding of miRNA networks.", "offsetInBeginSection": 300, "offsetInEndSection": 484, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24014594", "text": "The identification of competing endogenous RNA and circular RNA (circRNA) as important regulators of miRNA activity underscores the increasing complexity of ncRNA-mediated regulatory networks.", "offsetInBeginSection": 107, "offsetInEndSection": 299, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "text": "Here we show that this circRNA acts as a miR-7 sponge; we term this circular transcript ciRS-7 (circular RNA sponge for miR-7).", "offsetInBeginSection": 451, "offsetInEndSection": 578, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "text": "ciRS-7 contains more than 70 selectively conserved miRNA target sites, and it is highly and widely associated with Argonaute (AGO) proteins in a miR-7-dependent manner.", "offsetInBeginSection": 579, "offsetInEndSection": 747, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27929395", "text": "Structurally, ciRS-7 contains about ~70 tandem anti-miRNA-7 sequences and acts as an endogenous, anti-complementary miRNA-7 \"sponge\" that attracts, binds, and, hence, quenches, natural miRNA-7 functions.", "offsetInBeginSection": 864, "offsetInEndSection": 1067, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27929395", "text": "Deficits in ciRS-7-mediated \"sponging events\", resulting in excess ambient miRNA-7 appear to drive the selective down-regulation in the expression of miRNA-7-sensitive mRNA targets, such as that encoding the ubiquitin conjugating enzyme E2A (UBE2A; chr Xq24).", "offsetInBeginSection": 1428, "offsetInEndSection": 1687, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28296235", "text": "In this study, we report that the circular RNA circular RNA sponge for miR-7 (ciRS-7) has an important role in regulating BACE1 and APP protein levels.", "offsetInBeginSection": 353, "offsetInEndSection": 504, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28174233", "text": "Recently, a novel circular RNA, ciRS-7, was proposed to be a potential miR-7 sponge.", "offsetInBeginSection": 77, "offsetInEndSection": 161, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28608528", "text": "Currently, ciRS-7, a novel circular RNA, has emerged as a potential sponge for miR-7.", "offsetInBeginSection": 85, "offsetInEndSection": 170, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28253710", "text": "In addition, according to recent studies, circular RNA-7 (ciRS-7) acts as a sponge of miR-7 and thus inhibits its activity.", "offsetInBeginSection": 390, "offsetInEndSection": 513, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aae6a86fcf456587200000e", "body": "What are the 3 types of ultraviolet (UV) solar radiation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20519675", "http://www.ncbi.nlm.nih.gov/pubmed/8545368", "http://www.ncbi.nlm.nih.gov/pubmed/30065996", "http://www.ncbi.nlm.nih.gov/pubmed/22268421", "http://www.ncbi.nlm.nih.gov/pubmed/15269922", "http://www.ncbi.nlm.nih.gov/pubmed/30649121", "http://www.ncbi.nlm.nih.gov/pubmed/21950627", "http://www.ncbi.nlm.nih.gov/pubmed/11547564", "http://www.ncbi.nlm.nih.gov/pubmed/23525255", "http://www.ncbi.nlm.nih.gov/pubmed/12444953"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25040832", "text": "Furthermore, solar blue light instead of solar UV-B radiation can be the main regulator of phenolic compound accumulation in plants that germinate and develop outdoors.", "offsetInBeginSection": 1166, "offsetInEndSection": 1334, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25040832", "text": "These results show that pea plants regulate epidermal UV-A absorbance and accumulation of individual flavonoids by perceiving complex radiation signals that extend into the visible region of the solar spectrum.", "offsetInBeginSection": 955, "offsetInEndSection": 1165, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25040832", "text": "One large group of phenolics, flavonoids, is considered particularly responsive to ultraviolet (UV) radiation.", "offsetInBeginSection": 95, "offsetInEndSection": 205, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20519675", "text": "Ultraviolet (UV) radiation is an important environmental factor for plant communities; however, plant responses to solar UV are not fully understood.", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20519675", "text": "Here, we report differential effects of solar UV-A and UV-B radiation on the expression of flavonoid pathway genes and phenolic accumulation in leaves of Betula pendula Roth (silver birch) seedlings grown outdoors.", "offsetInBeginSection": 150, "offsetInEndSection": 364, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12821280", "text": "In addition, mutations induced by solar UV radiation in p53, ras and patched genes of non-melanoma skin cancer cells, and the role of ROS as both a promoter in UV-carcinogenesis and an inducer of UV-apoptosis, are described based primarily on the findings reported during the last decade.", "offsetInBeginSection": 777, "offsetInEndSection": 1065, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12821280", "text": "Among types of solar radiation, ultraviolet B (290-320 nm) radiation is highly mutagenic and carcinogenic in animal experiments compared to ultraviolet A (320-400 nm) radiation.", "offsetInBeginSection": 194, "offsetInEndSection": 371, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9577442", "text": "OBJECTIVE To determine the value of shade in protecting humans from solar ultraviolet (UV) radiation.", "offsetInBeginSection": 0, "offsetInEndSection": 101, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11920550", "text": "The purpose of the current study was to determine how many types of cancer are affected by solar radiation and how many premature deaths from cancer occur due to insufficient ultraviolet (UV)-B radiation.", "offsetInBeginSection": 389, "offsetInEndSection": 593, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22163847", "text": "Solar ultraviolet (UV) radiation is widely known as a genotoxic environmental agent that affects Earth ecosystems and the human population.", "offsetInBeginSection": 0, "offsetInEndSection": 139, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac08fe7d0c506ce46000003", "body": "Of what origin is the MCF-7 cell line?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/176383", "http://www.ncbi.nlm.nih.gov/pubmed/21116879", "http://www.ncbi.nlm.nih.gov/pubmed/15183541", "http://www.ncbi.nlm.nih.gov/pubmed/24724101", "http://www.ncbi.nlm.nih.gov/pubmed/427779", "http://www.ncbi.nlm.nih.gov/pubmed/25828948", "http://www.ncbi.nlm.nih.gov/pubmed/16158200", "http://www.ncbi.nlm.nih.gov/pubmed/16504380", "http://www.ncbi.nlm.nih.gov/pubmed/11836559", "http://www.ncbi.nlm.nih.gov/pubmed/20926015"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879", "text": "MCF-7/ADR and the breast cancer cell line MCF-7 are not of the same origin.", "offsetInBeginSection": 1277, "offsetInEndSection": 1352, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879", "text": "Since the MCF-7/ADR' cell line was definitely derived from parental MCF-7 cells, we were able to directly compare these cell lines together with MCF-7/ADR using immunocytochemical, morphological, and consecutive DNA fingerprinting analyses to determine the true origin of MCF-7/ADR.", "offsetInBeginSection": 556, "offsetInEndSection": 838, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21116879", "text": "Many recent studies still describe MCF-7/ADR cells as originating from the breast cancer cell line MCF-7.", "offsetInBeginSection": 222, "offsetInEndSection": 327, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/176383", "text": "A stable cell line (MCF-7), derived from a pleural effusion of a patient with metastatic breast carcinoma, was maintained in these laboratories for more than 3 years in conventional monolayer culture.", "offsetInBeginSection": 0, "offsetInEndSection": 200, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15183541", "text": "The adriamycin resistant breast cancer cell line (MCF-7/ADR) is a subject of ongoing debate concerning its origin and or source.", "offsetInBeginSection": 0, "offsetInEndSection": 128, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25725141", "text": "We investigated cytotoxic effects of dichloromethane fractions of Scrophularia oxysepala extract on the MCF-7 breast cancer cell line.", "offsetInBeginSection": 247, "offsetInEndSection": 381, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25321415", "text": "We conclude that BG-1 FR is the original ovarian cancer cell line, whereas the BG-1 NIEHS is a variant from the MCF-7 cells.", "offsetInBeginSection": 1264, "offsetInEndSection": 1388, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25733816", "text": "The flow cytometry cell cycle analysis on the MCF-7 cell line treated with the IC50 dose of DHAQC (2) for 48 hours showed that DHAQC (2) arrested MCF-7 cell line at the G2/M phase in association with an inhibited expression of PLK1 genes.", "offsetInBeginSection": 944, "offsetInEndSection": 1182, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25733816", "text": "DHAQC (2) showed a slightly higher IC50 (inhibitory concentration with 50% cell viability) value in the MCF-7 cell line compared to damnacanthal, but it is more selective in terms of the ratio of IC50 on MCF-7 cells and normal MCF-10A cells.", "offsetInBeginSection": 636, "offsetInEndSection": 877, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10962451", "text": "Both retinoic acid and carotenoids stimulated oestrone sulphatase activity in the MCF-7 cell line.", "offsetInBeginSection": 951, "offsetInEndSection": 1049, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "589a247078275d0c4a000035", "body": "Dinutuximab is used for treatment of which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25851859", "http://www.ncbi.nlm.nih.gov/pubmed/29238760", "http://www.ncbi.nlm.nih.gov/pubmed/25940913", "http://www.ncbi.nlm.nih.gov/pubmed/30433831", "http://www.ncbi.nlm.nih.gov/pubmed/28389455", "http://www.ncbi.nlm.nih.gov/pubmed/28061552", "http://www.ncbi.nlm.nih.gov/pubmed/33181583", "http://www.ncbi.nlm.nih.gov/pubmed/33324208", "http://www.ncbi.nlm.nih.gov/pubmed/28748630", "http://www.ncbi.nlm.nih.gov/pubmed/30613134"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26917818", "text": "Dinutuximab is a chimeric, human-murine, anti-GD2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "offsetInBeginSection": 939, "offsetInEndSection": 1343, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26917818", "text": "CONCLUSIONS Dinutuximab is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "offsetInBeginSection": 1596, "offsetInEndSection": 1877, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28389455", "text": "SUMMARY Dinutuximab (Unituxin, United Therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "offsetInBeginSection": 186, "offsetInEndSection": 467, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28389455", "text": "CONCLUSION Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "offsetInBeginSection": 1499, "offsetInEndSection": 1661, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25940913", "text": "United Therapeutics Corporation and the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma.", "offsetInBeginSection": 0, "offsetInEndSection": 189, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26891967", "text": "Dinutuximab administered in combination with GM-CSF, IL-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "offsetInBeginSection": 1305, "offsetInEndSection": 1607, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26891967", "text": "Dinutuximab (ch14.18; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "offsetInBeginSection": 0, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28549783", "text": "Irinotecan-temozolomide-dinutuximab shows notable anti-tumour activity in patients with relapsed or refractory neuroblastoma.", "offsetInBeginSection": 4052, "offsetInEndSection": 4177, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28748630", "text": "Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "offsetInBeginSection": 0, "offsetInEndSection": 249, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28061552", "text": "Dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "offsetInBeginSection": 128, "offsetInEndSection": 323, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac24c9495d0062724000002", "body": "What is the ChIP-exo method used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28060339", "http://www.ncbi.nlm.nih.gov/pubmed/36427141", "http://www.ncbi.nlm.nih.gov/pubmed/24373287", "http://www.ncbi.nlm.nih.gov/pubmed/23026909", "http://www.ncbi.nlm.nih.gov/pubmed/32865524", "http://www.ncbi.nlm.nih.gov/pubmed/26404150", "http://www.ncbi.nlm.nih.gov/pubmed/34252930", "http://www.ncbi.nlm.nih.gov/pubmed/30030442", "http://www.ncbi.nlm.nih.gov/pubmed/27814676", "http://www.ncbi.nlm.nih.gov/pubmed/25249628"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28060339", "text": "The ChIP-exo method is a refined version of ChIP-seq that substantially improves upon both resolution and noise.", "offsetInBeginSection": 432, "offsetInEndSection": 544, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28060339", "text": "The key distinction of the ChIP-exo methodology is the incorporation of lambda exonuclease digestion in the library preparation workflow to effectively footprint the left and right 5' DNA borders of the protein-DNA crosslink site.", "offsetInBeginSection": 545, "offsetInEndSection": 775, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23026909", "text": "This unit describes the ChIP-exo methodology, which combines chromatin immunoprecipitation (ChIP) with lambda exonuclease digestion followed by high-throughput sequencing.", "offsetInBeginSection": 0, "offsetInEndSection": 171, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24373287", "text": "ChIP-exonuclease (ChIP-exo) is a modified ChIP-seq approach for high resolution mapping of transcription factor DNA sites.", "offsetInBeginSection": 0, "offsetInEndSection": 122, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24373287", "text": "We describe an Illumina-based ChIP-exo method which provides a global improvement of the data quality of estrogen receptor (ER) ChIP and insights into the motif structure for key ER-associated factors.", "offsetInBeginSection": 123, "offsetInEndSection": 324, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24373287", "text": "Our Illumina-based ChIP-exo provides high resolution mapping of transcription factor binding sites.", "offsetInBeginSection": 568, "offsetInEndSection": 667, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25249628", "text": "Chromatin immunoprecipitation-exo, an emerging technique using \u03bb exonuclease to digest TF unbound DNA after ChIP, is designed to reveal transcription factor binding site (TFBS) boundaries with near-single nucleotide resolution.", "offsetInBeginSection": 151, "offsetInEndSection": 379, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25249628", "text": "Here we describe a novel analysis framework, termed MACE (model-based analysis of ChIP-exo) dedicated to ChIP-exo data analysis.", "offsetInBeginSection": 668, "offsetInEndSection": 796, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28911122", "text": "ChIP-exo/nexus experiments rely on innovative modifications of the commonly used ChIP-seq protocol for high resolution mapping of transcription factor binding sites.", "offsetInBeginSection": 0, "offsetInEndSection": 165, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28911122", "text": "We evaluated our QC pipeline with both large collections of public ChIP-exo/nexus data and multiple, new ChIP-exo datasets from Escherichia coli.", "offsetInBeginSection": 819, "offsetInEndSection": 964, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a74acd80384be9551000006", "body": "Are AAV vectors considered for the treatment of retinal dystrophies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21818300", "http://www.ncbi.nlm.nih.gov/pubmed/33069860", "http://www.ncbi.nlm.nih.gov/pubmed/23150381", "http://www.ncbi.nlm.nih.gov/pubmed/24327302", "http://www.ncbi.nlm.nih.gov/pubmed/30970639", "http://www.ncbi.nlm.nih.gov/pubmed/33616280", "http://www.ncbi.nlm.nih.gov/pubmed/33752467", "http://www.ncbi.nlm.nih.gov/pubmed/22336072", "http://www.ncbi.nlm.nih.gov/pubmed/29721930", "http://www.ncbi.nlm.nih.gov/pubmed/32888388"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21818300", "text": "BACKGROUND Gene transfer using adeno-associated viral (AAV) vectors has been successfully applied in the retina for the treatment of inherited retinal dystrophies.", "offsetInBeginSection": 0, "offsetInEndSection": 163, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21880665", "text": "Defects in the photoreceptor-specific gene aryl hydrocarbon receptor interacting protein-like 1 (Aipl1) are associated with Leber congenital amaurosis (LCA), a childhood blinding disease with early-onset retinal degeneration and vision loss.", "offsetInBeginSection": 0, "offsetInEndSection": 241, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21880665", "text": "Our results provide important considerations for viral vectors to be used in future gene therapy clinical trials targeting a wider severity spectrum of inherited retinal dystrophies.", "offsetInBeginSection": 1313, "offsetInEndSection": 1495, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21880665", "text": "Specifically, we demonstrated that the novel self-complementary Y733F capsid mutant AAV2/8 (sc-Y733F-AAV) provided greater preservation of photoreceptors and functional vision in Aipl1 null mice compared with single-stranded AAV2/8.", "offsetInBeginSection": 655, "offsetInEndSection": 887, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24327302", "text": "Depending on the size of the gene copy to be transferred, two vectors are currently used in clinical trials: vectors based on adeno-associated virus (AAV) or on lentivirus (equine infectious anaemia virus, EIAV).", "offsetInBeginSection": 438, "offsetInEndSection": 650, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27416076", "text": "Gene therapy using adeno-associated viral (AAV) vectors for the treatment of retinal degenerations has shown safety and efficacy in clinical trials.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27653967", "text": "In animal models of RPE65 deficiency, subretinal injection of recombinant adeno-associated virus (AAV) 2/2 vectors carrying RPE65 cDNA improves rod photoreceptor function, and intervention at an early stage of disease provides sustained benefit by protecting cone photoreceptors against retinal degeneration.", "offsetInBeginSection": 287, "offsetInEndSection": 595, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27653967", "text": "The new configuration consists of an AAV vector serotype 5 carrying an optimized hRPE65 promoter and a codon-optimized hRPE65 gene.", "offsetInBeginSection": 1108, "offsetInEndSection": 1239, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15960597", "text": "Recombinant adeno-associated viral (AAV) vectors have become powerful gene delivery tools for the treatment of retinal degeneration in a variety of animal models that mimic corresponding human diseases.", "offsetInBeginSection": 0, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26015954", "text": "We also developed and tested smaller promoters to express the large CRB1 gene via AAV vectors.", "offsetInBeginSection": 710, "offsetInEndSection": 804, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ab2cc66fcf4565872000015", "body": "Cytochrome p450 CYP3A is induced by rifampicin  and compounds used to treat what virus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15726657", "http://www.ncbi.nlm.nih.gov/pubmed/23071008", "http://www.ncbi.nlm.nih.gov/pubmed/7628309", "http://www.ncbi.nlm.nih.gov/pubmed/8689947", "http://www.ncbi.nlm.nih.gov/pubmed/18799805", "http://www.ncbi.nlm.nih.gov/pubmed/11432536", "http://www.ncbi.nlm.nih.gov/pubmed/16308281", "http://www.ncbi.nlm.nih.gov/pubmed/22178124", "http://www.ncbi.nlm.nih.gov/pubmed/23974699", "http://www.ncbi.nlm.nih.gov/pubmed/31455676"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18799805", "text": "In TgCYP3A4/hPXR mice, CYP3A4 was strongly induced by rifampicin, a human-specific PXR ligand, but not by pregnenolone 16alpha-carbonitrile, a rodent-specific PXR ligand.", "offsetInBeginSection": 687, "offsetInEndSection": 857, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15726657", "text": "Induction of cytochrome P450 3A (CYP3A) has been suggested as a mechanism of action of ursodeoxycholic acid (UDCA) in cholestasis.", "offsetInBeginSection": 0, "offsetInEndSection": 130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10620362", "text": "Finally, in both chicken embryo liver and chicken hepatoma cells (LMH), CYP3A37 mRNA was increased after treatment with typical CYP3A inducers, such as metyrapone, phenobarbital, dexamethasone, and pregnenolone 16alpha-carbonitrile, but not rifampicin.", "offsetInBeginSection": 1320, "offsetInEndSection": 1572, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23071008", "text": "Induction of the cytochrome P450 (CYP) family of enzymes by coadministered compounds can result in drug-drug interactions, as in the case of the coadministration of rifampicin with many CYP3A substrates, including midazolam.", "offsetInBeginSection": 0, "offsetInEndSection": 224, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23974699", "text": "Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A are major factors involved in the metabolism of clinically prescribed drugs.", "offsetInBeginSection": 0, "offsetInEndSection": 138, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23974699", "text": "Seven-day rifampicin administration increased CYP2C19 and CYP3A enzyme activities.", "offsetInBeginSection": 701, "offsetInEndSection": 783, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11090943", "text": "And finally, PXRs from different species are differentially activated by certain compounds such as rifampicin and pregnenolone 16alpha-carbonitrile (PCN) in a manner that correlates with species-specific induction of CYP3A gene expression.", "offsetInBeginSection": 1035, "offsetInEndSection": 1274, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11090943", "text": "The key insights into PXR action was the finding that this nuclear receptor is linked to regulation of the cytochrome P450 3A monooxygenase (CYP3A) genes.", "offsetInBeginSection": 395, "offsetInEndSection": 549, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10628745", "text": "Transcription of genes encoding cytochrome P450 3A (CYP3A) monooxygenases is induced by a variety of xenobiotics and natural steroids.", "offsetInBeginSection": 0, "offsetInEndSection": 134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16432264", "text": "Moreover, medications prescribed to HIV-positive patients may also be CYP3A inhibitors and inducers: Tipranavir, in the absence of ritonavir, is a CYP3A inducer, and ritonavir is a CYP3A inhibitor.", "offsetInBeginSection": 444, "offsetInEndSection": 641, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac0fccf19833b0d7b000007", "body": "What is the dardarin protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16750377", "http://www.ncbi.nlm.nih.gov/pubmed/17394548", "http://www.ncbi.nlm.nih.gov/pubmed/24225420", "http://www.ncbi.nlm.nih.gov/pubmed/16115731", "http://www.ncbi.nlm.nih.gov/pubmed/17622782", "http://www.ncbi.nlm.nih.gov/pubmed/18213618", "http://www.ncbi.nlm.nih.gov/pubmed/22988875", "http://www.ncbi.nlm.nih.gov/pubmed/15541308", "http://www.ncbi.nlm.nih.gov/pubmed/26600626", "http://www.ncbi.nlm.nih.gov/pubmed/16991141"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377", "text": "Mutations in the LRRK2 gene, coding for dardarin, cause dominantly inherited Parkinson's disease (PD).", "offsetInBeginSection": 0, "offsetInEndSection": 102, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16750377", "text": "Dardarin is a large protein, and mutations are found throughout the gene including the kinase domain.", "offsetInBeginSection": 103, "offsetInEndSection": 204, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17394548", "text": "Several mutations have been found in the leucine-rich repeat kinase 2 gene (LRRK2), encoding the protein dardarin, which are associated with autosomal dominant Parkinson disease.", "offsetInBeginSection": 0, "offsetInEndSection": 178, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17394548", "text": "This work suggests that dardarin/LRRK2 is inherently more damaging than LRRK1.", "offsetInBeginSection": 785, "offsetInEndSection": 863, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16115731", "text": "Mutations in the leucine-rich repeat kinase 2 (LRRK 2), encoding dardarin protein, have been demonstrated to be linked to autosomal dominant Parkinson's disease (PD).", "offsetInBeginSection": 0, "offsetInEndSection": 166, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18496192", "text": "The present study analyzes the postoperative outcome of deep brain subthalamic stimulation in patients carrying the R1441G mutation in the leucine-rich repeat kinase-2 (LRRK2) (dardarin) gene.", "offsetInBeginSection": 111, "offsetInEndSection": 303, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18213618", "text": "Mutation of LRRK2, encoding dardarin, is the most common known genetic cause of Parkinson's disease (PD).", "offsetInBeginSection": 0, "offsetInEndSection": 105, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16102903", "text": "Mutations in the leucine-rich kinase 2 gene (LRRK 2) encoding dardarin, on chromosome 12, are a common cause of familial and sporadic Parkinson's disease.", "offsetInBeginSection": 0, "offsetInEndSection": 154, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16991141", "text": "The recent discovery of mutations in Dardarin (LRRK2) have been related to the appearance of Parkinson's disease in several families.", "offsetInBeginSection": 0, "offsetInEndSection": 133, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17085780", "text": "Although most patients suffering from PD have a sporadic disease, several genetic causes have been identified in recent years, including alpha-synuclein, parkin, PINK1, dardarin (LRRK2), and DJ-1.", "offsetInBeginSection": 155, "offsetInEndSection": 351, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "58ec709aeda5a5767200000e", "body": "Does International Citicoline Trial on acUte Stroke trial supports efficacy of citicoline for stroke treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18637642", "http://www.ncbi.nlm.nih.gov/pubmed/22691567", "http://www.ncbi.nlm.nih.gov/pubmed/27072975", "http://www.ncbi.nlm.nih.gov/pubmed/27234918", "http://www.ncbi.nlm.nih.gov/pubmed/23600725", "http://www.ncbi.nlm.nih.gov/pubmed/11706098", "http://www.ncbi.nlm.nih.gov/pubmed/10582983", "http://www.ncbi.nlm.nih.gov/pubmed/28617387", "http://www.ncbi.nlm.nih.gov/pubmed/9305321", "http://www.ncbi.nlm.nih.gov/pubmed/7477743"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18637642", "text": "The International Citicoline Trial in acUte Stroke is a sequential phase III study of the use of the drug citicoline in the treatment of acute ischaemic stroke, which was initiated in 2006 in 56 treatment centres.", "offsetInBeginSection": 0, "offsetInEndSection": 213, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22691567", "text": "BACKGROUND Citicoline is approved in some countries for the treatment of acute ischaemic stroke.", "offsetInBeginSection": 0, "offsetInEndSection": 96, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22691567", "text": "INTERPRETATION Under the circumstances of the ICTUS trial, citicoline is not efficacious in the treatment of moderate-to-severe acute ischaemic stroke.", "offsetInBeginSection": 1919, "offsetInEndSection": 2070, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23600725", "text": "In humans, although a recent trial International Citicoline Trial on Acute Stroke (ICTUS) has shown that global recovery is similar in CDP-choline and placebo groups, CDP-choline was shown to be more beneficial in some patients, such as those with moderate stroke severity and not treated with t-PA. Several mechanisms have been proposed to explain the beneficial actions of CDP-choline.", "offsetInBeginSection": 68, "offsetInEndSection": 455, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27234918", "text": "BACKGROUND Citicoline is a drug approved for the treatment of acute ischemic stroke.", "offsetInBeginSection": 0, "offsetInEndSection": 84, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27234918", "text": "CONCLUSIONS This systematic review supports some benefits of citicoline in the treatment of acute ischemic stroke.", "offsetInBeginSection": 1635, "offsetInEndSection": 1749, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19351232", "text": "A citicoline supplement is now available from several sources on the internet.", "offsetInBeginSection": 1130, "offsetInEndSection": 1208, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10582983", "text": "CONCLUSIONS The results of this study indicate that citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke who were enrolled in this trial.", "offsetInBeginSection": 1832, "offsetInEndSection": 2016, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9305321", "text": "This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment.", "offsetInBeginSection": 1455, "offsetInEndSection": 1567, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12468781", "text": "Citicoline has been studied worldwide in many clinical trials with positive findings, but only 1 trial has obtained significant results in the primary efficacy variables.", "offsetInBeginSection": 111, "offsetInEndSection": 281, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ace238e0340b9f05800000d", "body": "Which human chromosome is the product of fusion?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27423248", "http://www.ncbi.nlm.nih.gov/pubmed/15815621", "http://www.ncbi.nlm.nih.gov/pubmed/8921863", "http://www.ncbi.nlm.nih.gov/pubmed/7786792", "http://www.ncbi.nlm.nih.gov/pubmed/7227041", "http://www.ncbi.nlm.nih.gov/pubmed/2687156", "http://www.ncbi.nlm.nih.gov/pubmed/7566097", "http://www.ncbi.nlm.nih.gov/pubmed/7956350", "http://www.ncbi.nlm.nih.gov/pubmed/11196135", "http://www.ncbi.nlm.nih.gov/pubmed/2676087"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27423248", "text": "Human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "offsetInBeginSection": 0, "offsetInEndSection": 143, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3325883", "text": "The results also demonstrate that the product of the activated met gene is a fusion protein and that the amino terminal end of this fusion protein, which is encoded by human chromosome 1, exhibits homology to laminin B1.", "offsetInBeginSection": 372, "offsetInEndSection": 592, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7284984", "text": "We hypothesize that the near tetraploid chromosome number present in the tumor cells in both patients may be the product of fusion of two near diploid malignant cells.", "offsetInBeginSection": 205, "offsetInEndSection": 372, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28333343", "text": "We investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "offsetInBeginSection": 632, "offsetInEndSection": 961, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9310467", "text": "We have used here homologous recombination in ES cells to create an in-frame fusion of BCR-ABL(p190) that mimics the consequences of the human chromosomal translocation by fusion of BCR-ABL coding sequences into the bcr endogenous gene.", "offsetInBeginSection": 424, "offsetInEndSection": 660, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15815621", "text": "Human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "offsetInBeginSection": 0, "offsetInEndSection": 144, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8364539", "text": "Alu-PCR products from these hybrids were used for chromosome painting using the technique of chromosome in situ suppression hybridization, allowing assignment of the human HYRC (hyper-radiosensitivity of murine scid mutation, complementing) gene, a candidate for a V(D)J recombinase gene, to human chromosome 8q11.", "offsetInBeginSection": 257, "offsetInEndSection": 571, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3289649", "text": "The ABL proto-oncogene on the Philadelphia chromosome is 'activated' by its translocation in a manner similar to its activation by the murine Abelson leukemia virus--with the formation of a fusion protein with a new N-terminus and enhanced tyrosine kinase activity.", "offsetInBeginSection": 0, "offsetInEndSection": 265, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3289649", "text": "It is likely that this protein is the product of a fusion gene, as it is in chronic myelogenous leukemia, but definitive proof awaits molecular cloning of the translocation breakpoint.", "offsetInBeginSection": 763, "offsetInEndSection": 947, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7786792", "text": "We have recently identified a common ALL patient which harboured a chromosomal fusion between the TEL gene on chromosome 12 and the ABL gene on chromosome 9.", "offsetInBeginSection": 0, "offsetInEndSection": 157, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a7d5580faa1ab7d2e00001a", "body": "What in vivo tau tracers are being used?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29780868", "http://www.ncbi.nlm.nih.gov/pubmed/29716656", "http://www.ncbi.nlm.nih.gov/pubmed/30919054", "http://www.ncbi.nlm.nih.gov/pubmed/35649647", "http://www.ncbi.nlm.nih.gov/pubmed/28970331", "http://www.ncbi.nlm.nih.gov/pubmed/28750496", "http://www.ncbi.nlm.nih.gov/pubmed/34152739", "http://www.ncbi.nlm.nih.gov/pubmed/28587897", "http://www.ncbi.nlm.nih.gov/pubmed/25239654", "http://www.ncbi.nlm.nih.gov/pubmed/25358680"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24833492", "text": "Selective PET radiotracers for amyloid-\u03b2 are already available, and potential tau tracers are emerging as new-generation biomarkers.", "offsetInBeginSection": 528, "offsetInEndSection": 661, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28587897", "text": "The recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD).", "offsetInBeginSection": 0, "offsetInEndSection": 191, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28750496", "text": "In recent years, many efforts have contributed toward development of tau imaging agents to allow measurement of tau deposits in vivo using positron emission tomography (PET).", "offsetInBeginSection": 108, "offsetInEndSection": 282, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27683159", "text": "BACKGROUND The recent development of tau-specific positron emission tomography (PET) tracers has allowed in vivo quantification of regional tau deposition and offers the opportunity to monitor the progression of tau pathology along with cognitive impairment.", "offsetInBeginSection": 0, "offsetInEndSection": 258, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27334944", "text": "The 18F-labeled tau imaging agents 18F-THK-5351, 18F-T807 (18F-AV-1451), and 18F-RO6958948 are presently under evaluation in clinical studies and clinical trials worldwide.", "offsetInBeginSection": 721, "offsetInEndSection": 893, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26697966", "text": "In the past decade, we developed 2-arylquinoline (2-AQ) derivatives as PET tau tracers.", "offsetInBeginSection": 257, "offsetInEndSection": 344, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26802556", "text": "Recently, several tau PET tracers have been successfully developed and demonstrated as having high binding affinity and selectivity to tau protein deposits.", "offsetInBeginSection": 647, "offsetInEndSection": 803, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26802556", "text": "In vivo imaging of the tau deposits by positron emission tomography (PET) will facilitate the early and accurate diagnosis of these diseases, tracking of disease progression, assessment of disease severity, and prediction of disease prognosis.", "offsetInBeginSection": 217, "offsetInEndSection": 460, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25239654", "text": "For use of tau PET as a biomarker of tau pathology in Alzheimer's disease, PET tracers should have high affinity to PHF-tau and high selectivity for tau over amyloid-\u03b2 and other protein deposits.", "offsetInBeginSection": 497, "offsetInEndSection": 693, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25239654", "text": "Recently, several tau PET tracers including T807, THK-5117, and PBB3 have been developed and succeeded in imaging neurofibrillary pathology in vivo.", "offsetInBeginSection": 348, "offsetInEndSection": 496, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ab90a79fcf456587200001b", "body": "What drug treatment can cause a spinal epidural hematoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21397387", "http://www.ncbi.nlm.nih.gov/pubmed/35317631", "http://www.ncbi.nlm.nih.gov/pubmed/19857440", "http://www.ncbi.nlm.nih.gov/pubmed/15043358", "http://www.ncbi.nlm.nih.gov/pubmed/28614233", "http://www.ncbi.nlm.nih.gov/pubmed/8560344", "http://www.ncbi.nlm.nih.gov/pubmed/17393048", "http://www.ncbi.nlm.nih.gov/pubmed/8568560", "http://www.ncbi.nlm.nih.gov/pubmed/21082060", "http://www.ncbi.nlm.nih.gov/pubmed/6707270"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21082060", "text": "Surgical treatment is an effective option to resolve the spinal epidural hematoma.", "offsetInBeginSection": 1079, "offsetInEndSection": 1161, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21082060", "text": "Spinal epidural hematoma is a rare complication associated with pain control procedures such as facet block, acupuncture, epidural injection, etc.", "offsetInBeginSection": 0, "offsetInEndSection": 146, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28614233", "text": "Even though spinal epidural hematoma after caudal epidural injection is rare but it can cause serious neurologic complication.", "offsetInBeginSection": 96, "offsetInEndSection": 222, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28614233", "text": "LESSONS Continuous vigilance after caudal epidural injection is important to prevent catastrophic neurologic deterioration with early detection and early treatment.", "offsetInBeginSection": 815, "offsetInEndSection": 979, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28614233", "text": "DIAGNOSIS Magnetic resonance image showed acute cord compression due to a spinal epidural hematoma at L2-S1 level with concomitant central canal compromise at L2/3, L3/4 level.", "offsetInBeginSection": 437, "offsetInEndSection": 613, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18685937", "text": "This case may be the first report of spinal epidural hematoma associated with both cilostazol and epidural anesthesia.", "offsetInBeginSection": 625, "offsetInEndSection": 743, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18685937", "text": "After an epidural catheter (used for intraoperative/postoperative management) was removed, a spinal epidural hematoma involving the Th12 to L3 areas developed.", "offsetInBeginSection": 116, "offsetInEndSection": 275, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8447556", "text": "CONCLUSION This case shows that selected hemophilic patients with spinal epidural hematoma can be spared surgical decompression by prompt medical attention.", "offsetInBeginSection": 581, "offsetInEndSection": 737, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21799620", "text": "Magnetic resonance imaging (MRI) of the spine revealed an epidural hematoma at D12-L1 level.", "offsetInBeginSection": 409, "offsetInEndSection": 501, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21799620", "text": "We present a case of a 42-year-old male, an old case of deep vein thrombosis on warfarin and other drugs like quetiapine, aspirin, diclofenac sodium, fenofibrate, atorvastatin, propanolol and citalopram for concurrent illnesses, who presented with widespread mucocutaneous bleeding and epidural spinal hematoma.", "offsetInBeginSection": 0, "offsetInEndSection": 311, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac28c0c95d006272400000a", "body": "What is the basis of the Sp3 procedure used in proteomics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30464214", "http://www.ncbi.nlm.nih.gov/pubmed/35684327", "http://www.ncbi.nlm.nih.gov/pubmed/25358341", "http://www.ncbi.nlm.nih.gov/pubmed/33950501", "http://www.ncbi.nlm.nih.gov/pubmed/32650423", "http://www.ncbi.nlm.nih.gov/pubmed/32241812", "http://www.ncbi.nlm.nih.gov/pubmed/30094940", "http://www.ncbi.nlm.nih.gov/pubmed/33181311", "http://www.ncbi.nlm.nih.gov/pubmed/29046284", "http://www.ncbi.nlm.nih.gov/pubmed/5325248"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25358341", "text": "SP3 provides a rapid and unbiased means of proteomic sample preparation in a single tube that facilitates ultrasensitive analysis by outperforming existing protocols in terms of efficiency, scalability, speed, throughput, and flexibility.", "offsetInBeginSection": 460, "offsetInEndSection": 698, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25358341", "text": "To illustrate these benefits, characterization of 1,000 HeLa cells and single Drosophila embryos is used to establish that SP3 provides an enhanced platform for profiling proteomes derived from sub-microgram amounts of material.", "offsetInBeginSection": 699, "offsetInEndSection": 927, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25358341", "text": "Together, the findings of this work position SP3 as a superior protocol that facilitates exciting new directions in multiple areas of proteomics ranging from developmental biology to clinical applications.", "offsetInBeginSection": 1125, "offsetInEndSection": 1330, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28948796", "text": "Here, we performed an independent comparison between single-pot solid-phase-enhanced sample preparation (SP3), filter-aided sample preparation (FASP), and a commercial kit based on the in-StageTip (iST) method.", "offsetInBeginSection": 137, "offsetInEndSection": 347, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27668303", "text": "In this study, we examined the effect of TFF2 on gastric cancer cell lines in\u00a0vitro and characterized the interaction between TFF2 and Sp3, including the mechanisms that mediate this interaction, using genomics and proteomics approaches, as well as genetics techniques, such as RNA interference and gene knockdown.", "offsetInBeginSection": 197, "offsetInEndSection": 512, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15474306", "text": "In this study, bacterial artificial chromosome (BAC) sequencing, reverse transcription-polymerase chain reaction (RT-PCR), genomic PCR, and database mining indicate that the Sp3 gene encompasses seven exons spanning more than 55 kb of genomic DNA on Chromosome 2.", "offsetInBeginSection": 662, "offsetInEndSection": 925, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15362956", "text": "The physical binding of Sp1 and Sp3 to DNMT3A and DNMT3B promoters was confirmed by a gel shift assay.", "offsetInBeginSection": 672, "offsetInEndSection": 774, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25538045", "text": "Here, we show that in adult mice, conditional pan-hematopoietic (Mx1-Cre) ablation of either Sp1 or Sp3 has minimal impact on hematopoiesis, whereas the simultaneous loss of Sp1 and Sp3 results in severe macrothrombocytopenia.", "offsetInBeginSection": 431, "offsetInEndSection": 657, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27215607", "text": "Exploiting SP3, a novel technology for proteomic sample preparation using magnetic beads, we scaled down proteome analysis to single cells.", "offsetInBeginSection": 907, "offsetInEndSection": 1046, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27215607", "text": "This study demonstrates that an innovative proteomics workflow facilitates analysis of single human oocytes to investigate human oocyte biology and preimplantation development.", "offsetInBeginSection": 1539, "offsetInEndSection": 1715, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a896c26fcd1d6a10c000007", "body": "In which syndrome is the RPS19 gene most frequently mutated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23990987", "http://www.ncbi.nlm.nih.gov/pubmed/18515656", "http://www.ncbi.nlm.nih.gov/pubmed/34126174", "http://www.ncbi.nlm.nih.gov/pubmed/17053056", "http://www.ncbi.nlm.nih.gov/pubmed/12586610", "http://www.ncbi.nlm.nih.gov/pubmed/21223253", "http://www.ncbi.nlm.nih.gov/pubmed/21989989", "http://www.ncbi.nlm.nih.gov/pubmed/24675553", "http://www.ncbi.nlm.nih.gov/pubmed/18768533", "http://www.ncbi.nlm.nih.gov/pubmed/21435505"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24675553", "text": "Among these patients, RPS19 was the most frequently mutated gene.", "offsetInBeginSection": 1359, "offsetInEndSection": 1424, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23990987", "text": "It has been proven that defects of ribosomal proteins can lead to this disease and that RPS19 is the most frequently mutated gene in DBA patients.", "offsetInBeginSection": 163, "offsetInEndSection": 309, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12351378", "text": "Recent reports show that the ribosomal protein S19 (RPS19) gene is mutated in 25% of all patients with DBA.", "offsetInBeginSection": 203, "offsetInEndSection": 310, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12351378", "text": "These vectors were used to introduce the RPS19 gene into CD34(+) bone marrow (BM) cells from 4 patients with DBA with RPS19 gene mutations.", "offsetInBeginSection": 424, "offsetInEndSection": 563, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21223253", "text": "The ribosomal protein S19 gene (RPS19) is the most frequently mutated gene in DBA (~25%).", "offsetInBeginSection": 142, "offsetInEndSection": 231, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18515656", "text": "RPS19 is the most frequently mutated RP in DBA.", "offsetInBeginSection": 196, "offsetInEndSection": 243, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17053056", "text": "The gene encoding the ribosomal protein S19 (RPS19) is frequently mutated in Diamond-Blackfan anemia (DBA), a congenital erythroblastopenia.", "offsetInBeginSection": 0, "offsetInEndSection": 140, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21989989", "text": "Among these genes, ribosomal protein S19 (RPS19) is mutated most frequently.", "offsetInBeginSection": 151, "offsetInEndSection": 227, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21435505", "text": "Extensive study of the most frequently mutated gene, RPS19, has shown that mutations prevent the assembly of the ribosomal protein into forming pre-ribosomal particles.", "offsetInBeginSection": 481, "offsetInEndSection": 649, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18768533", "text": "BACKGROUND Mutations in the ribosomal protein S19 gene (RPS19) have been found in 25% of patients with Diamond-Blackfan anemia, a rare syndrome of congenital bone marrow failure characterized by erythroblastopenia and various malformations.", "offsetInBeginSection": 0, "offsetInEndSection": 240, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ab908d4fcf456587200001a", "body": "What is the alternative lengthening of telomeres?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28741530", "http://www.ncbi.nlm.nih.gov/pubmed/31924155", "http://www.ncbi.nlm.nih.gov/pubmed/22923525", "http://www.ncbi.nlm.nih.gov/pubmed/32101727", "http://www.ncbi.nlm.nih.gov/pubmed/35942347", "http://www.ncbi.nlm.nih.gov/pubmed/31086817", "http://www.ncbi.nlm.nih.gov/pubmed/31400850", "http://www.ncbi.nlm.nih.gov/pubmed/21574432", "http://www.ncbi.nlm.nih.gov/pubmed/26001292", "http://www.ncbi.nlm.nih.gov/pubmed/27585244"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317", "text": "Alternative lengthening of telomeres is a telomere-maintenance mechanism common in sarcomas.", "offsetInBeginSection": 105, "offsetInEndSection": 197, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317", "text": "We conclude that alternative lengthening of telomeres is a frequent telomere-maintenance mechanism in cytogenetically complex sarcomas.", "offsetInBeginSection": 1994, "offsetInEndSection": 2129, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26428317", "text": "Alternative lengthening of telomeres and/or loss of ATRX were uncommon in malignant peripheral nerve sheath tumors, gastrointestinal stromal tumors, and embryonal rhabdomyosarcomas.", "offsetInBeginSection": 1232, "offsetInEndSection": 1413, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26022452", "text": "Telomerase activation and alternative lengthening of telomeres are two major mechanisms of telomere length maintenance.", "offsetInBeginSection": 0, "offsetInEndSection": 119, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19154407", "text": "Maintenance of telomeric ends by the telomerase ribonucleoprotein complex or the telomerase-independent alternative lengthening of telomeres is necessary for the immortalization of human cells.", "offsetInBeginSection": 0, "offsetInEndSection": 193, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19154407", "text": "These results suggest that alternative lengthening of telomeres-mediated telomere maintenance plays an important role for microsatellite instability-mediated stomach carcinogenesis, as well as the telomerase ribonucleoprotein complex, although the incidence of MSI-H is low.", "offsetInBeginSection": 1557, "offsetInEndSection": 1831, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27726944", "text": "Silence of alternative lengthening of telomeres mechanism and telomerase mechanism related genes resulted in the shortening of telomere length in HEp-2 cell.", "offsetInBeginSection": 843, "offsetInEndSection": 1000, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26769142", "text": "Glioblastomas with an indeterminate telomere maintenance mechanism had an increased immune signature compared with alternative lengthening of telomeres and telomerase-positive tumors.", "offsetInBeginSection": 356, "offsetInEndSection": 539, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22575867", "text": "The observation that ATRX and DAXX defects and the alternative lengthening of telomeres phenotype occurred only in pancreatic neuroendocrine tumors measuring \u22653\u2009cm and their lymph node metastases suggests that these changes are late events in pancreatic neuroendocrine tumor development.", "offsetInBeginSection": 1983, "offsetInEndSection": 2274, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22575867", "text": "These findings establish the existence of ATRX and DAXX defects and the alternative lengthening of telomeres phenotype in pancreatic neuroendocrine tumors in the context of MEN-1 syndrome.", "offsetInBeginSection": 1794, "offsetInEndSection": 1982, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abcf010fcf4565872000023", "body": "What nerve is involved in carpal tunnel syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26014322", "http://www.ncbi.nlm.nih.gov/pubmed/1739233", "http://www.ncbi.nlm.nih.gov/pubmed/1558334", "http://www.ncbi.nlm.nih.gov/pubmed/1550309", "http://www.ncbi.nlm.nih.gov/pubmed/3283274", "http://www.ncbi.nlm.nih.gov/pubmed/6642310", "http://www.ncbi.nlm.nih.gov/pubmed/29199603", "http://www.ncbi.nlm.nih.gov/pubmed/18683528", "http://www.ncbi.nlm.nih.gov/pubmed/25630774", "http://www.ncbi.nlm.nih.gov/pubmed/36442295"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853", "text": "Of the 344 cases, 322 involved carpal tunnel syndrome alone, 1 involved pronator syndrome alone, and 21 involved carpal tunnel syndrome combined with pronator syndrome.", "offsetInBeginSection": 1427, "offsetInEndSection": 1595, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853", "text": "CONCLUSION It is important to consider the diagnosis of double crush syndrome of the median nerve, as carpal tunnel syndrome combined with pronator syndrome may impede treatment of the carpal tunnel syndrome.", "offsetInBeginSection": 2460, "offsetInEndSection": 2668, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27894853", "text": "If paresthesia involved the thenar eminence and proximal forearm pain was noted in cases of carpal tunnel syndrome, carpal tunnel syndrome combined with pronator syndrome was considered.", "offsetInBeginSection": 351, "offsetInEndSection": 537, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19336461", "text": "Our findings revealed bilateral widespread pressure hypersensitivity in subjects with carpal tunnel syndrome, which suggest that widespread central sensitization is involved in patients with unilateral carpal tunnel syndrome.", "offsetInBeginSection": 944, "offsetInEndSection": 1169, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25206437", "text": "These findings indicate that in patients with minimal to moderate carpal tunnel syndrome, there is some electrophysiological evidence of traction on the adjacent ulnar nerve fibers.", "offsetInBeginSection": 1182, "offsetInEndSection": 1363, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25206437", "text": "There were no significant differences in ulnar sensory nerve peak latencies or conduction velocities from the 4(th) and 5(th) fingers between patients with carpal tunnel syndrome and the control group.", "offsetInBeginSection": 632, "offsetInEndSection": 833, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25206437", "text": "The ulnar sensory nerve action potential amplitudes from the 4(th) and 5(th) fingers were lower in patients with carpal tunnel syndrome than in the control group.", "offsetInBeginSection": 834, "offsetInEndSection": 996, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26014322", "text": "These results suggest that morphologic changes in the ulnar nerve do not occur in carpal tunnel syndrome, although functional changes may occur.", "offsetInBeginSection": 1205, "offsetInEndSection": 1349, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26014322", "text": "OBJECTIVES Involvement of the ulnar nerve in patients with carpal tunnel syndrome is controversial.", "offsetInBeginSection": 0, "offsetInEndSection": 99, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7594983", "text": "This decrease in nerve mobility may be of significance in the pathophysiology of carpal tunnel syndrome.", "offsetInBeginSection": 620, "offsetInEndSection": 724, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ad240f70340b9f058000015", "body": "Is human lysyl oxidase-like 2 a glycoprotein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29619832", "http://www.ncbi.nlm.nih.gov/pubmed/20306300", "http://www.ncbi.nlm.nih.gov/pubmed/17018530", "http://www.ncbi.nlm.nih.gov/pubmed/31459939", "http://www.ncbi.nlm.nih.gov/pubmed/28112368", "http://www.ncbi.nlm.nih.gov/pubmed/25216702", "http://www.ncbi.nlm.nih.gov/pubmed/35682561", "http://www.ncbi.nlm.nih.gov/pubmed/25146937", "http://www.ncbi.nlm.nih.gov/pubmed/35628534", "http://www.ncbi.nlm.nih.gov/pubmed/28199967"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20306300", "text": "The lysyl oxidase-like 2 (LOXL2) protein is a human paralogue of lysyl oxidase (LOX) that functions as an amine oxidase for formation of lysine-derived cross-links found in collagen and elastin.", "offsetInBeginSection": 0, "offsetInEndSection": 194, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28112368", "text": "Human lysyl oxidase-like 3\u00a0(LOXL3) functions as a copper-dependent amine oxidase toward collagen and elastin.", "offsetInBeginSection": 0, "offsetInEndSection": 110, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25146937", "text": "Lysyl oxidase like-2 (LOXL2) belongs to the lysyl oxidase (LOX) family, which comprises Cu(2+)- and lysine tyrosylquinone (LTQ)-dependent amine oxidases.", "offsetInBeginSection": 0, "offsetInEndSection": 153, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28350101", "text": "Human lysyl oxidase-like 3\u00a0(LOXL3) functions as a copper-dependent amine oxidase toward collagen and elastin.", "offsetInBeginSection": 0, "offsetInEndSection": 110, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21954900", "text": "This method was successfully applied to a novel recombinant protein, human lysyl oxidase-like 2.", "offsetInBeginSection": 1382, "offsetInEndSection": 1478, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17018530", "text": "The human lysyl oxidase-like 3 (LOXL3) encodes a member of the emerging family of lysyl oxidase (LOX) that functions as a copper-dependent amine oxidase.", "offsetInBeginSection": 0, "offsetInEndSection": 153, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27063404", "text": "Lysyl oxidase-like 2 (LOXL2) is a member of the lysyl oxidase family, which plays an important role in extracellular matrix protein biosynthesis and tumor progression.", "offsetInBeginSection": 0, "offsetInEndSection": 167, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7706256", "text": "It appears therefore that the genes encoding lysyl oxidase and a lysyl oxidase-like protein share a common evolutionary origin and may also be functionally related.", "offsetInBeginSection": 823, "offsetInEndSection": 987, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23319596", "text": "Human lysyl oxidase-like 2 (hLOXL2) is highly up-regulated in metastatic breast cancer cells and tissues and induces epithelial-to-mesenchymal transition, the first step of metastasis/invasion.", "offsetInBeginSection": 0, "offsetInEndSection": 193, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11334717", "text": "Using the PCR primers generated from human expressed sequence tag (EST), the cDNA of lysyl oxidase-like gene 3 (LOXL3), a new member of human lysyl oxidases gene family, was cloned from the human fetal brain mRNA.", "offsetInBeginSection": 0, "offsetInEndSection": 213, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a86e6fafaa1ab7d2e000036", "body": "What is the nucleotide composition of the Lamin Associated Domains (LADs)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35239049", "http://www.ncbi.nlm.nih.gov/pubmed/28107752", "http://www.ncbi.nlm.nih.gov/pubmed/25602132", "http://www.ncbi.nlm.nih.gov/pubmed/22726435", "http://www.ncbi.nlm.nih.gov/pubmed/30143639", "http://www.ncbi.nlm.nih.gov/pubmed/23124521", "http://www.ncbi.nlm.nih.gov/pubmed/28525751", "http://www.ncbi.nlm.nih.gov/pubmed/36050765", "http://www.ncbi.nlm.nih.gov/pubmed/23523135", "http://www.ncbi.nlm.nih.gov/pubmed/35189475"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25602132", "text": "Using ChIP-seq, we show the existence of lamin A/C (LMNA) LiDs with distinct gene contents, histone composition enrichment and relationships to lamin B1-interacting domains.", "offsetInBeginSection": 602, "offsetInEndSection": 775, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25602132", "text": "Comparison of published LMNB1 DamID LADs with LMNB1 and LMNA LiDs identified here by ChIP-seq further shows that LMNA can associate with 'open' chromatin domains displaying euchromatin characteristics, and which are not associated with LMNB1.", "offsetInBeginSection": 1300, "offsetInEndSection": 1542, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26359231", "text": "Dynamic interactions of nuclear lamins with chromatin through lamin-associated domains (LADs) contribute to spatial arrangement of the genome.", "offsetInBeginSection": 0, "offsetInEndSection": 142, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26359231", "text": "De novo formation of adipogenic lamin A/C LADs occurs nonrandomly on GADs, which consist of megabase-size intergenic and repressive chromatin domains.", "offsetInBeginSection": 856, "offsetInEndSection": 1006, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26359231", "text": "Accordingly, whereas predifferentiation lamin A/C LADs are gene-rich, post-differentiation LADs harbor repressive features reminiscent of lamin B1 LADs.", "offsetInBeginSection": 1007, "offsetInEndSection": 1159, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26359231", "text": "Here, we provide evidence for prepatterning of differentiation-driven formation of lamin A/C LADs by domains of histone H2B modified on serine 112 by the nutrient sensor O-linked N-acetylglucosamine (H2BS112GlcNAc), which we term GADs.", "offsetInBeginSection": 143, "offsetInEndSection": 378, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26359231", "text": "Our results unveil an epigenetic prepatterning of adipogenic LADs by GADs, suggesting a coupling of developmentally regulated lamin A/C-genome interactions to a metabolically sensitive chromatin modification.", "offsetInBeginSection": 1378, "offsetInEndSection": 1586, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24717229", "text": "The nuclear lamina (NL) is thought to aid in the spatial organization of interphase chromosomes by providing an anchoring platform for hundreds of large genomic regions named lamina associated domains (LADs).", "offsetInBeginSection": 0, "offsetInEndSection": 208, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23934658", "text": "Mesas form at lamin B1-associated domains (LADs) in replicative senescence and oncogene-induced senescence and overlap DNA hypomethylation regions in cancer, suggesting that pre-malignant senescent chromatin changes foreshadow epigenetic cancer changes.", "offsetInBeginSection": 602, "offsetInEndSection": 855, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26883443", "text": "We suggest that in somatic cells lamin B1 meshwork growth is coordinated with replication of LADs, and lamin A meshwork assembly seems to be chromatin-independent process.", "offsetInBeginSection": 1597, "offsetInEndSection": 1768, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac716810340b9f058000003", "body": "Name an lncRNA associated with dilated cardiomyopathy.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26951817", "http://www.ncbi.nlm.nih.gov/pubmed/30720098", "http://www.ncbi.nlm.nih.gov/pubmed/33146560", "http://www.ncbi.nlm.nih.gov/pubmed/31803236", "http://www.ncbi.nlm.nih.gov/pubmed/30852379", "http://www.ncbi.nlm.nih.gov/pubmed/26676325", "http://www.ncbi.nlm.nih.gov/pubmed/34313541", "http://www.ncbi.nlm.nih.gov/pubmed/34921634", "http://www.ncbi.nlm.nih.gov/pubmed/31808029", "http://www.ncbi.nlm.nih.gov/pubmed/19397801"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26951817", "text": "Chagas disease causes a severe inflammatory dilated chronic cardiomyopathy (CCC).", "offsetInBeginSection": 259, "offsetInEndSection": 340, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26951817", "text": "Dysregulation of the lncRNA known as myocardial infarction-associated transcript (MIAT) has been associated with myocardial infarction.", "offsetInBeginSection": 123, "offsetInEndSection": 258, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28115490", "text": "In the heart, lncRNAs have been implicated in the regulation of development, ischemic and dilated cardiomyopathy, and myocardial infarction.", "offsetInBeginSection": 162, "offsetInEndSection": 302, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28430627", "text": "In the previous study, we generated a rat model of dilated cardiomyopathy (DCM) induced by adriamycin and found that the expression of lncRNA H19 was significantly upregulated in myocardial tissue.", "offsetInBeginSection": 0, "offsetInEndSection": 197, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29138229", "text": "We detected 3,898 individual SVs affecting all classes of gene transcripts (e.g., mRNA, miRNA, lncRNA) and regulatory genomic regions (e.g., enhancer or TFBS).", "offsetInBeginSection": 454, "offsetInEndSection": 613, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25834770", "text": "In dogs, dilated cardiomyopathy is the second most common cardiac disease and is most prevalent in the Irish Wolfhound, Doberman Pinscher and Newfoundland breeds.", "offsetInBeginSection": 245, "offsetInEndSection": 407, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25834770", "text": "Although multiple human loci have been implicated in the pathogenesis of dilated cardiomyopathy, the identified variants are typically associated with rare monogenic forms of dilated cardiomyopathy.", "offsetInBeginSection": 555, "offsetInEndSection": 753, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25834770", "text": "Dilated cardiomyopathy is a prevalent and often fatal disease in humans and dogs.", "offsetInBeginSection": 0, "offsetInEndSection": 81, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25119045", "text": "Human MHRT also originates from MYH7 loci and is repressed in various types of myopathic hearts, suggesting a conserved lncRNA mechanism in human cardiomyopathy.", "offsetInBeginSection": 1662, "offsetInEndSection": 1823, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20392463", "text": "Idiopathic dilated cardiomyopathy is reportedly associated with endothelial cell dysfunction.", "offsetInBeginSection": 284, "offsetInEndSection": 377, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abcf108fcf4565872000025", "body": "What is myelin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28925106", "http://www.ncbi.nlm.nih.gov/pubmed/19658508", "http://www.ncbi.nlm.nih.gov/pubmed/34475201", "http://www.ncbi.nlm.nih.gov/pubmed/1371603", "http://www.ncbi.nlm.nih.gov/pubmed/30510502", "http://www.ncbi.nlm.nih.gov/pubmed/33417972", "http://www.ncbi.nlm.nih.gov/pubmed/29054040", "http://www.ncbi.nlm.nih.gov/pubmed/11276118", "http://www.ncbi.nlm.nih.gov/pubmed/10739568", "http://www.ncbi.nlm.nih.gov/pubmed/30860619"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24684721", "text": "BACKGROUND The pathological hallmark of multiple sclerosis (MS) is myelin phagocytosis.", "offsetInBeginSection": 0, "offsetInEndSection": 87, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20186338", "text": "The myelin induced inflammatory response is myelin specific as sphingomyelin (the major lipid of myelin) and myelin basic protein (MBP, one of the major proteins of myelin) are not able to activate NF-kappaB signaling pathway.", "offsetInBeginSection": 1221, "offsetInEndSection": 1447, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20186338", "text": "In conclusion, our results demonstrate a crucial role of myelin as an endogenous inflammatory stimulus that induces pro-inflammatory responses and suggest that blocking myelin-CR3 interaction and enhancing myelin debris clearance may be effective interventions for treating SCI.", "offsetInBeginSection": 1448, "offsetInEndSection": 1726, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20186338", "text": "Mechanism study revealed that myelin-increased cytokine expression is through activation of FAK/PI3K/Akt/NF-kappaB signaling pathways and CR3 contributes to myelin-induced PI3K/Akt/NF-kappaB activation and cytokine production.", "offsetInBeginSection": 994, "offsetInEndSection": 1220, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25682762", "text": "Myelin - the multilayer membrane that envelops axons - is a facilitator of rapid nerve conduction.", "offsetInBeginSection": 0, "offsetInEndSection": 98, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25682762", "text": "The myelin sheath is generated by myelin membrane fusion inside an oligodendrocyte process.", "offsetInBeginSection": 812, "offsetInEndSection": 903, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25682762", "text": "Oligodendrocytes form CNS myelin; the prevailing hypothesis being that they do it by extending a process that circumnavigates the axon.", "offsetInBeginSection": 99, "offsetInEndSection": 234, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25682762", "text": "Myelin membranes are matured in and transported by myelinophore organelles within an oligodendrocyte process.", "offsetInBeginSection": 702, "offsetInEndSection": 811, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21401967", "text": "Thus, myelin CD47 produces SIRP\u03b1-dependent down-regulation of CD47+/+ myelin phagocytosis in phagocytes.", "offsetInBeginSection": 1872, "offsetInEndSection": 1977, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21401967", "text": "Thus, CD47 on myelin can bind to and subsequently activate SIRP\u03b1 on phagocytes, a prerequisite for CD47/SIRP\u03b1-dependent down-regulation of CD47+/+ myelin phagocytosis by itself.", "offsetInBeginSection": 1192, "offsetInEndSection": 1371, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ad3013d0340b9f058000019", "body": "Can GDF15 be a biomarker for metformin treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32427048", "http://www.ncbi.nlm.nih.gov/pubmed/27974345", "http://www.ncbi.nlm.nih.gov/pubmed/36273168", "http://www.ncbi.nlm.nih.gov/pubmed/34790753", "http://www.ncbi.nlm.nih.gov/pubmed/36444166", "http://www.ncbi.nlm.nih.gov/pubmed/33123476", "http://www.ncbi.nlm.nih.gov/pubmed/34849709", "http://www.ncbi.nlm.nih.gov/pubmed/29580231", "http://www.ncbi.nlm.nih.gov/pubmed/28855167", "http://www.ncbi.nlm.nih.gov/pubmed/35068064"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27974345", "text": "CONCLUSIONS GDF15 levels are a biomarker for the use of metformin in people with dysglycemia, and its concentration reflects the dose of metformin.", "offsetInBeginSection": 863, "offsetInEndSection": 1010, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24669014", "text": "CONCLUSIONS GDF15 expression can be used as a prognostic biomarker for OSCC, and as a predictive biomarker for benefitting from TPF induction chemotherapy.", "offsetInBeginSection": 1886, "offsetInEndSection": 2041, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25541611", "text": "GDF15 may be a novel biomarker for detecting IFG in nondiabetic patients.", "offsetInBeginSection": 1611, "offsetInEndSection": 1684, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28801589", "text": "Accumulating evidence suggests that GDF15 is a biomarker for ageing and morbidity of many somatic disorders such as cancer and inflammatory disorders.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17185363", "text": "There has been increasing interest in using circulating GDF15 as a biomarker in patients, for example those with cardiovascular disease.", "offsetInBeginSection": 136, "offsetInEndSection": 272, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17185363", "text": "BACKGROUND Growth-differentiation factor 15 (GDF15) is a member of the transforming growth factor beta (TGF-beta) cytokine superfamily.", "offsetInBeginSection": 0, "offsetInEndSection": 135, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22675198", "text": "BACKGROUND Growth differentiation factor 15 (GDF15) is a stress-responsive cytokine and biomarker that is produced after myocardial infarction and that is related to prognosis in acute coronary syndrome (ACS).", "offsetInBeginSection": 0, "offsetInEndSection": 209, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23710769", "text": "CONCLUSION Elevated GDF15 level may be not only a diagnostic biomarker for oral leukoplakia, but also a prognostic/predictive biomarker associated with decreased survival and diminished response to induction chemotherapy for patients with OSCC.", "offsetInBeginSection": 1553, "offsetInEndSection": 1797, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23710769", "text": "However, serum GDF15 levels in patients with oral leukoplakia and GDF15 as a potential predictive biomarker for response to induction chemotherapy in patients with OSCC have not been reported.", "offsetInBeginSection": 233, "offsetInEndSection": 425, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28898507", "text": "CONCLUSIONS Our findings suggest that GDF15 may serve as a novel biomarker of advanced fibrosis in NAFLD, thereby indicating the need for urgent anti-fibrotic pharmacotherapy.", "offsetInBeginSection": 1547, "offsetInEndSection": 1722, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8d8f39fcd1d6a10c000024", "body": "What is the TALE-iD method used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34828367", "http://www.ncbi.nlm.nih.gov/pubmed/26854857", "http://www.ncbi.nlm.nih.gov/pubmed/26443215", "http://www.ncbi.nlm.nih.gov/pubmed/30923728", "http://www.ncbi.nlm.nih.gov/pubmed/27883072", "http://www.ncbi.nlm.nih.gov/pubmed/27526029", "http://www.ncbi.nlm.nih.gov/pubmed/22222791", "http://www.ncbi.nlm.nih.gov/pubmed/30706389", "http://www.ncbi.nlm.nih.gov/pubmed/23821439", "http://www.ncbi.nlm.nih.gov/pubmed/36409599"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27940490", "text": "Using different cell types and loci, computational modeling, and a methylation-based orthogonal validation method, \"TALE-iD\", we show that native interactions resemble cross-linked ones, but display improved signal-to-noise ratios and are more focal on regulatory elements and CTCF sites, while strictly abiding to topologically associating domain restrictions.", "offsetInBeginSection": 778, "offsetInEndSection": 1139, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23840477", "text": "12 TALE constructs including 4 TALEN pairs targeted to mouse Gt(ROSA)26Sor gene and mouse Mstn gene sequences as well as 4 TALE-TF constructs targeted to mouse Oct4, c-Myc, Klf4 and Sox2 gene promoter sequences were generated by using our method.", "offsetInBeginSection": 1061, "offsetInEndSection": 1307, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23840477", "text": "Here, we described a simple and efficient method for generating customized TALE nucleases (TALENs) and TALE transcription factors (TALE-TFs) based on TALE repeat tetramer library.", "offsetInBeginSection": 637, "offsetInEndSection": 816, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26854857", "text": "Here we describe FusX, a streamlined Golden Gate TALE assembly system that (1) is backward compatible with popular TALE backbones, (2) is functionalized as a single-tube 3-day TALE assembly process, (3) requires only commonly used basic molecular biology reagents, and (4) is cost-effective.", "offsetInBeginSection": 771, "offsetInEndSection": 1062, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24976123", "text": "Here, we reported a rapid, efficient and easy method for TALE assembly.", "offsetInBeginSection": 340, "offsetInEndSection": 411, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28074901", "text": "Here, combining bimolecular fluorescence complementation (BiFC) and transcription activator-like effector (TALE) technologies, we developed a novel method for labeling genomic loci (BiFC-TALE), which largely reduces the background fluorescence level.", "offsetInBeginSection": 480, "offsetInEndSection": 730, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23316790", "text": "RESULTS We streamlined a Golden Gate-based method for custom TALE assembly.", "offsetInBeginSection": 514, "offsetInEndSection": 589, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23869221", "text": "To gain a systems perspective on the large TALE repertoires from X. oryzae strains, this program was used to predict rice gene targets for 99 sequenced family members.", "offsetInBeginSection": 912, "offsetInEndSection": 1079, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23821439", "text": "TALE nucleases (TALENs), composed of an engineered array of TALE repeats fused to the FokI nuclease domain, have been used successfully for directed genome editing in various organisms and cell types.", "offsetInBeginSection": 166, "offsetInEndSection": 366, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23821439", "text": "This unit also describes improvements to the Zinc Finger and TALE Targeter (ZiFiT Targeter) web server (http://ZiFiT.partners.org) that facilitate the design and construction of FLASH TALE repeat arrays in high throughput.", "offsetInBeginSection": 1259, "offsetInEndSection": 1481, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa395fcd6d6b54f79000007", "body": "Has rituximab been considered as a treatment for chronic fatigues syndrome? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34530254", "http://www.ncbi.nlm.nih.gov/pubmed/35370432", "http://www.ncbi.nlm.nih.gov/pubmed/32680716", "http://www.ncbi.nlm.nih.gov/pubmed/28235209", "http://www.ncbi.nlm.nih.gov/pubmed/10589082", "http://www.ncbi.nlm.nih.gov/pubmed/25645999", "http://www.ncbi.nlm.nih.gov/pubmed/30197220", "http://www.ncbi.nlm.nih.gov/pubmed/33818877", "http://www.ncbi.nlm.nih.gov/pubmed/33912740", "http://www.ncbi.nlm.nih.gov/pubmed/32577808"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28243993", "text": "Healthy, young patients with low-risk disease (mutated IgVH, del (13q)) should be offered fludarabine, chlorambucil, and rituximab (FCR), while similar patients with high-risk disease (unmutated IgVH, del (17p), del (11q), and complex karyotype) should be considered for ibrutinib therapy.", "offsetInBeginSection": 753, "offsetInEndSection": 1042, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28243993", "text": "For the high-risk patients, treatment with rituximab and lenalidomide is an option.", "offsetInBeginSection": 1755, "offsetInEndSection": 1838, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28243993", "text": "For the low-risk patients, bendamustine and rituximab or obinutuzumab and chlorambucil can be considered.", "offsetInBeginSection": 1649, "offsetInEndSection": 1754, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28984295", "text": "Our findings suggest that R-baclofen may have clinical utility for some of the core symptoms of human 16p11.2 microdeletion syndrome.Neuropsychopharmacology advance online publication, 15 November 2017; doi:10.1038/npp.2017.236.", "offsetInBeginSection": 1292, "offsetInEndSection": 1520, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28164324", "text": "Rituximab is a chimeric mouse/human anti-CD20 monoclonal immunoglobulin.", "offsetInBeginSection": 0, "offsetInEndSection": 72, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10589082", "text": "Rituximab, an anti-CD20 antibody, has been recently approved for the treatment of low-grade or follicular non-Hodgkin's lymphoma (NHL).", "offsetInBeginSection": 0, "offsetInEndSection": 135, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10589082", "text": "Recently, however, tumor lysis syndrome (TLS) resulting from rituximab has been reported in a patient with chronic lymphocytic leukemia (CLL).", "offsetInBeginSection": 253, "offsetInEndSection": 395, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28782884", "text": "For unfit patients, currently available evidence supports two options for a first-line therapy: chlorambucil combined with an anti-CD20 antibody (obinutuzumab or rituximab or ofatumumab) or a continuous therapy with ibrutinib.", "offsetInBeginSection": 1288, "offsetInEndSection": 1514, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28782884", "text": "If the disease relapses earlier, therapy should be changed using alternative agents such as bendamustine (plus rituximab), alemtuzumab, lenalidomide, ofatumumab, ibrutinib, idelalisib, or venetoclax.", "offsetInBeginSection": 1615, "offsetInEndSection": 1814, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28782884", "text": "Patients with a del(17p) or TP53 mutation can be treated with ibrutinib, venetoclax, or a combination of idelalisib and rituximab.", "offsetInBeginSection": 1815, "offsetInEndSection": 1945, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa67b4fd6d6b54f7900000f", "body": "What disease is tinea ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24134312", "http://www.ncbi.nlm.nih.gov/pubmed/29437818", "http://www.ncbi.nlm.nih.gov/pubmed/15050029", "http://www.ncbi.nlm.nih.gov/pubmed/8961583", "http://www.ncbi.nlm.nih.gov/pubmed/11990247", "http://www.ncbi.nlm.nih.gov/pubmed/25396139", "http://www.ncbi.nlm.nih.gov/pubmed/6697771", "http://www.ncbi.nlm.nih.gov/pubmed/11469758", "http://www.ncbi.nlm.nih.gov/pubmed/11807474", "http://www.ncbi.nlm.nih.gov/pubmed/25403034"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15050029", "text": "Three groups of fungal pathogens, referred to as dermatophytes, have been shown to cause tinea pedis: Trychophyton sp, Epidermophyton sp, and Microsporum sp.", "offsetInBeginSection": 882, "offsetInEndSection": 1039, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12040364", "text": "Intermittent terbinafine therapy is thus effective in the treatment of tinea pedis.", "offsetInBeginSection": 1119, "offsetInEndSection": 1202, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8021081", "text": "Patients with VL have a high prevalence of tinea versicolor.", "offsetInBeginSection": 284, "offsetInEndSection": 344, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8021081", "text": "Tinea infection during the course of VL is to be distinguished from lesions of post-kala-azar dermal leishmaniasis.", "offsetInBeginSection": 1021, "offsetInEndSection": 1136, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19231646", "text": "Tinea capitis is the most common dermatophyte infection in children.", "offsetInBeginSection": 0, "offsetInEndSection": 68, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8821157", "text": "Iatrogenic disease (tinea incognito) is a new and more subtle form.", "offsetInBeginSection": 195, "offsetInEndSection": 262, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/134458", "text": "The incidence of tinea manuum, tinea pedis and tinea unguium was similar (4-97%-6-38%).", "offsetInBeginSection": 852, "offsetInEndSection": 939, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/134458", "text": "In dermatophytoses, tinea corporis (49-71%) and tinea cruris (47-85%) commonest; tinea axillaris (3-42%), tinea capitis (1-72%) and tinea barbae (1-29%) were less common.", "offsetInBeginSection": 681, "offsetInEndSection": 851, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19942789", "text": "In Japan, any dermatophytosis other than favus or tinea imbricata is considered to be tinea, while outside Japan, favus and tinea imbricata are also classified as tinea.", "offsetInBeginSection": 274, "offsetInEndSection": 443, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19942789", "text": "Tinea capitis is classified together with trichophytia superficialis capillitii and kerion celsi, in a group that tends to include asymptomatic carriers.", "offsetInBeginSection": 444, "offsetInEndSection": 597, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ad4dd93133db5eb78000008", "body": "What is the clathrin triskelia structure?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18502808", "http://www.ncbi.nlm.nih.gov/pubmed/9827808", "http://www.ncbi.nlm.nih.gov/pubmed/11943181", "http://www.ncbi.nlm.nih.gov/pubmed/16968737", "http://www.ncbi.nlm.nih.gov/pubmed/7464911", "http://www.ncbi.nlm.nih.gov/pubmed/17702618", "http://www.ncbi.nlm.nih.gov/pubmed/20545906", "http://www.ncbi.nlm.nih.gov/pubmed/14722064", "http://www.ncbi.nlm.nih.gov/pubmed/28271490", "http://www.ncbi.nlm.nih.gov/pubmed/36114789"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22563470", "text": "Clathrin triskelia and cages were characterized by size, structure, protein concentration, and chelate and gadolinium contents.", "offsetInBeginSection": 657, "offsetInEndSection": 784, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22563470", "text": "METHODOLOGY/PRINCIPAL FINDINGS The first approach utilizes three-legged clathrin triskelia modified to carry 81 gadolinium chelates.", "offsetInBeginSection": 407, "offsetInEndSection": 539, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18502808", "text": "The clathrin triskelion, which is a three-legged pinwheel-shaped heteropolymer, is a major component in the protein coats of certain post-Golgi and endocytic vesicles.", "offsetInBeginSection": 0, "offsetInEndSection": 167, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7738035", "text": "The 42-kDa central region of AP-3 can bind to both clathrin triskelia and to clathrin cages, but cannot assemble clathrin triskelia into clathrin cages.", "offsetInBeginSection": 420, "offsetInEndSection": 572, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1587861", "text": "AP-2 and AP-3 are cellular proteins that drive the in vitro polymerization of clathrin triskelia into cage structures.", "offsetInBeginSection": 0, "offsetInEndSection": 118, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2571614", "text": "Likewise, incubation of soluble clathrin triskelia with purified uncoating ATPase also led to trimeric binding of the ATPase to the vertices of clathrin triskelia.", "offsetInBeginSection": 297, "offsetInEndSection": 460, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23270814", "text": "Atomic force microscopy (AFM), single molecule force spectroscopy (SMFS), and single particle force spectroscopy (SPFS) are used to characterize intermolecular interactions and domain structures of clathrin triskelia and clathrin-coated vesicles (CCVs).", "offsetInBeginSection": 0, "offsetInEndSection": 253, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11943181", "text": "Clathrin light chains (CLCs) are regulatory subunits of clathrin triskelia.", "offsetInBeginSection": 0, "offsetInEndSection": 75, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10926122", "text": "The clathrin assembly protein lymphoid myeloid leukemia (CALM) gene, encodes a homologoue of the neuronal clathrin assembly protein AP180.", "offsetInBeginSection": 187, "offsetInEndSection": 325, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10926122", "text": "The CALM protein could promote clathrin triskelia into clathrin cages and could bind the preformed clathrin cage.", "offsetInBeginSection": 515, "offsetInEndSection": 628, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ace37d50340b9f058000011", "body": "Which is the main reason for the increase in the incidence of cryptococcal disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19182676", "http://www.ncbi.nlm.nih.gov/pubmed/24939404", "http://www.ncbi.nlm.nih.gov/pubmed/29099826", "http://www.ncbi.nlm.nih.gov/pubmed/6564445", "http://www.ncbi.nlm.nih.gov/pubmed/19240459", "http://www.ncbi.nlm.nih.gov/pubmed/22916522", "http://www.ncbi.nlm.nih.gov/pubmed/1861120", "http://www.ncbi.nlm.nih.gov/pubmed/10272078", "http://www.ncbi.nlm.nih.gov/pubmed/3987365", "http://www.ncbi.nlm.nih.gov/pubmed/21850864"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16034947", "text": "AUTHORS' CONCLUSIONS Antifungal primary prophylaxis with either itraconazole or fluconazole is effective in reducing the incidence of cryptococcal disease in adults with advanced HIV disease.", "offsetInBeginSection": 3331, "offsetInEndSection": 3522, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16034947", "text": "Primary prophylaxis with antifungal interventions may decrease cryptococcal disease incidence and associated mortality.", "offsetInBeginSection": 130, "offsetInEndSection": 249, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19009138", "text": "AIDS is the main predisposing condition for cryptococcal meningitis, and thus the profile of most patients mirrors that of HIV infection.", "offsetInBeginSection": 496, "offsetInEndSection": 633, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19127040", "text": "BACKGROUND Cryptococcal meningitis is a common opportunistic infection in Human Immunodeficiency Virus (HIV)-infected individuals.", "offsetInBeginSection": 0, "offsetInEndSection": 130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19127040", "text": "CONCLUSIONS Cryptococcal meningitis is a common initial AIDS-defining illness.", "offsetInBeginSection": 1795, "offsetInEndSection": 1873, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21982529", "text": "CONCLUSIONS Fluconazole was safe and effective as primary prophylaxis against cryptococcal disease, both before and during early antiretroviral treatment.", "offsetInBeginSection": 2822, "offsetInEndSection": 2976, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14617302", "text": "New pulmonary radiographic findings should prompt an aggressive diagnostic evaluation including serum and CSF cryptococcal antigen assays, and a biopsy of pulmonary lesions.", "offsetInBeginSection": 1623, "offsetInEndSection": 1796, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14617302", "text": "An increase in the incidence of primary pulmonary cryptococcal infections has been reported recently in solid organ recipients; these infections were generally symptomatic with an accelerated clinical course.", "offsetInBeginSection": 255, "offsetInEndSection": 463, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19245939", "text": "The increasing incidence of cryptococcal infection as a result of the AIDS epidemic, the recent emergence of a hypervirulent cryptococcal strain in Canada and the fact that mortality from cryptococcal disease remains high have stimulated intensive research into this organism.", "offsetInBeginSection": 169, "offsetInEndSection": 445, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21905781", "text": "Cryptococcal meningitis (CM), a fungal disease caused by Cryptococcus spp., is the most common form of meningitis and a leading cause of death among persons with HIV/AIDS in sub-Saharan Africa.", "offsetInBeginSection": 0, "offsetInEndSection": 193, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ab8fb5bfcf4565872000017", "body": "How is the nuclear localization of lncRNA mediated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24732794", "http://www.ncbi.nlm.nih.gov/pubmed/31218107", "http://www.ncbi.nlm.nih.gov/pubmed/32800670", "http://www.ncbi.nlm.nih.gov/pubmed/32026224", "http://www.ncbi.nlm.nih.gov/pubmed/34604357", "http://www.ncbi.nlm.nih.gov/pubmed/24463464", "http://www.ncbi.nlm.nih.gov/pubmed/32238924", "http://www.ncbi.nlm.nih.gov/pubmed/35883037", "http://www.ncbi.nlm.nih.gov/pubmed/34056657", "http://www.ncbi.nlm.nih.gov/pubmed/25482760"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24732794", "text": "As many lncRNAs regulate nuclear events and thus must localize to nuclei, we analyzed the sequence requirements for nuclear localization in an intergenic lncRNA named BORG (BMP2-OP1-responsive gene), which is both spliced and polyadenylated but is strictly localized in nuclei.", "offsetInBeginSection": 150, "offsetInEndSection": 427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27198227", "text": "Our findings indicate that RBPs HuR and GRSF1 govern the cytoplasmic and mitochondrial localization of the lncRNA RMRP, which is encoded by nuclear DNA but has key functions in mitochondria.", "offsetInBeginSection": 850, "offsetInEndSection": 1040, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26578588", "text": "To address whether localization of the lncRNA influences susceptibility to degradation by either ASOs or RNAi, nuclear lncRNAs (MALAT1 and NEAT1), cytoplasmic lncRNAs (DANCR and OIP5-AS1) and dual-localized lncRNAs (TUG1, CasC7 and HOTAIR) were compared for knockdown efficiency.", "offsetInBeginSection": 788, "offsetInEndSection": 1067, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25630241", "text": "Additionally, nuclear lncRNA foci dissolve during mitosis and become widely dispersed, suggesting these lncRNAs are not mitotic bookmarking factors.", "offsetInBeginSection": 1086, "offsetInEndSection": 1234, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24463464", "text": "RNA, including long noncoding RNA (lncRNA), is known to be an abundant and important structural component of the nuclear matrix.", "offsetInBeginSection": 0, "offsetInEndSection": 128, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24463464", "text": "Here, we describe one lncRNA, Firre, that interacts with the nuclear-matrix factor hnRNPU through a 156-bp repeating sequence and localizes across an ~5-Mb domain on the X chromosome.", "offsetInBeginSection": 280, "offsetInEndSection": 463, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27250657", "text": "Further, lncRNA SPRY4-IT1 can directly increase the transcription, expression, and nuclear localization of Snail, one key transcription factor during the EMT processes of cancer cells, while siRNA-mediated specific knockdown of Snail can significantly attenuate SPRY4-IT1-induced EMT of ESCC cells.", "offsetInBeginSection": 907, "offsetInEndSection": 1205, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27250657", "text": "Our results suggest that lncRNA SPRY4-IT1 might be considered as a novel oncogene involved in ESCC progression.", "offsetInBeginSection": 1206, "offsetInEndSection": 1317, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27821766", "text": "Importantly, we show that TP53TG1 binds to the multifaceted DNA/RNA binding protein YBX1 to prevent its nuclear localization and thus the YBX1-mediated activation of oncogenes.", "offsetInBeginSection": 423, "offsetInEndSection": 599, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25555588", "text": "Recent evidence implicated several long noncoding RNA (lncRNA) in gene expression in cis or trans through regulating the local chromosomal architecture.", "offsetInBeginSection": 0, "offsetInEndSection": 152, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa67b6ad6d6b54f79000010", "body": "What is Paget's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11123042", "http://www.ncbi.nlm.nih.gov/pubmed/11705325", "http://www.ncbi.nlm.nih.gov/pubmed/23929251", "http://www.ncbi.nlm.nih.gov/pubmed/27815949", "http://www.ncbi.nlm.nih.gov/pubmed/16429324", "http://www.ncbi.nlm.nih.gov/pubmed/16876624", "http://www.ncbi.nlm.nih.gov/pubmed/19032921", "http://www.ncbi.nlm.nih.gov/pubmed/17447970", "http://www.ncbi.nlm.nih.gov/pubmed/23739693", "http://www.ncbi.nlm.nih.gov/pubmed/15389972"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15389972", "text": "Paget's disease is primarily a disease of the osteoclast.", "offsetInBeginSection": 129, "offsetInEndSection": 186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15389972", "text": "Recurrent mutations in the ubiquitin-associated (UBA) domain of sequestosome 1 (SQSTM1/p62) are identified in patients with Paget's disease.", "offsetInBeginSection": 599, "offsetInEndSection": 739, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15389972", "text": "Paget's disease is an autosomal dominant trait with genetic heterogeneity.", "offsetInBeginSection": 524, "offsetInEndSection": 598, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25025000", "text": "To date, the only gene with mutations in the coding region linked to Paget's disease is sequestosome-1 (SQSTM1), which encodes the p62 protein, and these mutations lead to elevated cytokine activation of NF-B in osteoclasts but do not induce a \"pagetic osteoclast\" phenotype.", "offsetInBeginSection": 529, "offsetInEndSection": 804, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16429324", "text": "Paget's disease is an autosomal dominant trait with genetic heterogeneity.", "offsetInBeginSection": 195, "offsetInEndSection": 269, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16429324", "text": "Paget's disease of bone is a chronic focal skeletal disorder characterized by increased bone resorption by the osteoclasts.", "offsetInBeginSection": 0, "offsetInEndSection": 123, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16429324", "text": "Similarly, mutations in the valosin-containing protein (VCP) gene have been shown to cause inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia.", "offsetInBeginSection": 415, "offsetInEndSection": 598, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16429324", "text": "Several mutations in the ubiquitin-associated (UBA) domain of sequestosome 1 (SQSTM1/p62) have been identified in patients with Paget's disease.", "offsetInBeginSection": 270, "offsetInEndSection": 414, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19032921", "text": "Paget's disease of bone is a focal disorder of aging bone.", "offsetInBeginSection": 0, "offsetInEndSection": 58, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19032921", "text": "The classic late-onset Paget's disease is often caused by a P392L mutation in the gene SQSTM1, which disturbs signaling pathways in osteoclasts on cell activation.", "offsetInBeginSection": 59, "offsetInEndSection": 222, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a8980d2fcd1d6a10c00000d", "body": "Which is the main protein in brown adipose tissue (BAT) active in thermogenesis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32170654", "http://www.ncbi.nlm.nih.gov/pubmed/9180264", "http://www.ncbi.nlm.nih.gov/pubmed/32208359", "http://www.ncbi.nlm.nih.gov/pubmed/27561621", "http://www.ncbi.nlm.nih.gov/pubmed/24876128", "http://www.ncbi.nlm.nih.gov/pubmed/30415772", "http://www.ncbi.nlm.nih.gov/pubmed/6653675", "http://www.ncbi.nlm.nih.gov/pubmed/3887525", "http://www.ncbi.nlm.nih.gov/pubmed/21373720", "http://www.ncbi.nlm.nih.gov/pubmed/34176254"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24809334", "text": "Brown adipose tissue (BAT) is specialized for energy expenditure, a process called adaptive thermogenesis.", "offsetInBeginSection": 0, "offsetInEndSection": 106, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27339605", "text": "BACKGROUND Brown adipose tissue (BAT) thermogenesis is an adaptive process, essential for energy expenditure and involved in the control of obesity.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19906816", "text": "Cold-induced adaptive (or nonshivering) thermogenesis in small mammals is produced primarily in brown adipose tissue (BAT).", "offsetInBeginSection": 0, "offsetInEndSection": 123, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1763812", "text": "Brown adipose tissue (BAT) is the main effector of nonshivering thermogenesis and diet-induced thermogenesis in mammals.", "offsetInBeginSection": 0, "offsetInEndSection": 120, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22535970", "text": "CONTEXT Stimulation of thermogenesis in brown adipose tissue (BAT) is a potential target to treat obesity.", "offsetInBeginSection": 0, "offsetInEndSection": 106, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18407130", "text": "The finding of type II-thyroxine (T(4)) 5'-deiodinase in brown adipose tissue (BAT) has opened a way to uncover a more important role for thyroid hormone in adaptive thermogenesis.", "offsetInBeginSection": 217, "offsetInEndSection": 397, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21373720", "text": "Brown adipose tissue (BAT) is responsible for cold-induced thermogenesis in rodents.", "offsetInBeginSection": 191, "offsetInEndSection": 275, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16464973", "text": "Heat production during hibernation is provided, in part, by nonshivering thermogenesis that occurs in large deposits of brown adipose tissue (BAT).", "offsetInBeginSection": 365, "offsetInEndSection": 512, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27498420", "text": "Brown adipose tissue (BAT) has been also considered as the main thermogenic organ responsible of maintenance body temperature through heat production.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27641099", "text": "Promoting brown adipose tissue (BAT) development is an attractive strategy for the treatment of obesity, as activated BAT dissipates energy through thermogenesis; however, the mechanisms controlling BAT formation are not fully understood.", "offsetInBeginSection": 0, "offsetInEndSection": 238, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a99566e1d1251d03b00000f", "body": "With which personality traits has the human monoamine oxidase A (MAOA) gene been associated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12566936", "http://www.ncbi.nlm.nih.gov/pubmed/16110245", "http://www.ncbi.nlm.nih.gov/pubmed/15870836", "http://www.ncbi.nlm.nih.gov/pubmed/19657584", "http://www.ncbi.nlm.nih.gov/pubmed/25606465", "http://www.ncbi.nlm.nih.gov/pubmed/16139427", "http://www.ncbi.nlm.nih.gov/pubmed/18845200", "http://www.ncbi.nlm.nih.gov/pubmed/21601990", "http://www.ncbi.nlm.nih.gov/pubmed/21295226", "http://www.ncbi.nlm.nih.gov/pubmed/12815746"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/12566936", "text": "We hypothesised that a functional polymorphism in the 5' untranslated region of the MAOA gene is associated with specific personality traits.", "offsetInBeginSection": 133, "offsetInEndSection": 274, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12566936", "text": "Monoamine oxidase type A (MAOA) has been implicated to be part of mechanisms underlying human temperament and psychiatric disorders.", "offsetInBeginSection": 0, "offsetInEndSection": 132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16436187", "text": "By conferring allele-specific transcriptional activity on the monoamine oxidase A (MAOA) gene in humans, length variation of a repetitive sequence [(variable number of tandem repeat (VNTR)] in the MAOA promoter influences a constellation of personality traits related to aggressive and antisocial behavior and increases the risk of neurodevelopmental and psychiatric disorders.", "offsetInBeginSection": 0, "offsetInEndSection": 377, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16110245", "text": "Monoamine oxidase A (MAOA), a mitochondrial outer membrane enzyme, degrades biogenic amines including norepinephrine, dopamine and serotonin, which have been implicated in the expression of personality traits.", "offsetInBeginSection": 0, "offsetInEndSection": 209, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16360899", "text": "In the present study, we investigated the association between personality traits and systematic combination of functional polymorphisms in three genes that regulate the metabolism of catecholamines, namely, tyrosine hydroxylase (TH), monoamine oxidase A (MAOA), and catechol-O-methyltransferase (COMT).", "offsetInBeginSection": 306, "offsetInEndSection": 608, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19657584", "text": "Monoamine oxidase A and B (MAOA and MAOB) appear to be involved in the pathogenesis of Major Depression, and vulnerability of Major Depression is associated with personality traits relating to positive and negative affect.", "offsetInBeginSection": 0, "offsetInEndSection": 222, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19194374", "text": "Association studies suggest that the low activity variant of the monoamine oxidase A (MAOA)-uVNTR polymorphism confers risk for emotional disturbances associated with antisocial traits, particularly in males.", "offsetInBeginSection": 0, "offsetInEndSection": 208, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25794322", "text": "AIMS We have analysed the MAOA-uVNTR polymorphism in the promoter region of the X-chromosomal monoamine oxidase A (MAOA) gene.", "offsetInBeginSection": 0, "offsetInEndSection": 126, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25794322", "text": "CONCLUSION Taken together, these findings suggest that the MAOA-L genotype is to some extent associated with impulsive and antisocial personality traits in alcoholic men.", "offsetInBeginSection": 1428, "offsetInEndSection": 1598, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12554604", "text": "AIMS We analysed the MAOAuVNTR functional polymorphism in the promoter region of the X-chromosomal monoamine oxidase A (MAOA) gene.", "offsetInBeginSection": 0, "offsetInEndSection": 131, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ab9032afcf4565872000018", "body": "Does oncogene-induced DNA replication stress inhibit genomic instability?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31211234", "http://www.ncbi.nlm.nih.gov/pubmed/29653955", "http://www.ncbi.nlm.nih.gov/pubmed/29466339", "http://www.ncbi.nlm.nih.gov/pubmed/23479741", "http://www.ncbi.nlm.nih.gov/pubmed/33028815", "http://www.ncbi.nlm.nih.gov/pubmed/27725641", "http://www.ncbi.nlm.nih.gov/pubmed/23204322", "http://www.ncbi.nlm.nih.gov/pubmed/25959793", "http://www.ncbi.nlm.nih.gov/pubmed/22410776", "http://www.ncbi.nlm.nih.gov/pubmed/29692334"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20177397", "text": "Instead, the mutation patterns of the tumour suppressor TP53 (which encodes p53), ataxia telangiectasia mutated (ATM) and cyclin-dependent kinase inhibitor 2A (CDKN2A; which encodes p16INK4A and p14ARF) support the oncogene-induced DNA replication stress model, which attributes genomic instability and TP53 and ATM mutations to oncogene-induced DNA damage.", "offsetInBeginSection": 489, "offsetInEndSection": 846, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27725641", "text": "Furthermore, overexpression of TBP alone causes the hallmarks of oncogene-induced replication stress, including replication fork slowing, DNA damage and senescence.", "offsetInBeginSection": 766, "offsetInEndSection": 930, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27725641", "text": "Consequently, we reveal that increased transcription can be a mechanism of oncogene-induced DNA damage, providing a molecular link between upregulation of the transcription machinery and genomic instability in cancer.", "offsetInBeginSection": 931, "offsetInEndSection": 1148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25959793", "text": "Aberrant oncogene expression induces replication stress, leading to DNA breaks and genomic instability.", "offsetInBeginSection": 389, "offsetInEndSection": 492, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25959793", "text": "Among these regions are fragile sites (FSs), genomic regions sensitive to replication stress conditions induced by the DNA polymerase inhibitor aphidicolin.", "offsetInBeginSection": 140, "offsetInEndSection": 296, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21311564", "text": "We have previously shown that expression of oncogenes leads to DNA replication stress and genomic instability, explaining the high frequency of p53 mutations in human cancers.", "offsetInBeginSection": 307, "offsetInEndSection": 482, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23204322", "text": "Oncogene-induced DNA replication stress is thought to drive genomic instability in cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 90, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27160911", "text": "Importantly, we also find that, in the context of oncogene-induced replication stress, where increased E2F activity is thought to cause replication stress, E2F activity is required to limit levels of DNA damage.", "offsetInBeginSection": 651, "offsetInEndSection": 862, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20098673", "text": "Although oncogene acceleration primarily induces DNA replication stress and the resulting lesions in the S phase, these lesions are carried over into the M phase and cause cytokinesis failure and genomic instability.", "offsetInBeginSection": 461, "offsetInEndSection": 677, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20098673", "text": "Thus, our results reveal a process of genomic instability generation triggered by precancerous DNA replication stress.", "offsetInBeginSection": 1078, "offsetInEndSection": 1196, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aa6800ad6d6b54f79000011", "body": "Is Brucella abortus the organism that causes brucillosis known to cause spontaneous abortions in humans?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22812618", "http://www.ncbi.nlm.nih.gov/pubmed/25566611", "http://www.ncbi.nlm.nih.gov/pubmed/17296251", "http://www.ncbi.nlm.nih.gov/pubmed/28167945", "http://www.ncbi.nlm.nih.gov/pubmed/26578650", "http://www.ncbi.nlm.nih.gov/pubmed/30894428", "http://www.ncbi.nlm.nih.gov/pubmed/32411617", "http://www.ncbi.nlm.nih.gov/pubmed/27800616", "http://www.ncbi.nlm.nih.gov/pubmed/21844234", "http://www.ncbi.nlm.nih.gov/pubmed/16739129"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25566611", "text": "In conclusion, Brucella abortus cannot cause spontaneous abortion by altering the mouse cytokine profile towards Th1 in pregnancy.", "offsetInBeginSection": 1594, "offsetInEndSection": 1724, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17296251", "text": "Brucella abortus, a facultative intracellular pathogen, is of tremendous zoonotic importance because of its ability to induce spontaneous abortion in cattle and other livestock.", "offsetInBeginSection": 0, "offsetInEndSection": 177, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16739129", "text": "Brucella abortus is the etiologic agent of bovine brucellosis and causes a chronic disease in humans known as undulant fever.", "offsetInBeginSection": 0, "offsetInEndSection": 125, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16739129", "text": "The elucidation of the immunome of B. abortus CE identified a number of candidate proteins for developing vaccines against Brucella infection in bovine and humans.", "offsetInBeginSection": 1038, "offsetInEndSection": 1201, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10941733", "text": "Brucella abortus strain RB51 vaccine is being considered as a means to control B. abortus induced abortions in cow elk.", "offsetInBeginSection": 186, "offsetInEndSection": 305, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25480485", "text": "PCR/RT-PCR assays targeted specific genes of abortifacient agents of cattle: bovine viral diarrhea virus (BVDV), bovine herpesvirus 1 (BoHV-1), Listeria monocytogenes, Neospora caninum, Leptospira spp., Brucella abortus, and Histophilus somni.", "offsetInBeginSection": 349, "offsetInEndSection": 592, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/4295848", "text": "The use of whole-cell antigens in agglutination and agglutinin-absorption tests showed that the organism causing abortion in dogs is similar to rough Brucella abortus, B. melitensis, and B. ovis, but different from smooth Brucella cultures.", "offsetInBeginSection": 0, "offsetInEndSection": 240, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23837364", "text": "Brucella melitensis, B. abortus and B. suis, which are transmitted between animals both vertically and horizontally, cause abortion and infertility in their primary natural hosts - goats and sheep (B. melitensis), cows (B. abortus) and sows (B. suis).", "offsetInBeginSection": 91, "offsetInEndSection": 342, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23837364", "text": "Brucella spp.", "offsetInBeginSection": 343, "offsetInEndSection": 356, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/4882024", "text": "The bacterium that causes canine abortion has polynucleotide sequences similar, in deoxyribonucleic acid (DNA)-DNA homology studies, to those of Brucella suis and, by inference from previous data, those of B. abortus and B. melitensis as well as B. neotomae.", "offsetInBeginSection": 0, "offsetInEndSection": 258, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abd3707fcf456587200002d", "body": "Is the petrous bone used in ancient DNA sampling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32405262", "http://www.ncbi.nlm.nih.gov/pubmed/30842617", "http://www.ncbi.nlm.nih.gov/pubmed/28625158", "http://www.ncbi.nlm.nih.gov/pubmed/32446165", "http://www.ncbi.nlm.nih.gov/pubmed/34425360", "http://www.ncbi.nlm.nih.gov/pubmed/33106554", "http://www.ncbi.nlm.nih.gov/pubmed/29301114", "http://www.ncbi.nlm.nih.gov/pubmed/29607044", "http://www.ncbi.nlm.nih.gov/pubmed/28129388", "http://www.ncbi.nlm.nih.gov/pubmed/29877032"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28129388", "text": "Lastly, we show that petrous bones from ancient cremated individuals contain no measurable levels of authentic human DNA.", "offsetInBeginSection": 1341, "offsetInEndSection": 1462, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28625158", "text": "We assessed this method by comparing the aDNA results from one petrous bone processed using our novel method to its pair, which was processed using established protocols for sampling disarticulated petrous bones.", "offsetInBeginSection": 731, "offsetInEndSection": 943, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26086078", "text": "We obtained shotgun DNA sequences from three distinct areas within the petrous: a spongy part of trabecular bone (part A), the dense part of cortical bone encircling the osseous inner ear, or otic capsule (part B), and the dense part within the otic capsule (part C).", "offsetInBeginSection": 1092, "offsetInEndSection": 1359, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26086078", "text": "Our results confirm that dense bone parts of the petrous bone can provide high endogenous aDNA yields and indicate that endogenous DNA fractions for part C can exceed those obtained for part B by up to 65-fold and those from part A by up to 177-fold, while total endogenous DNA concentrations are up to 126-fold and 109-fold higher for these comparisons.", "offsetInBeginSection": 1360, "offsetInEndSection": 1714, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26595274", "text": "The new samples include, to our knowledge, the first genome-wide ancient DNA from Anatolian Neolithic farmers, whose genetic material we obtained by extracting from petrous bones, and who we show were members of the population that was the source of Europe's first farmers.", "offsetInBeginSection": 375, "offsetInEndSection": 648, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28526291", "text": "The petrous part yielded more endogenous ancient DNA molecules than the squamous part of the same bone.", "offsetInBeginSection": 612, "offsetInEndSection": 715, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19493899", "text": "We conclude that Asx d/l is not a useful screening technique for ancient DNA from bone.", "offsetInBeginSection": 1303, "offsetInEndSection": 1390, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18773469", "text": "From the results of this study it is believed the petrous bone may be a new useful bone element and a supplement or a proxy for teeth in the analysis of early dietary patterns as it may reflect diet in fetal stages and early years of life.", "offsetInBeginSection": 1190, "offsetInEndSection": 1429, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26081994", "text": "Based on ancient human bone samples from temperate and tropical environments, we show that an EDTA-based enzymatic 'pre-digestion' of powdered bone increases the proportion of endogenous DNA several fold.", "offsetInBeginSection": 271, "offsetInEndSection": 475, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20229501", "text": "Our results highlight the combination of laser microdissection and low-volume PCR as a promising new technique in ancient DNA analysis.", "offsetInBeginSection": 1006, "offsetInEndSection": 1141, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abc9157fcf456587200001e", "body": "What is \"enhancer hijacking\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30659153", "http://www.ncbi.nlm.nih.gov/pubmed/33972799", "http://www.ncbi.nlm.nih.gov/pubmed/33858773", "http://www.ncbi.nlm.nih.gov/pubmed/34933939", "http://www.ncbi.nlm.nih.gov/pubmed/29059320", "http://www.ncbi.nlm.nih.gov/pubmed/34092790", "http://www.ncbi.nlm.nih.gov/pubmed/35982471", "http://www.ncbi.nlm.nih.gov/pubmed/26229090", "http://www.ncbi.nlm.nih.gov/pubmed/30687786", "http://www.ncbi.nlm.nih.gov/pubmed/31094928"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27869826", "text": "Recurrent tandem duplications intersecting with a TAD boundary mediate de novo formation of a 3D contact domain comprising IGF2 and a lineage-specific super-enhancer, resulting in high-level gene activation.", "offsetInBeginSection": 881, "offsetInEndSection": 1088, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27869826", "text": "We additionally pursued cancer-type-specific analyses and uncovered IGF2 as a target for enhancer hijacking in colorectal cancer.", "offsetInBeginSection": 751, "offsetInEndSection": 880, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25043047", "text": "Somatic structural variants juxtapose GFI1 or GFI1B coding sequences proximal to active enhancer elements, including super-enhancers, instigating oncogenic activity.", "offsetInBeginSection": 737, "offsetInEndSection": 902, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26229090", "text": "We identify novel mechanisms of enhancer-driven regulation of the oncogenes MYC and BCL6, and show that the BCL6 locus can serve as an enhancer donor in an \"enhancer hijacking\" translocation.", "offsetInBeginSection": 1313, "offsetInEndSection": 1504, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26229090", "text": "This method detects rearrangements involving known cancer genes, including CCND1, BCL2, MYC, PDCD1LG2, NOTCH1, CIITA, and SGK1, as well as novel enhancer duplication events of likely oncogenic significance.", "offsetInBeginSection": 389, "offsetInEndSection": 595, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26229090", "text": "We show that BCL6-locus enhancers are acetylated by the BCL6-activating transcription factor MEF2B, and can undergo genomic duplication, or target the MYC promoter for activation in the context of a \"pseudo-double-hit\" t(3;8)(q27;q24) rearrangement linking the BCL6 and MYC loci.", "offsetInBeginSection": 800, "offsetInEndSection": 1079, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27490482", "text": "At BCL2L11, we identify a haematopoietic enhancer hub that is inactivated by the EBV repressors EBNA3A and EBNA3C through recruitment of the H3K27 methyltransferase EZH2.", "offsetInBeginSection": 623, "offsetInEndSection": 793, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27490482", "text": "EBV therefore drives lymphomagenesis by hijacking long-range enhancer hubs and specific cellular co-factors.", "offsetInBeginSection": 895, "offsetInEndSection": 1003, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27490482", "text": "EBNA2 recruits the BRG1 ATPase of the SWI/SNF remodeller to MYC enhancers and BRG1 is required for enhancer-promoter interactions in EBV-infected cells.", "offsetInBeginSection": 470, "offsetInEndSection": 622, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27490482", "text": "EBV-driven MYC enhancer activation may contribute to the genesis and localisation of MYC-Immunoglobulin translocation breakpoints in Burkitt's lymphoma.", "offsetInBeginSection": 1004, "offsetInEndSection": 1156, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ab9050bfcf4565872000019", "body": "What is break induced replication?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23790415", "http://www.ncbi.nlm.nih.gov/pubmed/31495565", "http://www.ncbi.nlm.nih.gov/pubmed/29735283", "http://www.ncbi.nlm.nih.gov/pubmed/28427283", "http://www.ncbi.nlm.nih.gov/pubmed/34481360", "http://www.ncbi.nlm.nih.gov/pubmed/29523232", "http://www.ncbi.nlm.nih.gov/pubmed/23898170", "http://www.ncbi.nlm.nih.gov/pubmed/33470420", "http://www.ncbi.nlm.nih.gov/pubmed/31663812", "http://www.ncbi.nlm.nih.gov/pubmed/24586181"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28427283", "text": "Break-induced replication (BIR) is an important pathway specializing in repair of one-ended double-strand DNA breaks (DSBs).", "offsetInBeginSection": 0, "offsetInEndSection": 124, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28427283", "text": "This type of DSB break typically arises at collapsed replication forks or at eroded telomeres.", "offsetInBeginSection": 125, "offsetInEndSection": 219, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25329304", "text": "Broken replication forks result in DNA breaks that are normally repaired via homologous recombination or break induced replication (BIR).", "offsetInBeginSection": 0, "offsetInEndSection": 137, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25329304", "text": "This telomere lengthening required functional telomerase, the core DNA damage signaling cascade Mec1-Rad9-Rad53, and the components of the BIR repair pathway - Rad51, Rad52, Pol32, and Pif1.", "offsetInBeginSection": 412, "offsetInEndSection": 602, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12660252", "text": "gammaH2AX foci are required for recruiting repair and checkpoint protein complexes to the replication break sites.", "offsetInBeginSection": 1492, "offsetInEndSection": 1606, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17671506", "text": "Break-induced replication (BIR) is an efficient homologous recombination process to initiate DNA replication when only one end of a chromosome double-strand break shares homology with a template.", "offsetInBeginSection": 0, "offsetInEndSection": 195, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21183718", "text": "DNA replication fork movement is impeded by collisions with transcription elongation complexes (TEC).", "offsetInBeginSection": 0, "offsetInEndSection": 101, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21183718", "text": "Deleting recombination genes required for replication fork repair (recB and ruvC) increased sensitivity to bicyclomycin, as did loss of the replication fork reloading helicases rep and priA.", "offsetInBeginSection": 820, "offsetInEndSection": 1010, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26055704", "text": "The anticancer agent camptothecin (CPT) is a DNA topoisomerase I inhibitor that causes fork collapse and double-strand breaks amid DNA replication.", "offsetInBeginSection": 106, "offsetInEndSection": 253, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6275090", "text": "(a) Ultraviolet (UV) irradiation of SV40-infected cells inhibits viral DNA replication.", "offsetInBeginSection": 179, "offsetInEndSection": 266, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aac543bfcf4565872000004", "body": "What biologic process in the body is associated with Mast cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/6178551", "http://www.ncbi.nlm.nih.gov/pubmed/1991845", "http://www.ncbi.nlm.nih.gov/pubmed/3109295", "http://www.ncbi.nlm.nih.gov/pubmed/1608656", "http://www.ncbi.nlm.nih.gov/pubmed/10608502", "http://www.ncbi.nlm.nih.gov/pubmed/11127270", "http://www.ncbi.nlm.nih.gov/pubmed/9596172", "http://www.ncbi.nlm.nih.gov/pubmed/26840764", "http://www.ncbi.nlm.nih.gov/pubmed/7602107", "http://www.ncbi.nlm.nih.gov/pubmed/16141514"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22706316", "text": "Lipid body accumulation in mast cells is associated with enhanced levels of leukotriene-synthesizing enzymes (LTC4S and 5-LO).", "offsetInBeginSection": 328, "offsetInEndSection": 454, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22706316", "text": "Lipid body accumulation in mast cells is mechanistically distinct from the process in adipocytes; for example, it is independent of PPAR\u03b3 up-regulation and does not involve significant accumulation of conjugated glycerides.", "offsetInBeginSection": 1076, "offsetInEndSection": 1300, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22706316", "text": "Mast cells exposed to insulin exhibit altered scatter and fluorescence properties, accumulating in a SSC(lo)FSC(hi) population that exhibits decreased BS staining and degranulation responses and is enriched in NR-positive lipid bodies and eicosanoid synthesis enzymes.", "offsetInBeginSection": 807, "offsetInEndSection": 1075, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17386403", "text": "Since mast cells clearly play both physiological and pathophysiological functions in the body, it is important to learn about the components of mast cells that drive these responses.", "offsetInBeginSection": 330, "offsetInEndSection": 512, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17386403", "text": "Mast cells have long been known to play a detrimental role in the pathogenesis of IgE-associated allergic disorders by their ability to release a wide variety of pro-inflammatory mediators.", "offsetInBeginSection": 0, "offsetInEndSection": 189, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9354811", "text": "Biological functions of mast cells appear to include a role in innate immunity, involvement in host defense mechanisms against parasitic infestations, immunomodulation of the immune system, and tissue repair and angiogenesis.", "offsetInBeginSection": 1123, "offsetInEndSection": 1348, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10359893", "text": "RESULTS HgCl2 was found to directly activate murine mast cells to release the granule-associated enzyme N-acetyl-beta-D-hexosaminidase and to secrete the proinflammatory cytokines IL-4 and TNF-alpha.", "offsetInBeginSection": 676, "offsetInEndSection": 875, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16141514", "text": "The activation of mast cells results in secretion of the preformed chemical mediators in their granules by a regulated process of exocytosis and leads to synthesis and secretion of lipid mediators and cytokines.", "offsetInBeginSection": 195, "offsetInEndSection": 406, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16141514", "text": "Mast cells are widely distributed throughout the body, predominantly near blood vessels and nerves, and express effector functions in allergic reactions, inflammatory diseases, and host defense.", "offsetInBeginSection": 0, "offsetInEndSection": 194, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17468237", "text": "Mast cells are important elements of the body response to foreign antigens, being those represented either by small molecules (allergic response) or harbored by foreign microorganisms (response to parasite infection).", "offsetInBeginSection": 0, "offsetInEndSection": 217, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abd44b1fcf4565872000030", "body": "List proteins with HEAT repeats", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11042144", "http://www.ncbi.nlm.nih.gov/pubmed/15099583", "http://www.ncbi.nlm.nih.gov/pubmed/10378263", "http://www.ncbi.nlm.nih.gov/pubmed/20887736", "http://www.ncbi.nlm.nih.gov/pubmed/11491282", "http://www.ncbi.nlm.nih.gov/pubmed/23895768", "http://www.ncbi.nlm.nih.gov/pubmed/10361086", "http://www.ncbi.nlm.nih.gov/pubmed/25435324", "http://www.ncbi.nlm.nih.gov/pubmed/24053231", "http://www.ncbi.nlm.nih.gov/pubmed/31279628"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19777061", "text": "BACKGROUND HEAT and ARM repeats occur in a large number of eukaryotic proteins.", "offsetInBeginSection": 0, "offsetInEndSection": 79, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11042144", "text": "Using sensitive sequence analysis techniques we detected HEAT repeats in various chromosome-associated proteins, including four families of proteins associated with condensins and cohesins, which are nuclear complexes that contain structural maintenance of chromosome (SMC) proteins.", "offsetInBeginSection": 155, "offsetInEndSection": 438, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11042144", "text": "HEAT repeats were also found in the TBP-associated TIP120 protein, a global enhancer of transcription, and in the budding yeast Mot1p protein, which is a member of the SWI2/SNF2 family.", "offsetInBeginSection": 903, "offsetInEndSection": 1088, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11042144", "text": "HEAT repeats also were found in dis1-TOG family and cofactor D family microtubule-associated proteins, which, owing to their roles in microtubule dynamics, perform functions related to mitotic progression and chromosome segregation.", "offsetInBeginSection": 1266, "offsetInEndSection": 1498, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11042144", "text": "Among the proteins detected were the XCAP-D2 and XCAP-G subunits of the Xenopus laevis 13S condensin complex, the Aspergillus BimD and Sordaria macrospora Spo76p proteins, the budding yeast Scc2p protein, and the related Drosophila transcriptional activator Nipped-B.", "offsetInBeginSection": 439, "offsetInEndSection": 706, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11042144", "text": "Clathrin adaptor and COP-I coatomer subunits, which function in vesicle coat assembly and were previously noted to share weak sequence similarity to condensin subunits, also contain HEAT repeats.", "offsetInBeginSection": 707, "offsetInEndSection": 902, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23895768", "text": "A structure-based sequence alignment of the \u03b1-helical repeats identified a conserved pattern of hydrophobic or aliphatic residues reminiscent of the consensus sequence of eukaryotic HEAT repeats.", "offsetInBeginSection": 516, "offsetInEndSection": 712, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23895768", "text": "The individual repeats of TON1937 also share high structural similarity with the canonical eukaryotic HEAT repeats.", "offsetInBeginSection": 713, "offsetInEndSection": 828, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23895768", "text": "These observations lead us to speculate that the archaeal HEAT-like repeats of TON1937 have evolved to engage in protein-protein interactions in the same manner as eukaryotic HEAT repeats.", "offsetInBeginSection": 987, "offsetInEndSection": 1175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27802131", "text": "In this Opinion article, we will focus on HEAT repeats, flexible arrays of amphiphilic helices found in many eukaryotic proteins, such as karyopherins and condensins, and discuss how these uniquely designed helical repeats might underlie dynamic protein-protein interactions and support cellular functions in crowded environments.", "offsetInBeginSection": 393, "offsetInEndSection": 723, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abc974bfcf456587200001f", "body": "Is recursive splicing more common in short introns?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30148878", "http://www.ncbi.nlm.nih.gov/pubmed/19683670", "http://www.ncbi.nlm.nih.gov/pubmed/30148885", "http://www.ncbi.nlm.nih.gov/pubmed/30803940", "http://www.ncbi.nlm.nih.gov/pubmed/29632374", "http://www.ncbi.nlm.nih.gov/pubmed/25970244", "http://www.ncbi.nlm.nih.gov/pubmed/17324281", "http://www.ncbi.nlm.nih.gov/pubmed/25970246", "http://www.ncbi.nlm.nih.gov/pubmed/9111348", "http://www.ncbi.nlm.nih.gov/pubmed/15802507"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27965595", "text": "This process, called \"recursive splicing,\" often involves non-canonical splicing elements positioned deep within introns, and different mechanisms for its deployment have been proposed.", "offsetInBeginSection": 844, "offsetInEndSection": 1029, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15802507", "text": "We discuss currently known and potential roles for recursive splicing.", "offsetInBeginSection": 1428, "offsetInEndSection": 1498, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15802507", "text": "Mutation of nonexonic site RP3 within Ultrabithorax also confirmed that recursive splicing is the predominant processing pathway even with a shortened version of the intron.", "offsetInBeginSection": 1254, "offsetInEndSection": 1427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15802507", "text": "We present bioinformatic, phylogenetic, and experimental evidence in Drosophila for a mechanism that subdivides many large introns by recursive splicing at nonexonic elements and alternative exons.", "offsetInBeginSection": 167, "offsetInEndSection": 364, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15802507", "text": "Experimental analyses of in vivo processing intermediates and lariat products from four large introns in the unrelated genes kuzbanian, outspread, and Ultrabithorax confirmed that these introns are removed by a series of recursive splicing steps using the predicted nonexonic sites.", "offsetInBeginSection": 971, "offsetInEndSection": 1253, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25970244", "text": "Recursive splicing is a process in which large introns are removed in multiple steps by re-splicing at ratchet points--5' splice sites recreated after splicing.", "offsetInBeginSection": 0, "offsetInEndSection": 160, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25970244", "text": "We also show that recursive splicing is a constitutive process, that depletion of U2AF inhibits recursive splicing, and that the sequence and function of ratchet points are evolutionarily conserved in Drosophila.", "offsetInBeginSection": 710, "offsetInEndSection": 922, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25970246", "text": "However, some long Drosophila melanogaster introns contain a cryptic site, known as a recursive splice site (RS-site), that enables a multi-step process of intron removal termed recursive splicing.", "offsetInBeginSection": 113, "offsetInEndSection": 310, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28520720", "text": "Non-canonical splicing-intron excision without the spliceosome-has been documented; most notably, some tRNAs and the XBP1 mRNA contain short introns that are not removed by the spliceosome.", "offsetInBeginSection": 178, "offsetInEndSection": 367, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19683670", "text": "In the alternative splicing, intron retention, of histamine H(3) receptors in rats and mice, the short transcript isoforms that are excised alternatively spliced introns are easily detected in a very low level in rats and are undetectable in mice using the regular PCR protocol.", "offsetInBeginSection": 0, "offsetInEndSection": 278, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac0a82d19833b0d7b000003", "body": "In what percentage of skeletal muscle fibers is dystrophin expression restored after PPMO- mediated exon skipping?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36420217", "http://www.ncbi.nlm.nih.gov/pubmed/19796077", "http://www.ncbi.nlm.nih.gov/pubmed/20924363", "http://www.ncbi.nlm.nih.gov/pubmed/22683468", "http://www.ncbi.nlm.nih.gov/pubmed/30883742", "http://www.ncbi.nlm.nih.gov/pubmed/24942628", "http://www.ncbi.nlm.nih.gov/pubmed/19759562", "http://www.ncbi.nlm.nih.gov/pubmed/19277018", "http://www.ncbi.nlm.nih.gov/pubmed/35944903", "http://www.ncbi.nlm.nih.gov/pubmed/27279388"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28373570", "text": "Intravenous injections with PPMOs restored dystrophin expression in the myocardium and cardiac Purkinje fibers, as well as skeletal muscles.", "offsetInBeginSection": 767, "offsetInEndSection": 907, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28373570", "text": "The present study reports the rescue of dystrophin expression and recovery of the conduction system in the heart of dystrophic dogs by PPMO-mediated multiexon skipping.", "offsetInBeginSection": 1423, "offsetInEndSection": 1591, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24942628", "text": "administration of the PPMO restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups.", "offsetInBeginSection": 730, "offsetInEndSection": 848, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19277018", "text": "Reading frame restoration of the dystrophin transcript can be achieved by AON-mediated exon skipping in the dystrophic mdx mouse model.", "offsetInBeginSection": 112, "offsetInEndSection": 247, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8213828", "text": "The results provide further evidence of exon skipping in the dystrophin gene and indicate that this may be involved in the synthesis of dystrophin by revertant fibers.", "offsetInBeginSection": 925, "offsetInEndSection": 1092, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8213828", "text": "Although many Duchenne muscular dystrophy patients have a deletion in the dystrophin gene which disrupts the translational reading frame, they express dystrophin in a small proportion of skeletal muscle fibers (\"revertant fibers\").", "offsetInBeginSection": 0, "offsetInEndSection": 231, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22968479", "text": "Widespread restoration of dystrophin expression via adeno-associated virus (AAV)-mediated exon skipping has been successfully demonstrated in the mdx mouse model and in cardiac muscle after percutaneous transendocardial delivery in the golden retriever muscular dystrophy dog (GRMD) model.", "offsetInBeginSection": 488, "offsetInEndSection": 777, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19815563", "text": "METHODS AND RESULTS Mice lacking dystrophin due to a truncation mutation (mdx) were given an arginine-rich, cell-penetrating, peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) that delivered a splice-switching oligonucleotide-mediated exon skipping therapy to restore dystrophin in mdx mice before the development of detectable cardiomyopathy.", "offsetInBeginSection": 665, "offsetInEndSection": 1023, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19815563", "text": "CONCLUSION These results demonstrate for the first time that PPMO-mediated exon skipping therapy early in the course of DMD may effectively prevent or slow down associated cardiac hypertrophy and diastolic dysfunction with significant long-term impact.", "offsetInBeginSection": 1837, "offsetInEndSection": 2089, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27285612", "text": "In the current study, a cocktail of antisense morpholinos targeting exon 6 and exon 8 was designed and it restored dystrophin expression in body-wide skeletal muscles.", "offsetInBeginSection": 1309, "offsetInEndSection": 1476, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aac5469fcf4565872000005", "body": "What are 7 symptoms of yellow fever?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11000957", "http://www.ncbi.nlm.nih.gov/pubmed/23873723", "http://www.ncbi.nlm.nih.gov/pubmed/19868337", "http://www.ncbi.nlm.nih.gov/pubmed/24630625", "http://www.ncbi.nlm.nih.gov/pubmed/16117712", "http://www.ncbi.nlm.nih.gov/pubmed/30358370", "http://www.ncbi.nlm.nih.gov/pubmed/31077273", "http://www.ncbi.nlm.nih.gov/pubmed/8599063", "http://www.ncbi.nlm.nih.gov/pubmed/29634624", "http://www.ncbi.nlm.nih.gov/pubmed/20300380"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19868337", "text": "The injection of the yellow fever blood into ringtail monkeys, rabbits, cats, guatusas, weasels, and sloths among the mammalians, and pigeons, ground-doves, bluebirds, mantas, blackbirds, parrakeets, reedbirds, blancos, and toucans among the birds, gave negative results.", "offsetInBeginSection": 1427, "offsetInEndSection": 1698, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19868337", "text": "In the blood, liver, and kidneys of the guinea pigs experimentally infected with the blood of yellow fever patients a minute organism was demonstrated which closely resembles in morphology the causative agent of infectious jaundice (Leptospira icterohamorrhagiae).", "offsetInBeginSection": 1699, "offsetInEndSection": 1963, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19868337", "text": "By injecting into guinea pigs the blood of yellow fever cases occurring in Guayaquil a group of symptoms and lesions closely resembling those observed in human yellow fever were induced in a limited number of instances.", "offsetInBeginSection": 0, "offsetInEndSection": 219, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19868337", "text": "The leptospira transmitted from yellow fever cases to guinea pigs was found to induce similar symptoms and lesions upon further passage into normal guinea pigs.", "offsetInBeginSection": 1964, "offsetInEndSection": 2124, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20300380", "text": "Humoral immune response to yellow fever, Mayaro, Venezuelan equine encephalitis, Oropouche, and dengue 2 infection was assessed by evaluating IgM and IgG specific antibodies.", "offsetInBeginSection": 308, "offsetInEndSection": 482, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20300380", "text": "Clinical symptoms and signs observed among yellow fever cases are also described.", "offsetInBeginSection": 226, "offsetInEndSection": 307, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20300380", "text": "The association between clearing the rainforest and also being at the detachments with yellow fever infection confirms that clearing is the main factor in the jungle model of transmission, which takes place deep in the Amazonian rainforest.", "offsetInBeginSection": 1112, "offsetInEndSection": 1352, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28358796", "text": "Although not well-documented for this outbreak, malaria, viral hepatitis, and typhoid fever are common differential diagnoses among suspected yellow fever cases in this region.", "offsetInBeginSection": 900, "offsetInEndSection": 1076, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11000957", "text": "Yellow fever is an arthropod-borne disease with symptoms ranging from mild fever to acute hepatonephritis, hemorrhages and shock often fatal.", "offsetInBeginSection": 0, "offsetInEndSection": 141, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11000957", "text": "Yellow fever virus replicates in K\u00fcpffer cells and in hepatocytes in the liver.", "offsetInBeginSection": 255, "offsetInEndSection": 335, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac07b67dd95b2cd42000001", "body": "Is Lysyl oxidase crosslinking collagen?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/4531019", "http://www.ncbi.nlm.nih.gov/pubmed/7911384", "http://www.ncbi.nlm.nih.gov/pubmed/9402968", "http://www.ncbi.nlm.nih.gov/pubmed/28864775", "http://www.ncbi.nlm.nih.gov/pubmed/26918", "http://www.ncbi.nlm.nih.gov/pubmed/9401", "http://www.ncbi.nlm.nih.gov/pubmed/8555021", "http://www.ncbi.nlm.nih.gov/pubmed/2890532", "http://www.ncbi.nlm.nih.gov/pubmed/2866930", "http://www.ncbi.nlm.nih.gov/pubmed/9200411"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/2870873", "text": "These data indicate that although skin lysyl oxidase activity is decreased by glucocorticoid treatment, the crosslinking of acid extracted collagen as measured by the alpha/beta ratio and collagen solubility is increased.", "offsetInBeginSection": 556, "offsetInEndSection": 777, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/906929", "text": "Lysyl oxidase controls one of the initial steps in the crosslinking of elastin and collagen, i.e., the conversion of peptidyl lysine or hydroxylysine residues to peptidyl alpha-aminoadipic-delta-semialdehyde derivatives.", "offsetInBeginSection": 175, "offsetInEndSection": 395, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/906929", "text": "Nutritional copper deficiency effects marked changes in the crosslinking of collagen and elastin, presumably in relationship to copper's role as a cofactor for lysyl oxidase.", "offsetInBeginSection": 0, "offsetInEndSection": 174, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8096378", "text": "A decrease in the functional activity of lysyl oxidase, a cuproenzyme, is thought in part to be responsible for the decreased crosslinking of collagen and elastin.", "offsetInBeginSection": 185, "offsetInEndSection": 348, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/4531019", "text": "Lysyl oxidase catalyzes the formation of crosslinking aldehydes in collagen and elastin.", "offsetInBeginSection": 0, "offsetInEndSection": 88, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2890532", "text": "Lysyl oxidase, the only enzyme involved in collagen crosslinking, is shown to be present in embryos of the sea urchin Strongylocentrotus purpuratus.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2890532", "text": "The results suggest that lysyl oxidase and collagen crosslinking play a vital role in primary mesenchyme migration, gastrulation, and morphogenesis during sea urchin development and indicate that BAPN may be very useful in studying the extracellular matrix-cell interactions at the cellular and molecular level.", "offsetInBeginSection": 979, "offsetInEndSection": 1290, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26918", "text": "Lysyl oxidase catalyzes the crosslinking of collagen and elastin.", "offsetInBeginSection": 0, "offsetInEndSection": 65, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22633114", "text": "METHODS Protein and mRNA expression of major elastic fiber components (elastin, fibrillin-1, fibulin-4), collagens (types I, III, and IV), and lysyl oxidase crosslinking enzymes (LOX, LOXL1, LOXL2) were assessed in situ by quantitative real-time polymerase chain reaction, (immuno)histochemistry, and light and electron microscopy.", "offsetInBeginSection": 602, "offsetInEndSection": 933, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9524359", "text": "Lysyl oxidase (LO) is a copper-dependent amine oxidase that plays a critical role in the biogenesis of connective tissue matrices by crosslinking the extracellular matrix proteins, collagen and elastin.", "offsetInBeginSection": 0, "offsetInEndSection": 202, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abc9c1efcf4565872000020", "body": "How are deletion breakpoints defined?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11001932", "http://www.ncbi.nlm.nih.gov/pubmed/11477612", "http://www.ncbi.nlm.nih.gov/pubmed/1968791", "http://www.ncbi.nlm.nih.gov/pubmed/9184250", "http://www.ncbi.nlm.nih.gov/pubmed/21103668", "http://www.ncbi.nlm.nih.gov/pubmed/34251753", "http://www.ncbi.nlm.nih.gov/pubmed/19158820", "http://www.ncbi.nlm.nih.gov/pubmed/1684331", "http://www.ncbi.nlm.nih.gov/pubmed/3032452", "http://www.ncbi.nlm.nih.gov/pubmed/30864493"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/1741389", "text": "Therefore, the Fah gene maps within or proximal to the hsdr-1 locus, as defined by deletion breakpoints, and disruption of this gene may be partially or completely responsible for the phenotypes associated with the hsdr-1 deletion syndrome.", "offsetInBeginSection": 1225, "offsetInEndSection": 1465, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16293123", "text": "Subsequently, the deletion of exon 2 of the copper metabolism domain containing 1 (COMMD1) gene (formerly MURR1) was shown to be the major cause of copper toxicosis, although the deletion breakpoints were not defined.", "offsetInBeginSection": 282, "offsetInEndSection": 499, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16293123", "text": "The breakpoints were positioned at 65.3091 and 65.3489 Mb of dog chromosome 10, in intron 1 and intron 2 of COMMD1 respectively, a deletion of 39.7 kb.", "offsetInBeginSection": 685, "offsetInEndSection": 836, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11001932", "text": "By sequence-tagged site (STS) content mapping, we roughly defined deletion breakpoints in two unrelated, azoospermic men with AZFa deletions.", "offsetInBeginSection": 231, "offsetInEndSection": 372, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11336982", "text": "The deletion breakpoints were defined by a combination of long polymerase chain reaction (PCR) amplifications, and conventional PCR and DNA sequencing.", "offsetInBeginSection": 788, "offsetInEndSection": 939, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17351135", "text": "Deletions of proximal 22q11.2 comprise the most frequently occurring microdeletion syndrome, DiGeorge/Velocardiofacial syndrome (DGS/VCFS), in which most breakpoints have been localized to a 3 Mb region containing four large LCRs.", "offsetInBeginSection": 295, "offsetInEndSection": 525, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17351135", "text": "We used paralog-specific primers and long-range PCR to clone, sequence, and examine the distal deletion breakpoints from two patients with de novo deletions mapping to these distal LCRs.", "offsetInBeginSection": 655, "offsetInEndSection": 841, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17351135", "text": "Our results present definitive evidence of the direct involvement of LCRs in 22q11 deletions and map both breakpoints to the BCRL module, common to most 22q11 LCRs, suggesting a potential region for LCR-mediated rearrangement both in the distal LCRs and in the DGS interval.", "offsetInBeginSection": 842, "offsetInEndSection": 1116, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17351135", "text": "These are the first reported cases of distal 22q11 deletions in which breakpoints have been characterized at the nucleotide level within LCRs, confirming that distal 22q11 LCRs can and do mediate rearrangements leading to genomic disorders.", "offsetInBeginSection": 1117, "offsetInEndSection": 1357, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12297986", "text": "Deletion breakpoints, mechanisms, and lengths, as well as inventories of affected genes, have been elucidated for deletions of AZFa and of AZFc but not for deletions of AZFb or of AZFb plus AZFc.", "offsetInBeginSection": 300, "offsetInEndSection": 495, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac7185f0340b9f058000004", "body": "Which cellular functions are affected by lncRNA H19 in the heart?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27317124", "http://www.ncbi.nlm.nih.gov/pubmed/35413741", "http://www.ncbi.nlm.nih.gov/pubmed/30496976", "http://www.ncbi.nlm.nih.gov/pubmed/34313541", "http://www.ncbi.nlm.nih.gov/pubmed/34840062", "http://www.ncbi.nlm.nih.gov/pubmed/31588235", "http://www.ncbi.nlm.nih.gov/pubmed/27895893", "http://www.ncbi.nlm.nih.gov/pubmed/29621481", "http://www.ncbi.nlm.nih.gov/pubmed/27040767", "http://www.ncbi.nlm.nih.gov/pubmed/33221454"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27317124", "text": "Nine of these lncRNAs (CDKN2B-AS1/ANRIL, EGOT, H19, HOTAIR, LOC285194/TUSC7, RMRP, RNY5, SOX2-OT and SRA1) were also confirmed in end-stage failing hearts.", "offsetInBeginSection": 1181, "offsetInEndSection": 1336, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27895893", "text": "H19 suppressed miR-19b expression and miR-19b targeted Sox6, which inhibited cell proliferation and promoted apoptosis in P19CL6 cells during late-stage cardiac differentiation.", "offsetInBeginSection": 1058, "offsetInEndSection": 1235, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27895893", "text": "The levels of lncRNA H19 and miR-19b were detected by qRT-PCR.", "offsetInBeginSection": 456, "offsetInEndSection": 518, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26853553", "text": "To sum up, these observations indicate that the lncRNA H19 modulates Wnt/\u03b2-catenin pathway by acting as a competing endogenous RNA, which may shed light on the functional role of lncRNAs in coordinating osteogenesis.", "offsetInBeginSection": 1225, "offsetInEndSection": 1442, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28063931", "text": "We reported that the long noncoding RNA H19 (LncRNA H19) and LncRNA H19-derived microRNA (miR-675) are overexpressed in neointima of balloon-injured artery.", "offsetInBeginSection": 189, "offsetInEndSection": 345, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28063931", "text": "Gain-of-function studies showed that the overexpression of LncRNA H19 accelerated T/G HA-VSMC proliferation in\u00a0vitro.", "offsetInBeginSection": 807, "offsetInEndSection": 925, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28063931", "text": "Finally, the results of the rescue experiment indicated that LncRNA H19 promoted the proliferation of T/G HA-VSMC in a miR-675-dependent manner.", "offsetInBeginSection": 1024, "offsetInEndSection": 1168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27307343", "text": "These findings suggest that lncRNA H19 mediate atRA-induced CP in mice.", "offsetInBeginSection": 1022, "offsetInEndSection": 1093, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28881833", "text": "Thus, these results indicate that lncRNA H19 functions as an important mediator of BMP9 signaling by modulating Notch signaling-targeting miRNAs.", "offsetInBeginSection": 1350, "offsetInEndSection": 1495, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28881833", "text": "Our findings suggest that the well-coordinated biphasic expression of lncRNA H19 may be essential in BMP9-induced osteogenic differentiation of MSCs, and that dysregulated H19 expression may impair normal osteogenesis, leading to pathogenic processes, such as bone tumor development.", "offsetInBeginSection": 1496, "offsetInEndSection": 1779, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aae651ffcf456587200000d", "body": "What is the function of penicillinase, also known as beta lactamase?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3296577", "http://www.ncbi.nlm.nih.gov/pubmed/9360991", "http://www.ncbi.nlm.nih.gov/pubmed/219920", "http://www.ncbi.nlm.nih.gov/pubmed/7476560", "http://www.ncbi.nlm.nih.gov/pubmed/1629597", "http://www.ncbi.nlm.nih.gov/pubmed/11520032", "http://www.ncbi.nlm.nih.gov/pubmed/9249198", "http://www.ncbi.nlm.nih.gov/pubmed/2678526", "http://www.ncbi.nlm.nih.gov/pubmed/6606391", "http://www.ncbi.nlm.nih.gov/pubmed/19538149"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/806305", "text": "In both cases, we have shown the simultaneous biosynthesis of two enzymes: an inducible and chromosome cephalosporinase frequently found in this germ, and a constitutive beta lactamase, with a penicillinase activity which has been identified with the extrachromosomic beta lactamase R-TEM.", "offsetInBeginSection": 212, "offsetInEndSection": 501, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3541135", "text": "beta-Lactam resistance in Bacteroides fragilis is most commonly mediated by the production of beta-lactamase, primarily of the cephalosporinase type.", "offsetInBeginSection": 417, "offsetInEndSection": 566, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3877980", "text": "Beta-lactam resistance in Bacteroides fragilis is most commonly mediated by beta-lactamase production mainly of cephalosporinase character.", "offsetInBeginSection": 403, "offsetInEndSection": 542, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9624479", "text": "We conclude that the major beta-lactamase of M. tuberculosis is a class A beta-lactamase with predominant penicillinase activity.", "offsetInBeginSection": 1595, "offsetInEndSection": 1724, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9624479", "text": "A second, minor beta-lactamase with relatively greater cephalosporinase activity is also present.", "offsetInBeginSection": 1725, "offsetInEndSection": 1822, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11399858", "text": "BACKGROUND Mechanisms of borderline resistance of Staphylococcus aureus to penicillinase-resistant penicillins (PRPs) may include hyperproduction of classical penicillinase and/or production of beta-lactamase hydrolyzing also PRPs.", "offsetInBeginSection": 0, "offsetInEndSection": 231, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6448580", "text": "Supportive evidence included the abrogation of recipient effectiveness by the beta-lactamase inhibitor clavulanic acid and the elimination of a plasmid requirement with recipient strains carrying a chromosomal beta-lactamase determinant.", "offsetInBeginSection": 687, "offsetInEndSection": 924, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9158769", "text": "The more recent discovery of a PRP-hydrolyzing beta-lactamase (methicillinase) produced, in addition to the conventional penicillinase, by borderline S. aureus strains suggests that this second, more specific beta-lactamase is more likely to be responsible for the borderline phenotype than an increased amount of the penicillinase.", "offsetInBeginSection": 970, "offsetInEndSection": 1302, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/4985545", "text": "Such derepression also occurs in a strain of B. cereus very sensitive to penicillin and in which both uninduced as well as \"spore-peptide\"-induced beta-lactamase is a small fraction of that produced by the typical penicillinase producer.", "offsetInBeginSection": 1169, "offsetInEndSection": 1406, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/5473897", "text": "Induction of penicillinase (beta-lactamase) in Bacillus licheniformis 749 by 2-(2'-carboxyphenyl)-benzoyl-6-aminopenicillanic acid (CBAP) was examined, since this compound was reported to be a gratuitous inducer of penicillinase in Staphylococcus aureus.", "offsetInBeginSection": 0, "offsetInEndSection": 254, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac0817cd0c506ce46000001", "body": "Is p53 a transcription factor?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15734577", "http://www.ncbi.nlm.nih.gov/pubmed/29125602", "http://www.ncbi.nlm.nih.gov/pubmed/32322927", "http://www.ncbi.nlm.nih.gov/pubmed/17383232", "http://www.ncbi.nlm.nih.gov/pubmed/17957787", "http://www.ncbi.nlm.nih.gov/pubmed/31861395", "http://www.ncbi.nlm.nih.gov/pubmed/8418500", "http://www.ncbi.nlm.nih.gov/pubmed/31152661", "http://www.ncbi.nlm.nih.gov/pubmed/16618797", "http://www.ncbi.nlm.nih.gov/pubmed/32702132"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/7651386", "text": "p53, a transcription factor, controls the expression of genes, leading to cell cycle arrest and apoptosis.", "offsetInBeginSection": 135, "offsetInEndSection": 241, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9690516", "text": "The p53 protein is a transcription factor involved in processes of cell growth and differentiation.", "offsetInBeginSection": 0, "offsetInEndSection": 99, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9690516", "text": "Moreover, p53 cooperates with MyoD in the induction of MCK transcription.", "offsetInBeginSection": 635, "offsetInEndSection": 708, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9690516", "text": "The muscle creatine kinase (MCK) gene whose transcription is induced during muscle differentiation contains p53-binding sites.", "offsetInBeginSection": 100, "offsetInEndSection": 226, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29125602", "text": "p53 is a transcription factor that suppresses tumor growth through regulation of dozens of target genes with diverse biological functions.", "offsetInBeginSection": 0, "offsetInEndSection": 138, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9215863", "text": "p53 is a transcription factor which is involved in cell cycle regulation and apoptosis.", "offsetInBeginSection": 332, "offsetInEndSection": 419, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7478550", "text": "We now provide evidence that p53 can repress transcription from the SV40 promoter by disrupting DNA/protein complexes involving transcription factor Sp1.", "offsetInBeginSection": 684, "offsetInEndSection": 837, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21042708", "text": "Using microarray analysis, we have identified the transcription factor early growth response 2 (EGR2) as a target of the p53 family, specifically p53, p63 and p73.", "offsetInBeginSection": 283, "offsetInEndSection": 446, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21042708", "text": "Tumor suppressor p53 is a transcription factor that induces growth arrest and/or apoptosis in response to cellular stress.", "offsetInBeginSection": 0, "offsetInEndSection": 122, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17762884", "text": "A hPitx1 mutant (hPitx1-R141P) acting as a dominant inhibitor repressed p53 transcription.", "offsetInBeginSection": 597, "offsetInEndSection": 687, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abc9ecffcf4565872000021", "body": "Where do mitochondrial DNA deletion breakpoints tend to occur?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8836157", "http://www.ncbi.nlm.nih.gov/pubmed/29257976", "http://www.ncbi.nlm.nih.gov/pubmed/22661583", "http://www.ncbi.nlm.nih.gov/pubmed/15313545", "http://www.ncbi.nlm.nih.gov/pubmed/9128755", "http://www.ncbi.nlm.nih.gov/pubmed/2308845", "http://www.ncbi.nlm.nih.gov/pubmed/24115352", "http://www.ncbi.nlm.nih.gov/pubmed/9726008", "http://www.ncbi.nlm.nih.gov/pubmed/7605803", "http://www.ncbi.nlm.nih.gov/pubmed/8619128"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25124333", "text": "Guanine-quadruplex (GQ) DNA structures are associated with nuclear DNA instability in cancer; recent evidence indicates they can also form in mitochondrial nucleic acids, suggesting that these non-B DNA structures could be associated with mtDNA deletions.", "offsetInBeginSection": 188, "offsetInEndSection": 443, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25124333", "text": "Notably, the most frequent deletion breakpoints, including those of the \"common deletion\", are bounded by 2G QFP sequence motifs.", "offsetInBeginSection": 1734, "offsetInEndSection": 1863, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25193669", "text": "Circular dichroism and UV spectral analysis demonstrated that mitochondrial G-rich sequences near deletion breakpoints prevalent in human disease form G-quadruplex DNA structures.", "offsetInBeginSection": 823, "offsetInEndSection": 1002, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25193669", "text": "Mitochondrial DNA deletions are prominent in human genetic disorders, cancer, and aging.", "offsetInBeginSection": 0, "offsetInEndSection": 88, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25193669", "text": "A biochemical analysis of purified recombinant human Twinkle protein (gene product of c10orf2) showed that the mitochondrial replicative helicase inefficiently unwinds well characterized intermolecular and intramolecular G-quadruplex DNA substrates, as well as a unimolecular G4 substrate derived from a mitochondrial sequence that nests a deletion breakpoint described in human renal cell carcinoma.", "offsetInBeginSection": 1003, "offsetInEndSection": 1403, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22661583", "text": "Furthermore, we discover that the most frequent deletion breakpoints occur within or near predicted structures, a result that is supported by data from transgenic mice with mitochondrial disease.", "offsetInBeginSection": 653, "offsetInEndSection": 848, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22529999", "text": "Deletion mutations within mitochondrial DNA (mtDNA) have been implicated in degenerative and aging related conditions, such as sarcopenia and neuro-degeneration.", "offsetInBeginSection": 0, "offsetInEndSection": 161, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16432145", "text": "The deletion breakpoints cluster in a few regions that are similar to what is found in human mtDNA deletions in general.", "offsetInBeginSection": 598, "offsetInEndSection": 718, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7814031", "text": "Mitochondrial myopathies and encephalopathies can be caused by nucleotide substitutions, deletions or duplications of the mitochondrial DNA (mtDNA).", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2308845", "text": "Large-scale deletions of mitochondrial DNA (mtDNA) have been described in patients with progressive external ophthalmoplegia (PEO) and ragged red fibers.", "offsetInBeginSection": 0, "offsetInEndSection": 153, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac721230340b9f058000005", "body": "Name 4 circular RNA molecules associated with carcinogenesis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35667198", "http://www.ncbi.nlm.nih.gov/pubmed/31609809", "http://www.ncbi.nlm.nih.gov/pubmed/34222420", "http://www.ncbi.nlm.nih.gov/pubmed/34532284", "http://www.ncbi.nlm.nih.gov/pubmed/34722322", "http://www.ncbi.nlm.nih.gov/pubmed/35222721", "http://www.ncbi.nlm.nih.gov/pubmed/36159776", "http://www.ncbi.nlm.nih.gov/pubmed/28185365", "http://www.ncbi.nlm.nih.gov/pubmed/35223991", "http://www.ncbi.nlm.nih.gov/pubmed/34232319"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28185365", "text": "Circular RNAs (circRNAs) are a class of new-found RNA molecules that have a special covalent loop structure without a 5' cap and 3' tail.", "offsetInBeginSection": 0, "offsetInEndSection": 137, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28185365", "text": "By serving as sponges of microRNAs, interacting with long non-coding RNAs, mRNA, or proteins, circRNAs regulate gene expression at transcriptional and post-transcriptional levels and contribute to carcinogenesis.", "offsetInBeginSection": 388, "offsetInEndSection": 600, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28342987", "text": "Circular RNAs (circRNAs) are a type of non-coding RNA molecules that lack a 5'-terminal cap and 3'-terminal poly A tail.", "offsetInBeginSection": 0, "offsetInEndSection": 120, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9154796", "text": "In rat testis, a similar analysis allowed the detection of a circular RNA molecule composed of exons 6 and 7 of the androgen binding protein (ABP) gene, with the donor splice site of exon 7 joined to the acceptor splice site of exon 6, and of an ABP mRNA which had skipped exons 6 and 7.", "offsetInBeginSection": 813, "offsetInEndSection": 1100, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27429839", "text": "Circular RNAs (circRNAs) are a naturally occurring type of universal and diverse endogenous noncoding RNAs which unlike linear RNAs, have covalently linked ends.", "offsetInBeginSection": 0, "offsetInEndSection": 161, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27429839", "text": "Functional circRNAs have been identified to act as microRNA sponges and RNA-binding protein (RBP) sequestering agents as well as transcriptional regulators.", "offsetInBeginSection": 287, "offsetInEndSection": 443, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26874353", "text": "The circRNA-miRNA-mRNA axis is a known regulatory pattern of several cancer-associated pathways, with both agonist and antagonist effects on carcinogenesis.", "offsetInBeginSection": 948, "offsetInEndSection": 1104, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19010924", "text": "These antisense RNA molecules originate in the early region of the SV40 circular chromosome and proceed in antisense orientation into the late gene region, leading to the formation of highly unstable double-strand RNA, which is rapidly degraded.", "offsetInBeginSection": 846, "offsetInEndSection": 1091, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/850304", "text": "We conclude that the three size classes of RNA that comprise the Uukuniemi virus genome are circular molecules probably maintained in that form by base pairing between inverted complementary sequences at the 3' and 5' ends of linear molecules.", "offsetInBeginSection": 1170, "offsetInEndSection": 1413, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28253710", "text": "Circular RNAs (circRNAs) are a class of newly-identified non-coding RNA molecules.", "offsetInBeginSection": 0, "offsetInEndSection": 82, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ab147edfcf4565872000013", "body": "The Mantoux test detects what latent infection/disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11089393", "http://www.ncbi.nlm.nih.gov/pubmed/20843417", "http://www.ncbi.nlm.nih.gov/pubmed/23405647", "http://www.ncbi.nlm.nih.gov/pubmed/23128409", "http://www.ncbi.nlm.nih.gov/pubmed/21554229", "http://www.ncbi.nlm.nih.gov/pubmed/16307510", "http://www.ncbi.nlm.nih.gov/pubmed/35360823", "http://www.ncbi.nlm.nih.gov/pubmed/17158278", "http://www.ncbi.nlm.nih.gov/pubmed/17501976", "http://www.ncbi.nlm.nih.gov/pubmed/18322990"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17663901", "text": "Latent tuberculosis treatment was recommended in all Mantoux-positive contacts.", "offsetInBeginSection": 1552, "offsetInEndSection": 1631, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16307510", "text": "Until recently, the 100-year-old tuberculin skin test (Mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "offsetInBeginSection": 474, "offsetInEndSection": 657, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16307510", "text": "They are more sensitive than the tuberculin skin test in detecting people with active tuberculosis, and their results correlate more closely with M. tuberculosis exposure risk factors than the tuberculin skin test in people likely to have latent tuberculosis infection.", "offsetInBeginSection": 1037, "offsetInEndSection": 1306, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17158278", "text": "OBJECTIVE To compare the ability of the T-SPOT.TB (Oxford Immunotec, Abingdon, UK), QuantiFERON-TB Gold (Cellestis, Melbourne, Australia), and Mantoux tests to identify latent tuberculosis in HIV-infected and uninfected persons.", "offsetInBeginSection": 237, "offsetInEndSection": 465, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1983096", "text": "Individuals who are infected with human immunodeficiency virus (HIV) are at high risk of developing tuberculosis, probably due to the reactivation of latent infection associated with HIV-induced immunosuppression.", "offsetInBeginSection": 0, "offsetInEndSection": 213, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1983096", "text": "By subdividing HIV seropositive subjects in two groups (reactive and non-reactive to tuberculin test) a significant decrease of CD 4 lymphocytes and CD 4/CD 8 ratio was found in HIV seropositive/Mantoux non-reactive group, without changes in total lymphocytes and CD 8 subset.", "offsetInBeginSection": 999, "offsetInEndSection": 1275, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10524588", "text": "CONCLUSION Mantoux test results suggest that this group of homeless people had a high prevalence of infection with the tubercle bacillus.", "offsetInBeginSection": 998, "offsetInEndSection": 1135, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10524588", "text": "Many aspects of the physical and social circumstances of homeless people predispose to reactivation and have the potential to enhance rapid spread should latent infection become active disease.", "offsetInBeginSection": 1136, "offsetInEndSection": 1329, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18579028", "text": "In Mantoux positive patients, it is very useful for ruling-out false positives due to BCG-vaccination and/or non-tuberculous mycobacterial infection.", "offsetInBeginSection": 1395, "offsetInEndSection": 1544, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18579028", "text": "CONCLUSIONS QFT test is suitable for routine latent tuberculosis diagnosis in hospital-based immunocompromised patients.", "offsetInBeginSection": 1123, "offsetInEndSection": 1243, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac08478d0c506ce46000002", "body": "What is the aim of  perfoming a \"cycloheximide chase assay\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29082276", "http://www.ncbi.nlm.nih.gov/pubmed/9143349", "http://www.ncbi.nlm.nih.gov/pubmed/30226276", "http://www.ncbi.nlm.nih.gov/pubmed/28660233", "http://www.ncbi.nlm.nih.gov/pubmed/19151744", "http://www.ncbi.nlm.nih.gov/pubmed/27167179", "http://www.ncbi.nlm.nih.gov/pubmed/34626566", "http://www.ncbi.nlm.nih.gov/pubmed/29122887", "http://www.ncbi.nlm.nih.gov/pubmed/27987332", "http://www.ncbi.nlm.nih.gov/pubmed/18008333"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29082276", "text": "Here we present a full cycloheximide chase assay in our laboratory using a lung adenocarcinoma cell line, CL1-5, as a model.", "offsetInBeginSection": 328, "offsetInEndSection": 452, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27167179", "text": "The cycloheximide chase procedure permits visualization of the degradation kinetics of the steady state population of a variety of cellular proteins.", "offsetInBeginSection": 1023, "offsetInEndSection": 1172, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19151744", "text": "The mechanism by which BAG-1 affected the function of Bcl-2 was exploredby using the cycloheximide chase assay.", "offsetInBeginSection": 730, "offsetInEndSection": 841, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19151744", "text": "Furthermore, the cycloheximide chase assay indicated that the degradation of Bcl-2 protein was extended in the BAG-1 p50 and p46 transfected MCF-7 cells.", "offsetInBeginSection": 1649, "offsetInEndSection": 1802, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27987332", "text": "In addition, cycloheximide chase assay revealed that the half-life of VE-cadherin protein was dramatically reduced by Cullin 3 depletion.", "offsetInBeginSection": 1249, "offsetInEndSection": 1386, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16081639", "text": "To address these potential mechanisms, metabolic pulse-chase labeling experiments and experiments in which the fate of previously synthesized GHR was followed by anti-GHR immunoblotting after cycloheximide treatment (cycloheximide chase experiments) were performed.", "offsetInBeginSection": 1391, "offsetInEndSection": 1656, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16925598", "text": "Finally, we show that Renilla luciferase may serve as a reporter of protein stability in a cycloheximide chase assay.", "offsetInBeginSection": 1244, "offsetInEndSection": 1361, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18008333", "text": "We determined the mechanism of AR downregulation with cycloheximide chase assays, proteasome inhibitor, and coimmunoprecipitation experiments.", "offsetInBeginSection": 678, "offsetInEndSection": 820, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27684355", "text": "Cycloheximide chase is combined with cell fractionation to examine the turnover rate of misfolding-prone proteins in various cellular fractions.", "offsetInBeginSection": 792, "offsetInEndSection": 936, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23432726", "text": "Finally, a cycloheximide chase assay indicated that coexpression of Chk11-365 decelerated the degradation of ectopically expressed RALT, but not that of the S250A mutant.", "offsetInBeginSection": 1087, "offsetInEndSection": 1257, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abcf6b9fcf4565872000027", "body": "What is caused by the ectopic expression of CTCF?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21465478", "http://www.ncbi.nlm.nih.gov/pubmed/11507042", "http://www.ncbi.nlm.nih.gov/pubmed/14980504", "http://www.ncbi.nlm.nih.gov/pubmed/15096508", "http://www.ncbi.nlm.nih.gov/pubmed/35167425", "http://www.ncbi.nlm.nih.gov/pubmed/21145498", "http://www.ncbi.nlm.nih.gov/pubmed/32232485", "http://www.ncbi.nlm.nih.gov/pubmed/34585664", "http://www.ncbi.nlm.nih.gov/pubmed/15941718", "http://www.ncbi.nlm.nih.gov/pubmed/26929370"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/11507042", "text": "The 11-zinc finger protein CCTC-binding factor (CTCF) employs different sets of zinc fingers to form distinct complexes with varying CTCF- target sequences (CTSs) that mediate the repression or activation of gene expression and the creation of hormone-responsive gene silencers and of diverse vertebrate enhancer-blocking elements (chromatin insulators).", "offsetInBeginSection": 0, "offsetInEndSection": 354, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356", "text": "Ectopic expression of Rad21 repressed CTCF-regulated transcription of KSHV lytic genes, and a Rad21-CTCF chimeric protein converted CTCF into an efficient transcriptional repressor of KSHV genes normally activated in the G(2) phase.", "offsetInBeginSection": 1173, "offsetInEndSection": 1405, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356", "text": "Deletion of the CTCF-cohesin binding site caused an inhibition of cell growth and viral genome instability.", "offsetInBeginSection": 676, "offsetInEndSection": 783, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21465478", "text": "Ectopic expression of CTCF in various normal and tumoral human cell lines inhibits cell division and clonogenicity, with the consequence to consider CTCF a potential tumor-suppressor factor.", "offsetInBeginSection": 120, "offsetInEndSection": 310, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28862757", "text": "Depletion of CTCF resulted in reduced motility and invasiveness in HCC cells that could be reversed by ectopic expression of FOXM1, suggesting that FOXM1 is one of the important downstream effectors of CTCF in HCC.", "offsetInBeginSection": 1014, "offsetInEndSection": 1228, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26929370", "text": "The presence of an ectopic CTCF-BS introduced by the retrovirus in tens of thousands of genomic locations has the potential to cause widespread abnormalities in host cell chromatin structure and gene expression.", "offsetInBeginSection": 1466, "offsetInEndSection": 1677, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26929370", "text": "CTCF is a zinc-finger protein that binds to an insulator region in genomic DNA and plays a fundamental role in controlling higher order chromatin structure and gene expression in vertebrate cells.", "offsetInBeginSection": 900, "offsetInEndSection": 1096, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26268681", "text": "Depletion of the BORIS gene leads to altered transcription of a large number of genes and the differentiation of K562 cells, while the ectopic expression of this CTCF paralog leads to specific changes in transcription in MCF7 cells.", "offsetInBeginSection": 834, "offsetInEndSection": 1066, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24725430", "text": "CCCTC-binding factor (CTCF), a highly conserved zinc finger protein, is a master organizer of genome spatial organization and has multiple functions in gene regulation.", "offsetInBeginSection": 0, "offsetInEndSection": 168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24725430", "text": "Moreover, vigilin is present at several known CTCF target sites, such as the promoter regions of c-myc and BRCA1, the locus control region of \u03b2-globin, and several regions within the Igf2/H19 locus.", "offsetInBeginSection": 620, "offsetInEndSection": 819, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ab2cdc5fcf4565872000016", "body": "Is sternotomy closure done using either a sternal ZipFix\u2122 implant  or conventional steel wire following cardiac surgery?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29548913", "http://www.ncbi.nlm.nih.gov/pubmed/23624983", "http://www.ncbi.nlm.nih.gov/pubmed/26290838", "http://www.ncbi.nlm.nih.gov/pubmed/20494064", "http://www.ncbi.nlm.nih.gov/pubmed/26153736", "http://www.ncbi.nlm.nih.gov/pubmed/30998904", "http://www.ncbi.nlm.nih.gov/pubmed/23006702", "http://www.ncbi.nlm.nih.gov/pubmed/16967378", "http://www.ncbi.nlm.nih.gov/pubmed/24889138", "http://www.ncbi.nlm.nih.gov/pubmed/34500523"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23624983", "text": "OBJECTIVES To determine the difference in sternal infection and other infectious events between conventional wire and cable-tie-based closure techniques post-sternotomy in a collective of patients after cardiac surgery.", "offsetInBeginSection": 0, "offsetInEndSection": 219, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26290838", "text": "METHODS Data were collected retrospectively on 1,354 patients who underwent sternal closure after major cardiac surgery, using either the multifilament cable wiring system or conventional steel wires between January 2009 and October 2010.", "offsetInBeginSection": 454, "offsetInEndSection": 692, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26290838", "text": "We aimed to compare conventional steel wiring to multifilament cable fixation for sternal closure in patients undergoing major cardiac surgery.", "offsetInBeginSection": 308, "offsetInEndSection": 451, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26290838", "text": "CONCLUSION The surgical outcomes of sternal closure using multifilament cable wires were comparable to those observed when conventional steel wires were used.", "offsetInBeginSection": 1473, "offsetInEndSection": 1631, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29075945", "text": "Sternal approximation in the historical control group was performed with conventional steel wire sutures.", "offsetInBeginSection": 425, "offsetInEndSection": 530, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29075945", "text": "Sternal closure was completed with conventional wire sutures in the first 148 patients (Group A) and with conventional wire sutures plus bone allografting in the subsequent 136 patients (Group B).", "offsetInBeginSection": 881, "offsetInEndSection": 1077, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16967378", "text": "RESULTS Conventional closure of primary sternotomy is done using many different methods, most often with surgical steel sutures (87 %) passed trans/peristernally (64 %).", "offsetInBeginSection": 565, "offsetInEndSection": 734, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20494064", "text": "PURPOSE Midline sternotomy remains the preferred technique for access in cardiac surgery.", "offsetInBeginSection": 0, "offsetInEndSection": 89, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27177262", "text": "Indications of sternal closure were similar.", "offsetInBeginSection": 944, "offsetInEndSection": 988, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15854093", "text": "The present prospective, randomized study was carried out to evaluate whether the reinforced sternal-closure system is an effective and safe fixation and approximation of the sternum in cardiac procedures, and to compare with the conventional sternal-closure method in elderly patients.", "offsetInBeginSection": 261, "offsetInEndSection": 547, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac09a7b19833b0d7b000001", "body": "Where is the EpCam protein mainly located?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27431859", "http://www.ncbi.nlm.nih.gov/pubmed/32046162", "http://www.ncbi.nlm.nih.gov/pubmed/33324790", "http://www.ncbi.nlm.nih.gov/pubmed/33416101", "http://www.ncbi.nlm.nih.gov/pubmed/25469266", "http://www.ncbi.nlm.nih.gov/pubmed/22391566", "http://www.ncbi.nlm.nih.gov/pubmed/26356670", "http://www.ncbi.nlm.nih.gov/pubmed/12926061", "http://www.ncbi.nlm.nih.gov/pubmed/16054130", "http://www.ncbi.nlm.nih.gov/pubmed/20974811"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21115857", "text": "Recently, germline deletions affecting the epithelial cell adhesion molecule (EPCAM) gene located upstream of MSH2 were identified as a novel mutational mechanism causing Lynch syndrome by epigenetic inactivation of the respective MSH2 allele.", "offsetInBeginSection": 156, "offsetInEndSection": 399, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23026194", "text": "Of interest, 3' exons deletions of the EPCAM gene, which is located upstream of MSH2 in chromosome 2, are associated with MSH2 promoter hypermethylation.", "offsetInBeginSection": 324, "offsetInEndSection": 477, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23026194", "text": "EPCAM protein, expressed in epithelial tissues, is encoded by the EPCAM/TACSTD1 gene.", "offsetInBeginSection": 478, "offsetInEndSection": 563, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26054340", "text": "Basolaterally located cld7 is enriched in glycolipid-enriched membrane domains (GEM), where it associates with EpCAM (EpC).", "offsetInBeginSection": 112, "offsetInEndSection": 235, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16054130", "text": "We recently described that in the metastasizing rat pancreatic carcinoma line BSp73ASML the cell-cell adhesion molecule EpCAM, CD44 variant isoforms and the tetraspanins D6.1A and CD9 form a complex that is located in glycolipid-enriched membrane microdomains.", "offsetInBeginSection": 0, "offsetInEndSection": 260, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22388758", "text": "Germline deletions affecting the epithelial cell adhesion molecule (EPCAM) gene lead to silencing of MSH2 and cause Lynch syndrome.", "offsetInBeginSection": 0, "offsetInEndSection": 131, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22388758", "text": "Moreover, we report lack of EPCAM protein expression in a colorectal adenoma, suggesting that EPCAM immunohistochemistry may detect EPCAM germline deletions already at a precancerous stage.", "offsetInBeginSection": 1335, "offsetInEndSection": 1524, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25893293", "text": "In liver tumors from animals modeling HBx- and HBV-mediated hepatocarcinogenesis, downregulation of chromatin regulating proteins SUZ12 and ZNF198 induces expression of several genes, including epithelial cell adhesion molecule (EpCAM).", "offsetInBeginSection": 178, "offsetInEndSection": 414, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25893293", "text": "In hepatocytes, EpCAM is silenced by polycomb repressive complex 2 (PRC2) and ZNF198/LSD1/Co-REST/HDAC1 chromatin-modifying complexes.", "offsetInBeginSection": 605, "offsetInEndSection": 739, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27431859", "text": "The epithelial cell adhesion molecule (EpCAM) is a type I glycoprotein located on the surface of epithelial cells.", "offsetInBeginSection": 0, "offsetInEndSection": 114, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac24f7595d0062724000003", "body": "Is transcription of eRNA bidirectional?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29760402", "http://www.ncbi.nlm.nih.gov/pubmed/33235186", "http://www.ncbi.nlm.nih.gov/pubmed/30447999", "http://www.ncbi.nlm.nih.gov/pubmed/23728302", "http://www.ncbi.nlm.nih.gov/pubmed/32810208", "http://www.ncbi.nlm.nih.gov/pubmed/34531317", "http://www.ncbi.nlm.nih.gov/pubmed/25810254", "http://www.ncbi.nlm.nih.gov/pubmed/25348400", "http://www.ncbi.nlm.nih.gov/pubmed/28533025", "http://www.ncbi.nlm.nih.gov/pubmed/29378788"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23728302", "text": "In addition to widespread transcription of long non-coding RNAs (lncRNAs) in mammalian cells, bidirectional ncRNAs are transcribed on enhancers, and are thus referred to as enhancer RNAs (eRNAs).", "offsetInBeginSection": 94, "offsetInEndSection": 289, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25810254", "text": "Dramatic changes also were seen in the chromatin, with an increase in total histone H3 occupancy throughout this region and a virtual loss of histone H3 Lys 4 trimethylation at the promoter following the eRNA knockdown.", "offsetInBeginSection": 1163, "offsetInEndSection": 1382, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24778216", "text": "Kallikrein-related peptidase 3 (KLK3), which codes for prostate-specific antigen (PSA), is a well-known AR-regulated gene and its upstream enhancers produce bidirectional enhancer RNAs (eRNAs), termed KLK3e.", "offsetInBeginSection": 226, "offsetInEndSection": 433, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25561718", "text": "eRNAs are distinct from long noncoding RNAs (lncRNAs), but these two species of noncoding RNAs may share a similar role in the activation of mRNA transcription.", "offsetInBeginSection": 134, "offsetInEndSection": 294, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25934506", "text": "XR-seq maps capture transcription-coupled repair at sites of divergent gene promoters and bidirectional enhancer RNA (eRNA) production at enhancers.", "offsetInBeginSection": 920, "offsetInEndSection": 1068, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27932455", "text": "Together, our findings suggest that eRNA accumulation at enhancer-promoter loops is not required to sustain target gene transcription.", "offsetInBeginSection": 1364, "offsetInEndSection": 1498, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27932455", "text": "Lastly, basal eRNA transcription at enhancers, but not E2-induced transcription, is maintained upon depletion of MLL1 and ER\u03b1, suggesting some degree of chromatin accessibility prior to signal-dependent activation of transcription.", "offsetInBeginSection": 1131, "offsetInEndSection": 1363, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23636943", "text": "We find that flavopiridol, a CDK9 inhibitor that blocks transcription elongation, inhibits eRNA production but does not affect other molecular indicators of enhancer activity, suggesting that eRNA production occurs after the assembly of active enhancers.", "offsetInBeginSection": 1038, "offsetInEndSection": 1292, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24909122", "text": "We identify 76 enhancer RNAs (eRNAs), 40 canonical lncRNAs, 65 antisense lncRNAs and 35 regions of bidirectional transcription (RBT) that are differentially expressed in response to bacterial lipopolysaccharide (LPS).", "offsetInBeginSection": 370, "offsetInEndSection": 587, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24909122", "text": "Crucially, we demonstrate that knockdown of nuclear-localized, NF-\u03baB-regulated, eRNAs (IL1\u03b2-eRNA) and RBT (IL1\u03b2-RBT46) surrounding the IL1\u03b2 locus, attenuates LPS-induced messenger RNA transcription and release of the proinflammatory mediators, IL1\u03b2 and CXCL8.", "offsetInBeginSection": 588, "offsetInEndSection": 852, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abbe429fcf456587200001c", "body": "What is the drug target for Eliquis (Apixaban)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27653758", "http://www.ncbi.nlm.nih.gov/pubmed/22686618", "http://www.ncbi.nlm.nih.gov/pubmed/24624626", "http://www.ncbi.nlm.nih.gov/pubmed/21985171", "http://www.ncbi.nlm.nih.gov/pubmed/31653627", "http://www.ncbi.nlm.nih.gov/pubmed/31958251", "http://www.ncbi.nlm.nih.gov/pubmed/23677804", "http://www.ncbi.nlm.nih.gov/pubmed/35032137", "http://www.ncbi.nlm.nih.gov/pubmed/22250655", "http://www.ncbi.nlm.nih.gov/pubmed/33660230"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23649961", "text": "The new oral anticoagulants (NOAC) include dabigatran etexilate (Pradaxa\u00ae), a direct thrombin inhibitor, and rivaroxaban (Xarelto\u00ae), Apixaban (Eliquis) and Edoxaban (Lixiana\u00ae), which are direct anti-Xa inhibitors.", "offsetInBeginSection": 245, "offsetInEndSection": 461, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26298448", "text": "STUDY OBJECTIVE Rivaroxaban and apixaban are part of a new group of oral anticoagulants targeting factor Xa and approved by the Food and Drug Administration in 2011 and 2012.", "offsetInBeginSection": 0, "offsetInEndSection": 174, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26298448", "text": "Bleeding was reported in\u00a015 patients (7%): 11 rivaroxaban and 4 apixaban.", "offsetInBeginSection": 1902, "offsetInEndSection": 1976, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23305476", "text": "New oral anticoagulants have been developed and among these, rivaroxaban, apixaban and dabigatran etexilate are in the most advanced stage of clinical development.", "offsetInBeginSection": 180, "offsetInEndSection": 343, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23305476", "text": "CONCLUSION Rivaroxaban, apixaban and dabigatran etexilate offer the possibility of simplified prevention and treatment strategies for thromboembolic disorders in the outpatient setting.", "offsetInBeginSection": 1652, "offsetInEndSection": 1837, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23821689", "text": "The new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) have predictable pharmacokinetic and pharmacodynamic profiles and are alternatives to warfarin.", "offsetInBeginSection": 0, "offsetInEndSection": 201, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28008269", "text": "The drugs were dabigatran etexilate mesylate (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa).", "offsetInBeginSection": 692, "offsetInEndSection": 814, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27984753", "text": "Apixaban and Tirofiban Hydrochloride are low molecular weight anticoagulants.", "offsetInBeginSection": 0, "offsetInEndSection": 77, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25195485", "text": "These new oral anticoagulants fall into two different categories: a direct thrombin inhibitor dabigatran etexilate (Pradaxa Boehringer-Ingelheim, Bracknell, Berkshire) and activated Factor X inhibitors rivaroxaban (Xarelto Bayer HealthCare, Newbury, Berkshire) and apixaban (Eliquis Bristol-Myers Squibb, Uxbridge, Middlesex).", "offsetInBeginSection": 364, "offsetInEndSection": 690, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26369819", "text": "Apixaban (Eliquis), rivaroxaban (Xarelto), and edoxaban (Savaysa) are the new Xa inhibitors that have been recently approved by the U.S. FDA and are in current clinical practice.", "offsetInBeginSection": 1764, "offsetInEndSection": 1942, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac0a36f19833b0d7b000002", "body": "What is an exosome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32578911", "http://www.ncbi.nlm.nih.gov/pubmed/25240800", "http://www.ncbi.nlm.nih.gov/pubmed/28733901", "http://www.ncbi.nlm.nih.gov/pubmed/20531389", "http://www.ncbi.nlm.nih.gov/pubmed/34069542", "http://www.ncbi.nlm.nih.gov/pubmed/15346807", "http://www.ncbi.nlm.nih.gov/pubmed/35988652", "http://www.ncbi.nlm.nih.gov/pubmed/16939780", "http://www.ncbi.nlm.nih.gov/pubmed/31768975", "http://www.ncbi.nlm.nih.gov/pubmed/22902556"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24462375", "text": "Exosomes from normal mammary epithelial cells also inhibit exosome secretion by breast cancer cells, which occurs in a tissue specific manner.", "offsetInBeginSection": 1116, "offsetInEndSection": 1258, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27599779", "text": "In conclusion, exosome levels may be useful as an independent prognostic factor for ESCC patients.", "offsetInBeginSection": 1462, "offsetInEndSection": 1560, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21618876", "text": "The exosome consists of a core often essential proteins that includes the ribonuclease Rrp44p and is present in both the cytoplasm and nucleus of eukaryotic cells.", "offsetInBeginSection": 0, "offsetInEndSection": 163, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21618876", "text": "The cytoplasmic exosome has been extensively characterized in the budding yeast Saccharomyces cerevisiae and some characterization of its metazoan counterpart indicates that most functional aspects are conserved.", "offsetInBeginSection": 164, "offsetInEndSection": 376, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21618876", "text": "For this, the exosome needs a set of four proteins that do not partake in nuclear exosome functions.", "offsetInBeginSection": 518, "offsetInEndSection": 618, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21713679", "text": "The exosome consists of a core of ten essential proteins that includes the ribonuclease Rrp44p and is present in both the cytoplasm and nucleus of eukaryotic cells.", "offsetInBeginSection": 0, "offsetInEndSection": 164, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21713679", "text": "The cytoplasmic exosome has been extensively characterized in the budding yeast Saccharomyces cerevisiae and some characterization of its metazoan counterpart indicates that most functional aspects are conserved.", "offsetInBeginSection": 165, "offsetInEndSection": 377, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21713679", "text": "For this, the exosome needs a set of four proteins that do not partake in nuclear exosome functions.", "offsetInBeginSection": 521, "offsetInEndSection": 621, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21713679", "text": "These studies have implicated the cytoplasmic exosome in the turnover of normal cellular mRNAs, as well as several mRNA surveillance pathways.", "offsetInBeginSection": 378, "offsetInEndSection": 520, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27756426", "text": "Exosome is an important part of TME.", "offsetInBeginSection": 151, "offsetInEndSection": 187, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac3699f0340b9f058000001", "body": "Are human enhancers or promoters evolving faster?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32579926", "http://www.ncbi.nlm.nih.gov/pubmed/29180706", "http://www.ncbi.nlm.nih.gov/pubmed/23827682", "http://www.ncbi.nlm.nih.gov/pubmed/36184520", "http://www.ncbi.nlm.nih.gov/pubmed/25745175", "http://www.ncbi.nlm.nih.gov/pubmed/33478249", "http://www.ncbi.nlm.nih.gov/pubmed/35594906", "http://www.ncbi.nlm.nih.gov/pubmed/25678556", "http://www.ncbi.nlm.nih.gov/pubmed/3016550", "http://www.ncbi.nlm.nih.gov/pubmed/19094206"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21282711", "text": "Promoters were primarily evolving under purifying selection but with certain categories of genes evolving faster.", "offsetInBeginSection": 1215, "offsetInEndSection": 1328, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12610136", "text": "To determine the effect of the human cytomegalovirus (CMV) major immediate-early (MIE) enhancer or promoter on the efficiency of viral replication in permissive human cells, we constructed recombinant viruses with their human MIE promoter, enhancer, and promoter plus enhancer replaced with the murine CMV components.", "offsetInBeginSection": 0, "offsetInEndSection": 317, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12610136", "text": "The effect of the human CMV enhancer substitution with the murine CMV enhancer was also demonstrated in different cell types by using recombinant virus with the UL127 promoter, driving the expression of green fluorescent protein (GFP).", "offsetInBeginSection": 668, "offsetInEndSection": 903, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12610136", "text": "After an MOI of 1, GFP expression was high with the human CMV enhancer and significantly lower with the murine CMV enhancer.", "offsetInBeginSection": 904, "offsetInEndSection": 1028, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1668145", "text": "The promoters and enhancers of cell type-specific genes are often conserved in evolution, and hence one might expect that a given enhancer has evolved to work best with its own promoter.", "offsetInBeginSection": 0, "offsetInEndSection": 186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28116828", "text": "During metazoan evolution, constitutive-type promoters of regulatory genes would have acquired novel receptivity to distal regulatory inputs from promoters of inducible genes that eventually specialized as enhancers.", "offsetInBeginSection": 905, "offsetInEndSection": 1121, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28116828", "text": "Promoters and enhancers are functionally similar; both can regulate the transcription of distal promoters and both direct local transcription.", "offsetInBeginSection": 461, "offsetInEndSection": 603, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28116828", "text": "Additionally, enhancers have experimentally characterized structural features that reveal their origin from inducible promoters.", "offsetInBeginSection": 604, "offsetInEndSection": 732, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21457775", "text": "Furthermore, we identified over-represented motifs, some of which displayed the highest similarity to motifs abundant in human RPG promoters and not present in Drosophila or yeast.", "offsetInBeginSection": 613, "offsetInEndSection": 793, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21326370", "text": "Moreover, a strong TATA \"motif\" was evident in the core region within the functional CArG elements in both human and mouse promoters.", "offsetInBeginSection": 599, "offsetInEndSection": 732, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abbfd97fcf456587200001d", "body": "What is the Formalin test used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31489182", "http://www.ncbi.nlm.nih.gov/pubmed/8731171", "http://www.ncbi.nlm.nih.gov/pubmed/1484716", "http://www.ncbi.nlm.nih.gov/pubmed/20832171", "http://www.ncbi.nlm.nih.gov/pubmed/17166125", "http://www.ncbi.nlm.nih.gov/pubmed/10568865", "http://www.ncbi.nlm.nih.gov/pubmed/23308208", "http://www.ncbi.nlm.nih.gov/pubmed/16860855", "http://www.ncbi.nlm.nih.gov/pubmed/9803050", "http://www.ncbi.nlm.nih.gov/pubmed/16492837"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17166125", "text": "A pharmacological validation of the formalin test and the CCI model in gerbils was performed.", "offsetInBeginSection": 202, "offsetInEndSection": 295, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17166125", "text": "Tramadol and CP-96345 tend to have more activity in the second phase of the formalin test, whereas morphine, SR-48968, SR-142801 and R116301 demonstrates to be more active in the cold plate test.", "offsetInBeginSection": 1284, "offsetInEndSection": 1479, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17166125", "text": "Clonidine tends to have more activity in the second phase of the formalin test, whereas baclofen, tramadol, amitryptiline, ketamine and topiramate demonstrate to be more active in the cold plate.", "offsetInBeginSection": 989, "offsetInEndSection": 1184, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16492837", "text": "This is a demonstration of USV during the formalin test, allowing the inclusion of an additional nonreflex behavioral measure to help characterize more clinically relevant integrated behavioral patterns in this rat model of pain.", "offsetInBeginSection": 1092, "offsetInEndSection": 1321, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19168051", "text": "The formalin test is used as a primary behavioural screen for assaying the antinociceptive activity of compounds in laboratory rodents.", "offsetInBeginSection": 0, "offsetInEndSection": 135, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15105218", "text": "For the formalin test, 50 microL of 5% formalin solution was injected into the hindpaw.", "offsetInBeginSection": 363, "offsetInEndSection": 450, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18799335", "text": "The ED(50) values for gabapentin and tiagabine, administered singly, in the phase I of the formalin test were 29.59 and 2mg/kg, whereas in the phase II of the formalin test were 8.22 and 0.50 mg/kg, respectively.", "offsetInBeginSection": 681, "offsetInEndSection": 893, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11226110", "text": "In the present study, using isobolographic analysis, we investigated the antinociceptive interaction of intrathecal clonidine and lidocaine in the rat formalin test.", "offsetInBeginSection": 279, "offsetInEndSection": 444, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11226110", "text": "Spinal lidocaine produced dose-dependent suppression of phase-2 activity in the formalin test.", "offsetInBeginSection": 1147, "offsetInEndSection": 1241, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9431444", "text": "We describe here a new, simple method of a subcutaneous application of formalin in conscious rats without restraint and needle insertion.", "offsetInBeginSection": 462, "offsetInEndSection": 599, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac2776195d0062724000006", "body": "List diseases caused by protein glutamine expanded repeats", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10098399", "http://www.ncbi.nlm.nih.gov/pubmed/21610160", "http://www.ncbi.nlm.nih.gov/pubmed/9635424", "http://www.ncbi.nlm.nih.gov/pubmed/15642849", "http://www.ncbi.nlm.nih.gov/pubmed/9536080", "http://www.ncbi.nlm.nih.gov/pubmed/32963411", "http://www.ncbi.nlm.nih.gov/pubmed/18216249", "http://www.ncbi.nlm.nih.gov/pubmed/8202492", "http://www.ncbi.nlm.nih.gov/pubmed/7581375", "http://www.ncbi.nlm.nih.gov/pubmed/11607033"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/9932422", "text": "Eight diseases are now known to be caused by an expansion mutation of the trinucleotide repeat CAG encoding glutamine.", "offsetInBeginSection": 0, "offsetInEndSection": 118, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9536080", "text": "Huntington's disease (HD) is caused by expansion of a glutamine repeat in huntingtin.", "offsetInBeginSection": 0, "offsetInEndSection": 85, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21933837", "text": "The CAG repeat specifies glutamine, and the expanded polyQ domain mutation confers dominant toxicity on the protein.", "offsetInBeginSection": 169, "offsetInEndSection": 285, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11200958", "text": "The trinucleotide CAG codes for the amino acid glutamine and the expanded CAG repeats are translated into a series of uninterrupted glutamine residues (a polyglutamine tract).", "offsetInBeginSection": 382, "offsetInEndSection": 557, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8980137", "text": "Five neurodegenerative diseases are caused by proteins with expanded polyglutamine domains.", "offsetInBeginSection": 0, "offsetInEndSection": 91, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8202492", "text": "Four inherited neurodegenerative diseases are linked to abnormally expanded repeats of glutamine residues in the affected proteins.", "offsetInBeginSection": 0, "offsetInEndSection": 131, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19692580", "text": "The expanded glutamine AR also altered hormone-dependent splicing of a calcitonin/calcitonin gene-related peptide minigene, suggesting that toxicity of the mutant protein additionally affects RNA processing pathways that are distinct from those regulated by CUGBP1.", "offsetInBeginSection": 1171, "offsetInEndSection": 1436, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9536081", "text": "Huntington's disease (HD) is a progressive neurodegenerative disorder caused by an expanding CAG repeat coding for polyglutamine in the huntingtin protein.", "offsetInBeginSection": 0, "offsetInEndSection": 155, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7604023", "text": "Many transcription factors and some other proteins contain glutamine repeats; their abnormal expansion has been linked to several dominantly inherited neuro-degenerative diseases.", "offsetInBeginSection": 0, "offsetInEndSection": 179, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7604023", "text": "Pathological effects may arise when expanded glutamine repeats cause proteins to acquire excessively high affinities for each other or for other proteins with glutamine repeats.", "offsetInBeginSection": 1479, "offsetInEndSection": 1656, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac37afc0340b9f058000002", "body": "What type of sequences do enhancers evolve from?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30842209", "http://www.ncbi.nlm.nih.gov/pubmed/34706247", "http://www.ncbi.nlm.nih.gov/pubmed/33154111", "http://www.ncbi.nlm.nih.gov/pubmed/33973014", "http://www.ncbi.nlm.nih.gov/pubmed/24714811", "http://www.ncbi.nlm.nih.gov/pubmed/33782603", "http://www.ncbi.nlm.nih.gov/pubmed/12028779", "http://www.ncbi.nlm.nih.gov/pubmed/30045748", "http://www.ncbi.nlm.nih.gov/pubmed/23281795", "http://www.ncbi.nlm.nih.gov/pubmed/25956793"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21593416", "text": "We suggest that the novel optic lobe enhancer evolved by exploiting the cryptic activity of extant regulatory sequences, and this may reflect a general mechanism whereby new enhancers evolve.", "offsetInBeginSection": 1283, "offsetInEndSection": 1474, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21593416", "text": "Dissection of the Nep1 cis-regulatory region localized a newly derived optic lobe enhancer activity to a region of an intron that has accumulated a small number of mutations.", "offsetInBeginSection": 994, "offsetInEndSection": 1168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28760812", "text": "Although many studies have elucidated how individual enhancers can evolve, most of this work has focused on what are called 'minimal' enhancers, the smallest DNA regions that drive expression that approximates an aspect of native gene expression.", "offsetInBeginSection": 93, "offsetInEndSection": 339, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21798176", "text": "The results show that the repetitive sequences are rapidly evolving in the S. purpuratus genome and may serve as a renewable pool of transcriptional enhancers.", "offsetInBeginSection": 1249, "offsetInEndSection": 1408, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21798176", "text": "We identified short, conserved motifs within the repetitive sequences that may represent novel cis-regulatory elements.", "offsetInBeginSection": 1008, "offsetInEndSection": 1127, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2134678", "text": "These findings suggest that new and more efficient enhancers evolve by a combination of basic enhancer elements.", "offsetInBeginSection": 811, "offsetInEndSection": 923, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21151964", "text": "cis-regulatory DNA sequences known as enhancers control gene expression in space and time.", "offsetInBeginSection": 0, "offsetInEndSection": 90, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1668145", "text": "The promoters and enhancers of cell type-specific genes are often conserved in evolution, and hence one might expect that a given enhancer has evolved to work best with its own promoter.", "offsetInBeginSection": 0, "offsetInEndSection": 186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15014138", "text": "The starting sequences considered are either real enhancers from the Drosophila melanogaster genome, or randomized versions of these.", "offsetInBeginSection": 877, "offsetInEndSection": 1010, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15014138", "text": "One way in which changes in gene expression can evolve is through the acquisition of new transcription factor targets in enhancer sequences.", "offsetInBeginSection": 260, "offsetInEndSection": 400, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abcf66afcf4565872000026", "body": "What is Dupuytren's contracture?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32684695", "http://www.ncbi.nlm.nih.gov/pubmed/18847012", "http://www.ncbi.nlm.nih.gov/pubmed/31781455", "http://www.ncbi.nlm.nih.gov/pubmed/30161050", "http://www.ncbi.nlm.nih.gov/pubmed/21935843", "http://www.ncbi.nlm.nih.gov/pubmed/34722869", "http://www.ncbi.nlm.nih.gov/pubmed/34754930", "http://www.ncbi.nlm.nih.gov/pubmed/32629785", "http://www.ncbi.nlm.nih.gov/pubmed/8074370", "http://www.ncbi.nlm.nih.gov/pubmed/22872850"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21935843", "text": "A short while ago Collagenase clostridium histolyticum was licensed as a non-surgical method to treat Dupuytren's contracture.", "offsetInBeginSection": 202, "offsetInEndSection": 328, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10409813", "text": "It is well known that Dupuytren's contracture is often associated with diabetes mellitus.", "offsetInBeginSection": 0, "offsetInEndSection": 89, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20676061", "text": "Some of the miRNAs identified in our Dupuytren's contracture samples, including miR-29c, miR-130b, miR-101, miR-30b, and miR-140-3p, were found to regulate important genes related to the \u03b2-catenin pathway: WNT5A, ZIC1, and TGFB1.", "offsetInBeginSection": 766, "offsetInEndSection": 996, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20676061", "text": "Identification of unique miRNA expression in Dupuytren's contracture may lead to the development of novel molecular therapy for its treatment.", "offsetInBeginSection": 1379, "offsetInEndSection": 1521, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6130030", "text": "These characteristic features; existence of myofibroblasts and intracellular collagen fibrils and increase in the activity of lysyl oxidase probably play a significant role in the establishment of flexion contracture of the fingers in Dupuytren's contracture.", "offsetInBeginSection": 1260, "offsetInEndSection": 1519, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18080603", "text": "BACKGROUND Dupuytren's contracture is one of the manifestations of the hand syndrome in diabetes mellitus (DM).", "offsetInBeginSection": 0, "offsetInEndSection": 111, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18080603", "text": "CONCLUSION Dupuytren's contracture is a rare presentation of diabetic hand syndrome.", "offsetInBeginSection": 1096, "offsetInEndSection": 1180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23908426", "text": "In Canada, Dupuytren's contracture is managed with partial fasciectomy or percutaneous needle aponeurotomy (PNA).", "offsetInBeginSection": 0, "offsetInEndSection": 113, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23908426", "text": "In summary, our model supports the trend towards non-surgical interventions for managing Dupuytren's contracture affecting a single finger.", "offsetInBeginSection": 1242, "offsetInEndSection": 1381, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1616255", "text": "During ischaemia, adenosine triphosphate (ATP) is converted to hypoxanthine and xanthine, and endothelial xanthine dehydrogenase to xanthine oxidase (alcohol also mediates this change, a finding of particular relevance given the association of Dupuytren's contracture with alcohol intake).", "offsetInBeginSection": 526, "offsetInEndSection": 815, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ad243e30340b9f058000016", "body": "What is the function of LOX proteins in the ECM?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31766500", "http://www.ncbi.nlm.nih.gov/pubmed/32693113", "http://www.ncbi.nlm.nih.gov/pubmed/36293126", "http://www.ncbi.nlm.nih.gov/pubmed/17471532", "http://www.ncbi.nlm.nih.gov/pubmed/28428687", "http://www.ncbi.nlm.nih.gov/pubmed/26024311", "http://www.ncbi.nlm.nih.gov/pubmed/29758265", "http://www.ncbi.nlm.nih.gov/pubmed/31130685", "http://www.ncbi.nlm.nih.gov/pubmed/31504232", "http://www.ncbi.nlm.nih.gov/pubmed/17981747"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17931358", "text": "While the catalytic function of LOX is essential for cross-linking of ECM proteins, we also reported that LOX induced invasive and metastatic properties in breast tumour epithelial cells through hydrogen peroxide-mediated FAK/Src activation.", "offsetInBeginSection": 404, "offsetInEndSection": 645, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26024311", "text": "Considering the current knowledge on the function of mammalian LOX isoforms in ECM remodeling, we propose that LOXL2/L3/L4 members might have preferentially been involved in making cross-linked collagen IV-based basement membrane, whereas the diversification of LOX/L1/L5 forms contributed to chordate/vertebrate-specific ECM innovations, such as elastin and fibronectin.", "offsetInBeginSection": 897, "offsetInEndSection": 1268, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24348049", "text": "The family of lysyl oxidase (LOX) enzymes cross-links collagens and elastin and, therefore, is a central player in ECM deposition and maturation.", "offsetInBeginSection": 207, "offsetInEndSection": 352, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16085123", "text": "Lysyl oxidase (LOX) is a copper- and lysyl-tyrosyl cofactor containing amine oxidase that has been known to play a critical role in the catalysis of lysine-derived crosslinks in extracellular matrix (ECM) proteins in the dermis.", "offsetInBeginSection": 0, "offsetInEndSection": 228, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27899976", "text": "Therefore, LOX expression level in the ECM may function as an independent predictor of Pca.", "offsetInBeginSection": 1018, "offsetInEndSection": 1109, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27899976", "text": "Remodeling of the extracellular matrix (ECM), which is induced by lysyl oxidase (LOX), has been demonstrated to accompany tumor progression; however, the association between LOX expression levels and the malignant behavior of prostate cancer (Pca) remains unclear.", "offsetInBeginSection": 0, "offsetInEndSection": 264, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25349139", "text": "The present study reported the effect of TM on the expression of LOX proteins (LOX, LOXL1, and LOXL2), collagen digestion enzymes (MMP2 and MMP8), and TIMP1 (a collagenase inhibitor) in PF.", "offsetInBeginSection": 322, "offsetInEndSection": 511, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25349139", "text": "The members of the copper-dependent lysyl oxidase (LOX) enzyme family regulate the collagen accumulation in the ECM.", "offsetInBeginSection": 159, "offsetInEndSection": 275, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26582054", "text": "A hallmark of heart failure (HF) is adverse extracellular matrix (ECM) remodeling, which is regulated by the collagen cross-linking enzyme, lysyl oxidase (LOX).", "offsetInBeginSection": 0, "offsetInEndSection": 160, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28273952", "text": "Lysyl oxidase (LOX) and LOX-like (LOXL) proteins play crucial roles in ECM remodeling due to their collagen crosslinking and intracellular functions.", "offsetInBeginSection": 136, "offsetInEndSection": 285, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ace12be0340b9f058000007", "body": "Which gene is responsible for proper speech development?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20571508", "http://www.ncbi.nlm.nih.gov/pubmed/26980647", "http://www.ncbi.nlm.nih.gov/pubmed/25269856", "http://www.ncbi.nlm.nih.gov/pubmed/18554997", "http://www.ncbi.nlm.nih.gov/pubmed/15983371", "http://www.ncbi.nlm.nih.gov/pubmed/11586359", "http://www.ncbi.nlm.nih.gov/pubmed/17574010", "http://www.ncbi.nlm.nih.gov/pubmed/17565757", "http://www.ncbi.nlm.nih.gov/pubmed/27793714", "http://www.ncbi.nlm.nih.gov/pubmed/23099646"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20571508", "text": "This patient presented with speech and motor developmental delays, a Chiari I malformation, and epileptiform discharges.", "offsetInBeginSection": 686, "offsetInEndSection": 806, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20571508", "text": "These findings suggest the possibility that FOXP1 may also contribute to proper speech development.", "offsetInBeginSection": 282, "offsetInEndSection": 381, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26980647", "text": "The FOXP2 gene is important for the development of proper speech motor control in humans.", "offsetInBeginSection": 0, "offsetInEndSection": 89, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22644823", "text": "Therefore early diagnosis and treatment with rehabilitation of hearing loss is important for proper speech development.", "offsetInBeginSection": 351, "offsetInEndSection": 470, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27771768", "text": "Patients harboring biallelic CIB2 mutations suffer from bilateral, early onset, moderate to profound HI.", "offsetInBeginSection": 1094, "offsetInEndSection": 1198, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25269856", "text": "BACKGROUND Mutations in the human FOXP2 gene cause speech and language impairments.", "offsetInBeginSection": 0, "offsetInEndSection": 83, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25269856", "text": "An adequate amount of functional FOXP2 protein is thought to be critical for the proper development of the neural circuitry underlying speech and language.", "offsetInBeginSection": 259, "offsetInEndSection": 414, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25269856", "text": "CONCLUSIONS Our results reveal novel regulatory functions of the human FOXP2 3' UTR sequence and regulatory interactions between multiple miRNAs and the human FOXP2 gene.", "offsetInBeginSection": 1168, "offsetInEndSection": 1338, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17565757", "text": "Although deletion and duplication of the WBS region have very different effects, both cause forms of language impairment and suggest that dosage-sensitive genes within the region are important for the proper development of human speech and language.", "offsetInBeginSection": 815, "offsetInEndSection": 1064, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21108403", "text": "CNTNAP2 is known to be involved in the cause of language and speech disorders and autism spectrum disorder and is in the same pathway as FOXP2, another important language gene, which makes it a candidate gene for causal studies speech and language disorders such as stuttering.", "offsetInBeginSection": 1133, "offsetInEndSection": 1410, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abcf755fcf4565872000028", "body": "Please list 3 diseases treated with Valtrex(valacyclovir)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11270274", "http://www.ncbi.nlm.nih.gov/pubmed/20691421", "http://www.ncbi.nlm.nih.gov/pubmed/16043964", "http://www.ncbi.nlm.nih.gov/pubmed/33572409", "http://www.ncbi.nlm.nih.gov/pubmed/22947428", "http://www.ncbi.nlm.nih.gov/pubmed/10887644", "http://www.ncbi.nlm.nih.gov/pubmed/18561175", "http://www.ncbi.nlm.nih.gov/pubmed/10320384", "http://www.ncbi.nlm.nih.gov/pubmed/16771614", "http://www.ncbi.nlm.nih.gov/pubmed/11772333"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28089147", "text": "Drug coated balloon (DCB) angioplasty has been shown to be a promising option in treatment of ISR.", "offsetInBeginSection": 92, "offsetInEndSection": 190, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28961065", "text": "As such, new findings linking mitochondrial function to the progression or outcome of this ever-increasing list of diseases has stimulated the discovery and development of the first true mitochondrial drugs, which are now entering the clinic and are discussed in this review.", "offsetInBeginSection": 818, "offsetInEndSection": 1093, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28961065", "text": "Diseases defined by mitochondrial dysfunction have also expanded from rare monogenic disorders in a strict sense to now also include many common polygenic diseases, including metabolic, cardiovascular, neurodegenerative, and neuromuscular diseases.", "offsetInBeginSection": 296, "offsetInEndSection": 544, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9589847", "text": "Many of these diseases require the use of nonsteroidal anti-inflammatory agents, well known to provoke wheezing in patients with intrinsic asthma, and diseases of the eye and cardiovascular system frequently require use of beta-blockers which can cause or exacerbate asthma.", "offsetInBeginSection": 723, "offsetInEndSection": 997, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9589847", "text": "The treatment for asthma usually involves a combination of drugs used for bronchodilation and to treat underlying airway inflammation.", "offsetInBeginSection": 0, "offsetInEndSection": 134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9589847", "text": "As patients with asthma get older, their medication regimen can become even more complex with the development of numerous other age-related diseases requiring their own list of medications.", "offsetInBeginSection": 284, "offsetInEndSection": 473, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9589847", "text": "When asthma is severe, the regimen used to treat asthma can become quite complicated, often using as many as 3 or 4 separate pharmacological agents.", "offsetInBeginSection": 135, "offsetInEndSection": 283, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9589847", "text": "Diseases of the joints, diseases of the eye, cardiovascular disease, neurological disease and urological problems represent the most common conditions that patients develop, at times needing medications which might interfere with asthma management.", "offsetInBeginSection": 474, "offsetInEndSection": 722, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24284060", "text": "Similar results were obtained with HepG2 cells, treated in vitro with DNA-methyltransferase inhibitor 5-aza-2'deoxicytidine.", "offsetInBeginSection": 1220, "offsetInEndSection": 1344, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17009693", "text": "Recently, a new occupational diseases list has been submitted to the Labour Ministry for approval.", "offsetInBeginSection": 461, "offsetInEndSection": 559, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ad35933133db5eb78000001", "body": "Is the protein pelota a ribosomal rescue factor?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25061210", "http://www.ncbi.nlm.nih.gov/pubmed/27863242", "http://www.ncbi.nlm.nih.gov/pubmed/27493551", "http://www.ncbi.nlm.nih.gov/pubmed/23031510", "http://www.ncbi.nlm.nih.gov/pubmed/33815344", "http://www.ncbi.nlm.nih.gov/pubmed/25233460", "http://www.ncbi.nlm.nih.gov/pubmed/2643515", "http://www.ncbi.nlm.nih.gov/pubmed/30527974", "http://www.ncbi.nlm.nih.gov/pubmed/31110136", "http://www.ncbi.nlm.nih.gov/pubmed/29771278"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27493551", "text": "In eukaryotes, Pelota (Dom34 in yeast) and Hbs1 are responsible for solving general problems of ribosomal stall in translation.", "offsetInBeginSection": 271, "offsetInEndSection": 398, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25061210", "text": "Here, we discover that loss of GTPBP2, a novel binding partner of the ribosome recycling protein Pelota, in mice with a mutation in a tRNA gene that is specifically expressed in the central nervous system causes ribosome stalling and widespread neurodegeneration.", "offsetInBeginSection": 308, "offsetInEndSection": 571, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9584085", "text": "A Drosophila homolog of Dom34p, pelota, is required for the proper coordination of meiosis and spermatogenesis.", "offsetInBeginSection": 677, "offsetInEndSection": 788, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28213379", "text": "Our data suggest that the decay of platelet mRNAs is slowed by the natural loss of the mRNA surveillance and ribosome rescue factor Pelota.", "offsetInBeginSection": 813, "offsetInEndSection": 952, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23031510", "text": "Both termination and ribosome rescue are mediated by class I release factors (eRF1/aRF1 in eukaryotic/archaeal termination) or their paralogs (Pelota/aPelota for ribosome rescue) and homologs of translational GTPases (eRF3/aEF1\u03b1 in termination, Hbs1/aEF1\u03b1 in ribosome rescue).", "offsetInBeginSection": 333, "offsetInEndSection": 611, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8900058", "text": "An open reading frame (pelA) specifying a homolog of pelota and DOM34, proteins required for meiotic cell division in Drosophila melanogaster and Saccharomyces cerevisiae, respectively, has been cloned, sequenced and identified from the archaebacterium Sulfolobus solfataricus.", "offsetInBeginSection": 0, "offsetInEndSection": 277, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8900058", "text": "The S. solfataricus PelA protein is about 20% identical with pelota, DOM34 and the hypothetical protein R74.6 of Caenorhabditis elegans.", "offsetInBeginSection": 278, "offsetInEndSection": 414, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20876129", "text": "In eukaryotes, the protein complex of Pelota (yeast Dom34) and Hbs1 translational GTPase recognizes the stalled ribosome containing the defective mRNA.", "offsetInBeginSection": 183, "offsetInEndSection": 334, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20876129", "text": "Recently, we found that archaeal Pelota (aPelota) associates with archaeal elongation factor 1\u03b1 (aEF1\u03b1) to act in the mRNA surveillance pathway, which accounts for the lack of an Hbs1 ortholog in archaea.", "offsetInBeginSection": 335, "offsetInEndSection": 541, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22909071", "text": "A small protein, ArfA of 55 amino acids (formerly called YdhL), mediates binding of release factor 2 to the ribosomal A site lacking a complete mRNA codon and thereby triggers translational termination and rescue of the stalled ribosome.", "offsetInBeginSection": 299, "offsetInEndSection": 536, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ace17c30340b9f058000009", "body": "Which olfactory gene senses androsterone?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8043710", "http://www.ncbi.nlm.nih.gov/pubmed/25091523", "http://www.ncbi.nlm.nih.gov/pubmed/30049923", "http://www.ncbi.nlm.nih.gov/pubmed/23321429", "http://www.ncbi.nlm.nih.gov/pubmed/18808328", "http://www.ncbi.nlm.nih.gov/pubmed/16675527", "http://www.ncbi.nlm.nih.gov/pubmed/8754248", "http://www.ncbi.nlm.nih.gov/pubmed/26140380", "http://www.ncbi.nlm.nih.gov/pubmed/11287957", "http://www.ncbi.nlm.nih.gov/pubmed/25041470"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18808328", "text": "The mammalian olfactory system senses an almost unlimited number of chemical stimuli and initiates a process of neural recognition that influences nearly every aspect of life.", "offsetInBeginSection": 0, "offsetInEndSection": 175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20221768", "text": "In health and disease, it has been shown that in two of these senses, the trigeminal and olfactory senses, modification of one sense leads to changes in the other sense and vice versa.", "offsetInBeginSection": 135, "offsetInEndSection": 319, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25091523", "text": "BACKGROUND Chemical senses are one of the foremost means by which organisms make sense of their environment, among them the olfactory and gustatory sense of vertebrates and arthropods.", "offsetInBeginSection": 0, "offsetInEndSection": 184, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25091523", "text": "The genomic neighborhood of t2r genes is enriched in repeat elements, which may have facilitated the extensive gene duplication events resulting in such a large family.", "offsetInBeginSection": 1062, "offsetInEndSection": 1230, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25091523", "text": "High evolutionary dynamics of some olfactory and gustatory receptor gene families result in considerable variance of chemosensory perception between species.", "offsetInBeginSection": 287, "offsetInEndSection": 444, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25091523", "text": "CONCLUSIONS The singularly large T2R repertoire of Latimeria may have been generated by facilitating local gene duplication via increased density of repeat elements, and efficient neofunctionalization via positive Darwinian selection.The high evolutionary dynamics of tetrapod t2r gene families precedes the emergence of tetrapods, i.e.", "offsetInBeginSection": 1926, "offsetInEndSection": 2262, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25091523", "text": "Some conserved sequence motifs of Latimeria T2Rs and V1Rs are shared with the respective teleost but not tetrapod genes, consistent with a potential role of such motifs in detection of aquatic chemosensory stimuli.", "offsetInBeginSection": 1709, "offsetInEndSection": 1923, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1737068", "text": "Genomic DNA amplifications with synthetic primers which have nucleotide sequences corresponding to the 5'-region of androsterone UDPGT cDNA, suggested that androsterone UDPGT gene has exon 1 with a length of some 700 bp and that this exon is deleted in LA Wistar rats.", "offsetInBeginSection": 623, "offsetInEndSection": 891, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1737068", "text": "Based on these lines of evidence, it is concluded that the large portion of androsterone UDPGT gene is deleted in LA Wistar rats, which results in the absence of androsterone UDPGT mRNA and consequently the corresponding enzyme protein.", "offsetInBeginSection": 892, "offsetInEndSection": 1128, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23721465", "text": "However, the nonsynonymous-to-synonymous substitution rate ratio was relatively higher between orthologous OR genes of L. frontalis and L. colubrina, indicating that L. frontalis and L. colubrina have evolved to possess different olfactory senses.", "offsetInBeginSection": 799, "offsetInEndSection": 1046, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abd13e1fcf4565872000029", "body": "Where in the body would the navicular bone be found?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15062212", "http://www.ncbi.nlm.nih.gov/pubmed/34418043", "http://www.ncbi.nlm.nih.gov/pubmed/2735530", "http://www.ncbi.nlm.nih.gov/pubmed/2591353", "http://www.ncbi.nlm.nih.gov/pubmed/9465778", "http://www.ncbi.nlm.nih.gov/pubmed/7106082", "http://www.ncbi.nlm.nih.gov/pubmed/27061802", "http://www.ncbi.nlm.nih.gov/pubmed/25210293", "http://www.ncbi.nlm.nih.gov/pubmed/29624012", "http://www.ncbi.nlm.nih.gov/pubmed/27708918"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20525052", "text": "RESULTS There were significant correlations between the presence of a cystic structure in the distal third of the navicular bone, or a distal border fragment, or increased signal intensity in fat suppressed images at the insertion of the DSIL on the distal phalanx and the histological grade of the body of the DSIL.", "offsetInBeginSection": 962, "offsetInEndSection": 1278, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2681808", "text": "Four patients sustaining tarsal navicular body fractures are presented.", "offsetInBeginSection": 0, "offsetInEndSection": 71, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28099198", "text": "Both an accessory navicular and the body of the navicular bone may develop osteomyelitis in immunocompromised patients; early diagnosis is important for prescribing effective conservative treatment.", "offsetInBeginSection": 523, "offsetInEndSection": 721, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28099198", "text": "He was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone.", "offsetInBeginSection": 155, "offsetInEndSection": 254, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9622323", "text": "The histological and histomorphometric changes in the navicular bone and palmar fibrocartilage were considered similar of those found in articular hyaline cartilage and subchondral bone in osteoarthritis.", "offsetInBeginSection": 2558, "offsetInEndSection": 2762, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9622323", "text": "Palmar fibrocartilage fibrillation, palmar cortical bone defects, fibromyxoid stromal change in the medulla, medullary pseudocyst formation and entheseous new bone formation were all seen in ND.", "offsetInBeginSection": 1361, "offsetInEndSection": 1555, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10029187", "text": "In ponies, navicular bone measurements were smallest for light ponies and regularly increased with body size, but in horses, navicular bone dimensions were smallest for the athletic halfbred, intermediate for draft horse, thoroughbreds and sedentary halfbreds and largest for heavy halfbreds.", "offsetInBeginSection": 303, "offsetInEndSection": 595, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10029187", "text": "Draft horses and heavy ponies showed marked thickening of cortical bone with minimum intracortical porosity, and a decrease in marrow spaces associated with more trabecular bone.", "offsetInBeginSection": 851, "offsetInEndSection": 1029, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10029187", "text": "Light horses and ponies possessed larger amounts of cancellous bone and less cortical bone.", "offsetInBeginSection": 759, "offsetInEndSection": 850, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9776073", "text": "The talus sustains the weight of the body and transmits the weight in different directions (i.e., the calcaneus and navicular).", "offsetInBeginSection": 124, "offsetInEndSection": 251, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d9ab94e03427e73000003", "body": "Is Cystatin D a biomarker?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21918259", "http://www.ncbi.nlm.nih.gov/pubmed/19623638", "http://www.ncbi.nlm.nih.gov/pubmed/30344712", "http://www.ncbi.nlm.nih.gov/pubmed/24266750", "http://www.ncbi.nlm.nih.gov/pubmed/28856234", "http://www.ncbi.nlm.nih.gov/pubmed/35738242", "http://www.ncbi.nlm.nih.gov/pubmed/33466214", "http://www.ncbi.nlm.nih.gov/pubmed/27861242", "http://www.ncbi.nlm.nih.gov/pubmed/24780555", "http://www.ncbi.nlm.nih.gov/pubmed/30284299"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27861242", "text": "Cystatin C, a biomarker of kidney functioning that has been linked to poor health outcomes, was measured in blood.", "offsetInBeginSection": 325, "offsetInEndSection": 439, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26066476", "text": "The use of cystatin C as a confirmatory biomarker in deciding medication dosages or as a confirmatory test in patients with an uncertain diagnosis of chronic kidney disease may be beneficial.", "offsetInBeginSection": 1028, "offsetInEndSection": 1219, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29087712", "text": "Because cathepsin D is a biomarker in aggressive forms of breast cancer and linked to poor prognosis, the effects of cathepsin D inhibition by 1 and 3 on the downstream cellular substrates cystatin C and PAI-1 were investigated.", "offsetInBeginSection": 653, "offsetInEndSection": 881, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21151566", "text": "The cysteine protease inhibitor cystatin C has recently gained interest as a candidate diagnostic biomarker for ALS, but further studies are required to fully characterize its biomarker utility.", "offsetInBeginSection": 382, "offsetInEndSection": 576, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22350134", "text": "Concluding, we could not confirm our hypothesis (supported by the Polish results) that cystatin C level is altered by HNF1A mutations; thus, it cannot be used as a biomarker for HNF1A-MODY.", "offsetInBeginSection": 1339, "offsetInEndSection": 1528, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22350134", "text": "We hypothesized that cystatin C level might be altered in HNF1A-MODY.", "offsetInBeginSection": 158, "offsetInEndSection": 227, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19444952", "text": "Cystatin C may be a useful biomarker of ALS and can be used to distinguish between ALS and polyneuropathy.", "offsetInBeginSection": 952, "offsetInEndSection": 1058, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21918259", "text": "Cystatin C (cysC) is an endogenous cysteine peptidase (proteinase) inhibitor that has been intensively investigated as a biomarker of kidney function for many years.", "offsetInBeginSection": 0, "offsetInEndSection": 165, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24713815", "text": "Cystatin C is more sensitive as an early biomarker of acute kidney injury in comparison with kidney injury molecule-1.", "offsetInBeginSection": 1280, "offsetInEndSection": 1398, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22795897", "text": "Cystatin C, a cysteine protease inhibitor, is a novel biomarker of renal damage.", "offsetInBeginSection": 0, "offsetInEndSection": 80, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ace19420340b9f05800000a", "body": "Which gene is responsible for red hair?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28024137", "http://www.ncbi.nlm.nih.gov/pubmed/17147521", "http://www.ncbi.nlm.nih.gov/pubmed/17316231", "http://www.ncbi.nlm.nih.gov/pubmed/11672965", "http://www.ncbi.nlm.nih.gov/pubmed/30531825", "http://www.ncbi.nlm.nih.gov/pubmed/31834199", "http://www.ncbi.nlm.nih.gov/pubmed/11689486", "http://www.ncbi.nlm.nih.gov/pubmed/23146638", "http://www.ncbi.nlm.nih.gov/pubmed/30657907", "http://www.ncbi.nlm.nih.gov/pubmed/28275654"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/12876664", "text": "Mutations in the P gene were responsible for classic phenotype of oculocutaneous albinism type 2 (OCA2) in all eight, and mutations in the MC1R gene were responsible for the red (rather than yellow/blond) hair in the six of eight who continued to have red hair after birth.", "offsetInBeginSection": 841, "offsetInEndSection": 1114, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12876664", "text": "Sequence variation in the melanocortin-1 receptor (MC1R) gene is associated with red hair in the normal population, but red hair is unusual in OCA.", "offsetInBeginSection": 628, "offsetInEndSection": 775, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28024137", "text": "A specific variant of MC1R gene (R allele) is responsible for the red hair.", "offsetInBeginSection": 115, "offsetInEndSection": 190, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2363420", "text": "A possible explanation for the existence of these 2 different group of patients is that the locus of the gene responsible for the syndrome is closely linked to the locus for a gene responsible for hair color with linkage disequilibrium in Tunisian Jews (Sepharadim).", "offsetInBeginSection": 598, "offsetInEndSection": 864, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19482440", "text": "The mode of inheritance for Tourette syndrome is thought to be autosomal recessive, same as for red hair with both aggregating in families.", "offsetInBeginSection": 812, "offsetInEndSection": 951, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11549109", "text": "Red hair individuals are usually compound heterozygotes or homozygous for one of a number of MC1R polymorphisms associated with red hair.", "offsetInBeginSection": 569, "offsetInEndSection": 706, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11549109", "text": "Variants of the Melanocortin 1 Receptor (MC1R) gene have been found to be associated with red hair and fair skin in humans.", "offsetInBeginSection": 445, "offsetInEndSection": 568, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11672965", "text": "We describe a minisequencing protocol for screening DNA samples for the presence of 12 mutations in the human melanocortin 1 receptor gene (MC1R), eight of which are associated with the red hair phenotype.", "offsetInBeginSection": 0, "offsetInEndSection": 205, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19571053", "text": "BACKGROUND Red hair color is caused by variants of the melanocortin-1 receptor (MC1R) gene.", "offsetInBeginSection": 0, "offsetInEndSection": 91, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11030758", "text": "We have investigated 174 individuals from 11 large kindreds with a preponderance of red hair and an additional 99 unrelated redheads, for MC1R variants and have confirmed that red hair is usually inherited as a recessive characteristic with the R151C, R160W, D294H, R142H, 86insA and 537insC alleles at this locus.", "offsetInBeginSection": 319, "offsetInEndSection": 633, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abd5a62fcf4565872000031", "body": "Which bacteria was EcoRI, restriction endonuclease isolated from?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2695392", "http://www.ncbi.nlm.nih.gov/pubmed/3038847", "http://www.ncbi.nlm.nih.gov/pubmed/1607867", "http://www.ncbi.nlm.nih.gov/pubmed/8178514", "http://www.ncbi.nlm.nih.gov/pubmed/1979278", "http://www.ncbi.nlm.nih.gov/pubmed/347245", "http://www.ncbi.nlm.nih.gov/pubmed/2158474", "http://www.ncbi.nlm.nih.gov/pubmed/2558629", "http://www.ncbi.nlm.nih.gov/pubmed/6251158", "http://www.ncbi.nlm.nih.gov/pubmed/210371"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/10573394", "text": "The isolates were initially classified according to their restriction endonuclease profiles using HindIII and EcoRI restriction endonucleases and further characterised by rRNA gene restriction patterns (ribotypes).", "offsetInBeginSection": 259, "offsetInEndSection": 473, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2695392", "text": "The RsrI endonuclease, a type-II restriction endonuclease (ENase) found in Rhodobacter sphaeroides, is an isoschizomer of the EcoRI ENase.", "offsetInBeginSection": 0, "offsetInEndSection": 138, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6263856", "text": "Restriction endonuclease cleavage maps of pTB51, pTB52, and pTB53 were constructed.", "offsetInBeginSection": 1065, "offsetInEndSection": 1148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6263856", "text": "The restriction endonuclease cleavage maps of the two plasmids, pTB19 and pTB20, were constructed.", "offsetInBeginSection": 547, "offsetInEndSection": 645, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1979278", "text": "Purified DNAs were digested with EcoRI restriction endonuclease, and restriction fragments separated by electrophoresis.", "offsetInBeginSection": 356, "offsetInEndSection": 476, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/403933", "text": "A fragment pattern of the products of EcoRI restriction endonuclease digestion of Euglena chloroplast DNA is also described.", "offsetInBeginSection": 530, "offsetInEndSection": 654, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/403933", "text": "Covalently close, circular chloroplast DNA is cleaved by restriction endonuclease SalI into three fragments and by restriction endonuclease BamHI into six fragments.", "offsetInBeginSection": 190, "offsetInEndSection": 355, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6265073", "text": "The DNA's isolated from five mouse hyperplastic mammary gland outgrowth lines from BALB/cfC3H mice were digested with the restriction endonucleases PsTI, BamHI, or EcoRI; electrophoresed; and analyzed by Southern blotting and autoradiography.", "offsetInBeginSection": 0, "offsetInEndSection": 242, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/776705", "text": "Restriction endonucleases EcoRI and HindIII were used to analyze the structure of the plasmid genome responsible for the EcoRI restriction endonuclease and modification methylase.", "offsetInBeginSection": 368, "offsetInEndSection": 547, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8760442", "text": "Each of these clones was analysed to map BamHI, EcoRI, Sa/l, Smal and Xhol restriction endonuclease sites to provide complete endonuclease maps for the entire genome.", "offsetInBeginSection": 1437, "offsetInEndSection": 1603, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9da37e4e03427e73000004", "body": "What is Mendelian randomization?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33781616", "http://www.ncbi.nlm.nih.gov/pubmed/16410347", "http://www.ncbi.nlm.nih.gov/pubmed/34426474", "http://www.ncbi.nlm.nih.gov/pubmed/20616999", "http://www.ncbi.nlm.nih.gov/pubmed/27486138", "http://www.ncbi.nlm.nih.gov/pubmed/30884619", "http://www.ncbi.nlm.nih.gov/pubmed/34155684", "http://www.ncbi.nlm.nih.gov/pubmed/29471399", "http://www.ncbi.nlm.nih.gov/pubmed/23934314", "http://www.ncbi.nlm.nih.gov/pubmed/34936225"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26201704", "text": "OBJECTIVE The term Mendelian randomization is popular in the current literature.", "offsetInBeginSection": 0, "offsetInEndSection": 80, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26201704", "text": "CONCLUSIONS Mendelian randomization and path models use different concepts for causal inference.", "offsetInBeginSection": 1092, "offsetInEndSection": 1188, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19432981", "text": "CONCLUSION Given an inheritance of gene expression from parents, Mendelian randomization studies not only need to assume a random distribution of alleles in the offspring, but also a random distribution of epigenetic changes (e.g.", "offsetInBeginSection": 2146, "offsetInEndSection": 2376, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23199790", "text": "Akin to a randomized trial, Mendelian randomization is a genetic study design that takes advantage of the \"randomization\" of genetic information at birth to evaluate a potential causal relationship between a genetically determined biomarker and an outcome.", "offsetInBeginSection": 336, "offsetInEndSection": 592, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20978399", "text": "Mendelian randomization is a genetic epidemiologic approach used to disentangle causation from association.", "offsetInBeginSection": 116, "offsetInEndSection": 223, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20978399", "text": "A formal Mendelian randomization study using a genetic marker as a proxy for the biomarker has not been conducted in the HIV field.", "offsetInBeginSection": 666, "offsetInEndSection": 797, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19674341", "text": "Mendelian randomization is a recently developed methodology that combines genetic and classical epidemiological analysis to infer causality for environmental exposures, based on the principle of Mendel's law of independent assortment.", "offsetInBeginSection": 288, "offsetInEndSection": 522, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16410347", "text": "The authors conclude that Mendelian randomization is a powerful addition to etiologic research tools.", "offsetInBeginSection": 770, "offsetInEndSection": 871, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20616999", "text": "Mendelian randomization refers to the random allocation of alleles at the time of gamete formation.", "offsetInBeginSection": 0, "offsetInEndSection": 99, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19174578", "text": "The Mendelian randomization strategy, building on both the accuracy of genotyping and the random assortment of alleles at meiosis, involves searching for an association between a nutritional exposure-mimicking gene variant (a type of \"instrumental variable\") and cancer outcome.", "offsetInBeginSection": 238, "offsetInEndSection": 516, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ace1a590340b9f05800000b", "body": "What percentage of Homo sapiens DNA is of Neanderthal origin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20369935", "http://www.ncbi.nlm.nih.gov/pubmed/17146600", "http://www.ncbi.nlm.nih.gov/pubmed/30672457", "http://www.ncbi.nlm.nih.gov/pubmed/17110569", "http://www.ncbi.nlm.nih.gov/pubmed/21151557", "http://www.ncbi.nlm.nih.gov/pubmed/1562057", "http://www.ncbi.nlm.nih.gov/pubmed/30281589", "http://www.ncbi.nlm.nih.gov/pubmed/15636070", "http://www.ncbi.nlm.nih.gov/pubmed/7942855", "http://www.ncbi.nlm.nih.gov/pubmed/10788336"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17146600", "text": "The retrieval of Neanderthal (Homo neanderthalsensis) mitochondrial DNA is thought to be among the most significant ancient DNA contributions to date, allowing conflicting hypotheses on modern human (Homo sapiens) evolution to be tested directly.", "offsetInBeginSection": 0, "offsetInEndSection": 246, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17110569", "text": "This initial analysis of the Neanderthal genome advances our understanding of the evolutionary relationship of Homo sapiens and Homo neanderthalensis and signifies the dawn of Neanderthal genomics.", "offsetInBeginSection": 1362, "offsetInEndSection": 1559, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10788336", "text": "When hybridized with genomic DNA of either human or Neanderthal origin, DNA extracted from two Neanderthal finds-the Os parietale, from Warendorf-Neuwarendorf, Germany, and a clavicula, from Krapina, Croatia-was shown to yield hybridization signals that differ by at least a factor of two compared to the signals obtained with the use of fossil DNA of an early Homo sapiens from the Vogelherd cave (Stetten I), Germany.", "offsetInBeginSection": 146, "offsetInEndSection": 565, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27429943", "text": "The availability of edible insects in East Asia aided the spread of the unaggressive, highly cooperative Neanderthals, who interbred with H. sapiens in Asia, resulting in a higher admixture of Neanderthal DNA in East Asian populations.", "offsetInBeginSection": 289, "offsetInEndSection": 524, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27429943", "text": "Mitochondrial Eve confirms the \"out of Africa\" theory, but the evidence also supports interbreeding between Homo sapiens and other hominins: Neanderthals, Denisovans, and Homo heidelbergensis.", "offsetInBeginSection": 0, "offsetInEndSection": 192, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18768141", "text": "If the Neanderthal population was large compared to the Homo sapiens population at the beginning of the contact period, we show that genetic introgression should have been fast and complete meaning that most of the Neanderthal private alleles should be found in the modern human gene pool in case of ancient admixture.", "offsetInBeginSection": 330, "offsetInEndSection": 648, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18768141", "text": "To study how the Neanderthal private alleles may have spread over the genes of Homo sapiens, we propose a deterministic model based on recursive equations and ordinary differential equations.", "offsetInBeginSection": 138, "offsetInEndSection": 329, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21404232", "text": "Based on the results, it is suggested that the Homo sapiens non-supranuchal fossa and Neanderthal suprainiac fossa are convergent traits.", "offsetInBeginSection": 1290, "offsetInEndSection": 1427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11484052", "text": "Homo neanderthalensis has a unique combination of craniofacial features that are distinct from fossil and extant 'anatomically modern' Homo sapiens (modern humans).", "offsetInBeginSection": 0, "offsetInEndSection": 164, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7942855", "text": "Although ancient, none of these haplogroups is old enough to be compatible with a Neanderthal origin, suggesting that Homo sapiens sapiens displaced H. s. neanderthaliensis, rather than mixed with it.", "offsetInBeginSection": 470, "offsetInEndSection": 670, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac0f7b919833b0d7b000006", "body": "What are the 3 antidotes for anticoagulant (anti-blood clotting) drugs, including factor Xa inhibitors, as of November 2017.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25485923", "http://www.ncbi.nlm.nih.gov/pubmed/28415603", "http://www.ncbi.nlm.nih.gov/pubmed/16269995", "http://www.ncbi.nlm.nih.gov/pubmed/30135185", "http://www.ncbi.nlm.nih.gov/pubmed/26336492", "http://www.ncbi.nlm.nih.gov/pubmed/18574264", "http://www.ncbi.nlm.nih.gov/pubmed/25832311", "http://www.ncbi.nlm.nih.gov/pubmed/25516695", "http://www.ncbi.nlm.nih.gov/pubmed/26492202", "http://www.ncbi.nlm.nih.gov/pubmed/28471371"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26378211", "text": "Similar to the vitamin K antagonist, warfarin, all of the factor Xa inhibitors are administered orally.", "offsetInBeginSection": 719, "offsetInEndSection": 822, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27082776", "text": "Aripazine (PER-977), the third reversal agent, has shown promising activity against dabigatran, apixaban, rivaroxaban, as well as subcutaneous fondaparinux and LMWH.", "offsetInBeginSection": 1451, "offsetInEndSection": 1616, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27082776", "text": "Direct thrombin inhibitor: dabigatran and factor Xa inhibitors: apixaban, rivaroxaban, and edoxaban directly inhibit the coagulation cascade.", "offsetInBeginSection": 267, "offsetInEndSection": 408, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27082776", "text": "Andexanet alfa (PRT064445), a specific reversal agent against factor Xa inhibitors, showed a complete reversal of anticoagulant activity of apixaban and rivaroxaban within minutes after administration without adverse effects in two recently completed parallel phase III trials ANNEXA-A and ANNEXA-R respectively.", "offsetInBeginSection": 1077, "offsetInEndSection": 1389, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12516682", "text": "In addition, the direct factor Xa inhibitors prolong the Russell's viper venom test (RWT) and Heptest clotting times.", "offsetInBeginSection": 309, "offsetInEndSection": 426, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23953907", "text": "Specific antidotes for the reversal of the anticoagulant effect of these drugs, such as monoclonal antibodies against the direct thrombin inhibitor dabigatran or recombinant Xa-analog in the case of factor Xa inhibitors, are still being investigated in early clinical trials.", "offsetInBeginSection": 301, "offsetInEndSection": 576, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23953907", "text": "Activated prothrombin complex concentrate seems promising for the reversal of dabigatran, while non-activated prothrombin complex concentrates have potential for the reversal of anti-factor Xa.", "offsetInBeginSection": 1061, "offsetInEndSection": 1254, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28471371", "text": "Several direct oral anticoagulants (DOACs), including direct thrombin and factor Xa inhibitors, have been approved as alternatives to vitamin K antagonist anticoagulants.", "offsetInBeginSection": 0, "offsetInEndSection": 170, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27626268", "text": "NOACs are classified into two groups: direct thrombin inhibitor (notably dabigatran) and factor Xa inhibitors (including rivaroxaban, apixaban, and edoxaban).", "offsetInBeginSection": 267, "offsetInEndSection": 425, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21254900", "text": "The anti-Xa inhibitor rivaroxaban and the direct thrombin inhibitor dabigatran etexilate are licensed for prophylaxis of venous thromboembolism (VTE) in high-risk orthopedic surgery.", "offsetInBeginSection": 351, "offsetInEndSection": 533, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9da59c4e03427e73000005", "body": "What is PNPPP?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26551787", "http://www.ncbi.nlm.nih.gov/pubmed/25658120", "http://www.ncbi.nlm.nih.gov/pubmed/24201366", "http://www.ncbi.nlm.nih.gov/pubmed/21747892", "http://www.ncbi.nlm.nih.gov/pubmed/29445694", "http://www.ncbi.nlm.nih.gov/pubmed/19702537", "http://www.ncbi.nlm.nih.gov/pubmed/30656893", "http://www.ncbi.nlm.nih.gov/pubmed/31798210", "http://www.ncbi.nlm.nih.gov/pubmed/15734663", "http://www.ncbi.nlm.nih.gov/pubmed/6683883"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26551787", "text": "CONCLUSION PNPPP efficiently controls for non-disease-related variance, allowing both for efficient discovery of novel biomarkers and for covariate-independent linear cut-offs suitable for clinical use.", "offsetInBeginSection": 520, "offsetInEndSection": 722, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25658120", "text": "PdeM, thus, is a novel representative of new subclass of class III phosphodiesterases.", "offsetInBeginSection": 1829, "offsetInEndSection": 1915, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25658120", "text": "Bioinformatic analysis showed that PdeM sequence possessed the characteristic signature motifs of the class III phosphodiesterases and phylogenetic study of PdeM enabled us to identify three distinct subclasses (A, B, and C) within class III phosphodiesterases, PdeM clustering in new subclass IIIB.", "offsetInBeginSection": 428, "offsetInEndSection": 727, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25658120", "text": "The recombinant PdeM possessed phosphodiesterase, phosphonate-ester hydrolase and nuclease activity.", "offsetInBeginSection": 1052, "offsetInEndSection": 1152, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25658120", "text": "It lacked phosphomonoesterase, phosphotriesterase, and RNAse activities.", "offsetInBeginSection": 1153, "offsetInEndSection": 1225, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25658120", "text": "In our search to find novel phosphodiesterases using metagenomic approach, we cloned a gene encoding a putative phosphodiesterase (PdeM) from the metagenome of the formation water collected from an Indian coal bed.", "offsetInBeginSection": 213, "offsetInEndSection": 427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25658120", "text": "PdeM is a monomer of 29.3 kDa, which exhibits optimum activity at 25\u00b0C and pH 8.5, but low affinity for bis(pNPP) as well as pNPPP.", "offsetInBeginSection": 919, "offsetInEndSection": 1051, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21747892", "text": "The effects of C. capitatum were also examined on isolated Guinea pig atria alone, in the presence of calcium chloride (Ca(2+) channel blocker), atropine (cholinergic blocker), and glibenclamide (ATP-sensitive K(+) channel blocker).", "offsetInBeginSection": 358, "offsetInEndSection": 590, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21747892", "text": "Clerodendron capitatum (Willd) (family: verbenaceae) is locally named as Gung and used traditionally to treat erectile dysfunction.", "offsetInBeginSection": 0, "offsetInEndSection": 131, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21747892", "text": "The extract, when tested colorimetrically for its inhibitory activities on phosphordiesterase-5 (PDE-5) in vitro towards p-nitrophenyl phenyl phosphate (PNPPP), was observed to induce significant dose-dependent inhibition of PDE-5, with an ID(50) of 0.161\u2009mg/ml (P < .05).", "offsetInBeginSection": 654, "offsetInEndSection": 928, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ace20fa0340b9f05800000c", "body": "Which genes are responsible for the high-altitude adaptation of Tibetans?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22503288", "http://www.ncbi.nlm.nih.gov/pubmed/28585440", "http://www.ncbi.nlm.nih.gov/pubmed/26053282", "http://www.ncbi.nlm.nih.gov/pubmed/25917616", "http://www.ncbi.nlm.nih.gov/pubmed/28585439", "http://www.ncbi.nlm.nih.gov/pubmed/28373541", "http://www.ncbi.nlm.nih.gov/pubmed/25501874", "http://www.ncbi.nlm.nih.gov/pubmed/22117106", "http://www.ncbi.nlm.nih.gov/pubmed/20466884", "http://www.ncbi.nlm.nih.gov/pubmed/21718161"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25501874", "text": "EPAS1 involves in the hypoxic response and is suggested to be responsible for the genetic adaptation of high-altitude hypoxia in Tibetans.", "offsetInBeginSection": 0, "offsetInEndSection": 138, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28585439", "text": "Tibetans are well adapted to high-altitude hypoxia.", "offsetInBeginSection": 0, "offsetInEndSection": 51, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28585439", "text": "Taken together, we propose that GCH1 plays a role in the genetic adaptation of Tibetans to high altitude hypoxia.", "offsetInBeginSection": 979, "offsetInEndSection": 1092, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26053282", "text": "Recent studies have identified genes involved in high-altitude adaptation in Tibetans.", "offsetInBeginSection": 383, "offsetInEndSection": 469, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20838600", "text": "Our results indicate that several key HIF-regulatory and targeted genes are responsible for adaptation to high altitude in Andeans and Tibetans, and several different chromosomal regions are implicated in the putative response to selection.", "offsetInBeginSection": 1617, "offsetInEndSection": 1857, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22503288", "text": "Recent studies have identified genes involved in high-altitude adaptation in Tibetans.", "offsetInBeginSection": 0, "offsetInEndSection": 86, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22503288", "text": "Genetic variants/haplotypes within regions containing three of these genes (EPAS1, EGLN1, and PPARA) are associated with relatively decreased hemoglobin levels observed in Tibetans at high altitude, providing corroborative evidence for genetic adaptation to this extreme environment.", "offsetInBeginSection": 87, "offsetInEndSection": 370, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28585440", "text": "The genetic adaptation of Tibetans to high altitude hypoxia likely involves a group of genes in the hypoxic pathway, as suggested by earlier studies.", "offsetInBeginSection": 0, "offsetInEndSection": 149, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23874230", "text": "Hemoglobin concentration, a trait associated with high-altitude adaptation in Tibetans, is at an intermediate level in DU Mongolians compared to Tibetans and Han Chinese at comparable altitude.", "offsetInBeginSection": 1017, "offsetInEndSection": 1210, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23666208", "text": "Tibetans are well adapted to high-altitude hypoxic conditions, and in recent genome-wide scans, many candidate genes have been reported involved in the physiological response to hypoxic conditions.", "offsetInBeginSection": 0, "offsetInEndSection": 197, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a74eaa50384be955100000b", "body": "What part of the body is affected by mesotheliomia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22879850", "http://www.ncbi.nlm.nih.gov/pubmed/31161267", "http://www.ncbi.nlm.nih.gov/pubmed/9262427", "http://www.ncbi.nlm.nih.gov/pubmed/17852885", "http://www.ncbi.nlm.nih.gov/pubmed/18443890", "http://www.ncbi.nlm.nih.gov/pubmed/23140807", "http://www.ncbi.nlm.nih.gov/pubmed/16524715", "http://www.ncbi.nlm.nih.gov/pubmed/31761830", "http://www.ncbi.nlm.nih.gov/pubmed/22374624", "http://www.ncbi.nlm.nih.gov/pubmed/8216764"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22879850", "text": "Symptoms vary from person to person, and may come and go, depend on what part of the body is affected, can be mild, moderate, or severe.", "offsetInBeginSection": 628, "offsetInEndSection": 764, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22879850", "text": "Systemic lupus erythematosus (SLE) is a chronic, multifaceted autoimmune inflammatory disease that can affect any part of the body.", "offsetInBeginSection": 0, "offsetInEndSection": 131, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16163658", "text": "These movements appear in the non-affected part of the body throughout cerebrovascular disease evolution, and which could be caused by maintained hypersolicitation of the unaffected part of the body and the neuroplastic process following a stroke.", "offsetInBeginSection": 1372, "offsetInEndSection": 1619, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16163658", "text": "DEVELOPMENT To review the main hypotheses which try to explain the presence of AM in the part of the body ipsilesional to the injured hemisphere of the brain.", "offsetInBeginSection": 381, "offsetInEndSection": 539, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26007284", "text": "For PTs specialized in acute care, geriatrics and pediatrics, the body part most commonly affected was the low back, while for PTs specialized in orthopedics and neurology, the body part most commonly affected was the neck.", "offsetInBeginSection": 573, "offsetInEndSection": 796, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24531623", "text": "The reduced response to sensory threats approaching the body suggests a deep detachment of the affected body part from the patient's body representation.", "offsetInBeginSection": 1981, "offsetInEndSection": 2134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16051171", "text": "Here, we demonstrate that an intrinsic primary quality of a tactile object, for example its size, is directly affected by the perceived size of the body part touching it.", "offsetInBeginSection": 240, "offsetInEndSection": 410, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23204474", "text": "How this body image is affected by changes in sensory inputs from, and motor outputs to, the body remains unclear.", "offsetInBeginSection": 246, "offsetInEndSection": 360, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11058423", "text": "Being in cephalic presentation, in a caudal direction, the fetus relieves body segments of the weight of the hypotonic-atonic part of the body in the cranial direction.", "offsetInBeginSection": 371, "offsetInEndSection": 539, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11058423", "text": "The hypothesis is that from the 24th week of gestation an increasing percentage of fetuses occupies an exclusively cephalic presentation, since it allows an uncompromised posture in the caudal direction of body segments whose muscles are first affected by the occurrence and progressive increase of tone.", "offsetInBeginSection": 66, "offsetInEndSection": 370, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9db99ffd02ddc336000001", "body": "Is CXCL7 a chemokine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35837284", "http://www.ncbi.nlm.nih.gov/pubmed/28245630", "http://www.ncbi.nlm.nih.gov/pubmed/24678812", "http://www.ncbi.nlm.nih.gov/pubmed/29038657", "http://www.ncbi.nlm.nih.gov/pubmed/26233476", "http://www.ncbi.nlm.nih.gov/pubmed/27959418", "http://www.ncbi.nlm.nih.gov/pubmed/18954601", "http://www.ncbi.nlm.nih.gov/pubmed/18723831", "http://www.ncbi.nlm.nih.gov/pubmed/23136963", "http://www.ncbi.nlm.nih.gov/pubmed/20022386"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20652876", "text": "Micro-masses stimulated with TGF\u03b23 and CXCL7 developed chondrogenic cells and formed a cartilaginous matrix rich in proteoglycans, accompanied by the induction of typical chondrogenic marker genes, such as cartilage oligomeric matrix protein, aggrecan, type II\u03b11 collagen and by regulation of matrix metalloproteinases and their inhibitors.", "offsetInBeginSection": 921, "offsetInEndSection": 1263, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28245630", "text": "CXCL7, a chemokine highly expressed in platelets, orchestrates neutrophil recruitment during thrombosis and related pathophysiological processes by interacting with CXCR2 receptor and sulfated glycosaminoglycans (GAG).", "offsetInBeginSection": 0, "offsetInEndSection": 218, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28368308", "text": "Solution nuclear magnetic resonance (NMR) and molecular dynamics characterization of platelet-derived chemokine CXCL7 heterodimerization with chemokines CXCL1, CXCL4, and CXCL8 indicated that packing interactions promote CXCL7-CXCL1 and CXCL7-CXCL4 heterodimers, and electrostatic repulsive interactions disfavor the CXCL7-CXCL8 heterodimer.", "offsetInBeginSection": 461, "offsetInEndSection": 802, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26233476", "text": "Levels of CXC chemokine ligand 7 (CXCL7) protein vary during tumorigenesis, and the evidence suggests that this chemokine serves as a novel biomarker of early-stage lung cancer.", "offsetInBeginSection": 90, "offsetInEndSection": 267, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20022386", "text": "Many cells, including leucocytes and stromal cells, express CXCL7, a member of the CXC chemokine family, also known as platelet basic protein.", "offsetInBeginSection": 0, "offsetInEndSection": 142, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20022386", "text": "CXCL7 is a potent chemoattractant and activator of neutrophil function.", "offsetInBeginSection": 143, "offsetInEndSection": 214, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12193731", "text": "In this study, we have examined the major platelet-derived CXC chemokines connective tissue-activating peptide III (CTAP-III), its truncation product neutrophil-activating peptide 2 (CXC chemokine ligand 7 (CXCL7)), as well as the structurally related platelet factor 4 (CXCL4) for their impact on neutrophil adhesion to and transmigration through unstimulated vascular endothelium.", "offsetInBeginSection": 0, "offsetInEndSection": 382, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29038657", "text": "CXCL7 exerts its function by activating the CXC chemokine receptor 2 (CXCR2) receptor and binding sulfated glycosaminoglycans (GAGs) that regulate receptor activity.", "offsetInBeginSection": 148, "offsetInEndSection": 313, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29038657", "text": "Platelet-derived chemokine CXCL7 (also known as NAP-2) plays a crucial role in orchestrating neutrophil recruitment in response to vascular injury.", "offsetInBeginSection": 0, "offsetInEndSection": 147, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20652010", "text": "The chemokine CXCL7 binds heparin and the G-protein-linked receptor CXCR2.", "offsetInBeginSection": 243, "offsetInEndSection": 317, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ace2d600340b9f05800000e", "body": "What phenotype is associated with the V60L mutation in the human MC1R gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15972726", "http://www.ncbi.nlm.nih.gov/pubmed/17616515", "http://www.ncbi.nlm.nih.gov/pubmed/18366057", "http://www.ncbi.nlm.nih.gov/pubmed/18006116", "http://www.ncbi.nlm.nih.gov/pubmed/16567973", "http://www.ncbi.nlm.nih.gov/pubmed/20477788", "http://www.ncbi.nlm.nih.gov/pubmed/12851336", "http://www.ncbi.nlm.nih.gov/pubmed/18484624", "http://www.ncbi.nlm.nih.gov/pubmed/9665397", "http://www.ncbi.nlm.nih.gov/pubmed/24917043"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25794181", "text": "Here we used 11 computational tools based on different approaches to predict the damage-associated non-synonymous single nucleotide polymorphisms (nsSNPs) in the coding region of the human MC1R gene.", "offsetInBeginSection": 222, "offsetInEndSection": 421, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15972726", "text": "The human melanocortin-1 receptor gene (MC1R) encodes a G-protein coupled receptor that is primarily expressed on melanocytes, where it plays a key role in pigmentation regulation.", "offsetInBeginSection": 0, "offsetInEndSection": 180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20876876", "text": "CONCLUSION Results show that MC1R variants, hair color, and number of nevi were jointly associated with melanoma risk in CDKN2A mutation carriers.", "offsetInBeginSection": 2038, "offsetInEndSection": 2184, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20876876", "text": "RESULTS Carrying any one of the four most frequent MC1R variants (V60L, V92M, R151C, R160W) in CDKN2A mutation carriers was associated with a statistically significantly increased risk for melanoma across all continents (1.24 \u00d7 10(-6) \u2264 P \u2264 .0007).", "offsetInBeginSection": 1147, "offsetInEndSection": 1400, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20876876", "text": "BACKGROUND Carrying the cyclin-dependent kinase inhibitor 2A (CDKN2A) germline mutations is associated with a high risk for melanoma.", "offsetInBeginSection": 0, "offsetInEndSection": 133, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20876876", "text": "Penetrance of CDKN2A mutations is modified by pigmentation characteristics, nevus phenotypes, and some variants of the melanocortin-1 receptor gene (MC1R), which is known to have a role in the pigmentation process.", "offsetInBeginSection": 134, "offsetInEndSection": 348, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16567973", "text": "The melanocortin-1 receptor (MC1R) gene is a key determinant of the physiological variation in human skin pigmentation.", "offsetInBeginSection": 0, "offsetInEndSection": 119, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12006619", "text": "The human MC1R gene is highly polymorphic and certain allelic variants of the gene are associated with red hair phenotype, melanoma and non-melanoma skin cancer.", "offsetInBeginSection": 366, "offsetInEndSection": 527, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11030758", "text": "The V60L variant, which is common in the population may act as a partially penetrant recessive allele.", "offsetInBeginSection": 634, "offsetInEndSection": 736, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11030758", "text": "Variants of the melanocortin 1 receptor (MC1R) gene are common in individuals with red hair and fair skin, but the relative contribution to these pigmentary traits in heterozygotes, homozygotes and compound heterozygotes for variants at this locus from the multiple alleles present in Caucasian populations is unclear.", "offsetInBeginSection": 0, "offsetInEndSection": 318, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aae6499fcf456587200000c", "body": "What is BORSA?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28893360", "http://www.ncbi.nlm.nih.gov/pubmed/1563385", "http://www.ncbi.nlm.nih.gov/pubmed/15770100", "http://www.ncbi.nlm.nih.gov/pubmed/32991274", "http://www.ncbi.nlm.nih.gov/pubmed/34269673", "http://www.ncbi.nlm.nih.gov/pubmed/32200127", "http://www.ncbi.nlm.nih.gov/pubmed/31540335", "http://www.ncbi.nlm.nih.gov/pubmed/17108271", "http://www.ncbi.nlm.nih.gov/pubmed/21563482", "http://www.ncbi.nlm.nih.gov/pubmed/29505885"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28893360", "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance.", "offsetInBeginSection": 0, "offsetInEndSection": 159, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2261916", "text": "Under conditions used to elicit intrinsic methicillin resistance in Staphylococcus aureus, a large percentage of BORSA appeared resistant to amoxicillin/clavulanic acid.", "offsetInBeginSection": 896, "offsetInEndSection": 1065, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20880412", "text": "In conclusion, oxacillin was non-effective in the eradication of either (i) BORSA with oxacillin MICs \u22654 mg/L or (ii) \u03b2-lactamase-hyperproducing BORSA (MICs \u22642 mg/L).", "offsetInBeginSection": 1004, "offsetInEndSection": 1175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20880412", "text": "Since it is unknown whether \u03b2-lactam antimicrobial agents can be used effectively against borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L, the in vitro bactericidal activity and pharmacodynamic effect of oxacillin against clinical BORSA isolates was evaluated.", "offsetInBeginSection": 0, "offsetInEndSection": 304, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21875361", "text": "Besides decreased susceptibility to oxacillin, all MRSA and BORSA of these two major clonal lineages displayed resistance to gentamicin and kanamycin conferred by the aac(6')-Ie-aph(2')-Ia gene and to trimethoprim conferred by dfr(K) in MRSA and dfr(A) in BORSA.", "offsetInBeginSection": 740, "offsetInEndSection": 1002, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21875361", "text": "Among them, 12 isolates were methicillin-susceptible S. aureus (MSSA), 18 were borderline-oxacillin-resistant S. aureus (BORSA), and 40 were methicillin-resistant S. aureus (MRSA).", "offsetInBeginSection": 151, "offsetInEndSection": 331, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17108271", "text": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) exhibit oxacillin MIC values of 1-8 microg ml(-1), but lack mecA, which encodes the low-affinity penicillin-binding protein (PBP)2a.", "offsetInBeginSection": 0, "offsetInEndSection": 193, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2069374", "text": "These data show that infections caused by beta-lactamase-producing BORSA strains respond therapeutically in a manner similar to that of infections caused by oxacillin-susceptible strains, with both oxacillin and ampicillin plus sulbactam being highly efficacious.", "offsetInBeginSection": 1554, "offsetInEndSection": 1817, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26064878", "text": "spa t034 dominated among BORSA from pigs and t091 among meat-derived BORSA.", "offsetInBeginSection": 702, "offsetInEndSection": 777, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18630132", "text": "hospital associated MRSA (HA-MRSA) and community associated MRSA (CA-MRSA), the presence of homogeneous and heterogeneous type of methicillin resistance, and border-line resistance in Staphylococcus aureus (BORSA).", "offsetInBeginSection": 444, "offsetInEndSection": 658, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9e202bde7cb99d40000002", "body": "Which method is Proseek based on?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29051715", "http://www.ncbi.nlm.nih.gov/pubmed/29876303", "http://www.ncbi.nlm.nih.gov/pubmed/25987887", "http://www.ncbi.nlm.nih.gov/pubmed/30709840", "http://www.ncbi.nlm.nih.gov/pubmed/32267595", "http://www.ncbi.nlm.nih.gov/pubmed/19040730", "http://www.ncbi.nlm.nih.gov/pubmed/29026368", "http://www.ncbi.nlm.nih.gov/pubmed/28437237", "http://www.ncbi.nlm.nih.gov/pubmed/28936257", "http://www.ncbi.nlm.nih.gov/pubmed/32754594"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25987887", "text": "RESULTS Similar quantitative expression patterns for 13 plasma antigens common to both platforms endorsed the potential efficacy of Proseek as an immune-based multiplex assay for proteomic biomarker research.", "offsetInBeginSection": 1286, "offsetInEndSection": 1494, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25987887", "text": "BACKGROUND Current methods widely deployed for colorectal cancers (CRC) screening lack the necessary sensitivity and specificity required for population-based early disease detection.", "offsetInBeginSection": 0, "offsetInEndSection": 183, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19040730", "text": "ProSeeK will become a useful tool for all laboratories that are currently using MLPA in their research projects for CNV studies.", "offsetInBeginSection": 1548, "offsetInEndSection": 1676, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19040730", "text": "Multiplex Ligation-dependent Probe Amplification (MLPA) is a targeted method to assess copy number differences for up to 40 genomic loci in one single experiment.", "offsetInBeginSection": 331, "offsetInEndSection": 493, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28437237", "text": "Blood samples were obtained from 119 patients with STEMI, randomized to hypothermia as adjunctive therapy to percutaneous coronary intervention (PCI) or standard care with PCI only.", "offsetInBeginSection": 568, "offsetInEndSection": 749, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29026368", "text": "METHODS We used proximity extension immunoassay (PEA, Proseek Multiplex, Olink) to assess the serum levels of ninety-two inflammation-related proteins in Czech patients with SLE (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "offsetInBeginSection": 416, "offsetInEndSection": 657, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26204497", "text": "CONCLUSION A novel targeted proteomics approach using the proximity extension technique discovered several new associations of candidate proteins with carotid artery plaque prevalence in a large human sample.", "offsetInBeginSection": 1431, "offsetInEndSection": 1639, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26204497", "text": "Levels of 82 proteins were assessed in plasma by a proximity extension assay (Proseek Multiplex CVD, Olink Bioscience, Uppsala, Sweden) and related to carotid measures in a regression framework.", "offsetInBeginSection": 440, "offsetInEndSection": 634, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28083617", "text": "Serum concentrations of 92 inflammation-associated proteins were measured in samples obtained from 80 aHSCT patients 14\u00a0days after transplantation and from 23 healthy control subjects by a novel sensitive proximity extension assay technology using Proseek Multiplex Inflammation I kit.", "offsetInBeginSection": 543, "offsetInEndSection": 829, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27710869", "text": "Samples were analyzed by Mesoscale Discovery, Myriad RBM MAP technology and Olink Proseek.", "offsetInBeginSection": 498, "offsetInEndSection": 588, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ace34eb0340b9f058000010", "body": "Which genes are associated with Epidermolysis Bullosa Simplex?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7539246", "http://www.ncbi.nlm.nih.gov/pubmed/21674528", "http://www.ncbi.nlm.nih.gov/pubmed/9406827", "http://www.ncbi.nlm.nih.gov/pubmed/19797037", "http://www.ncbi.nlm.nih.gov/pubmed/29574966", "http://www.ncbi.nlm.nih.gov/pubmed/7537032", "http://www.ncbi.nlm.nih.gov/pubmed/12677430", "http://www.ncbi.nlm.nih.gov/pubmed/35656234", "http://www.ncbi.nlm.nih.gov/pubmed/35741135", "http://www.ncbi.nlm.nih.gov/pubmed/30240119"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/9406827", "text": "Epidermolysis bullosa simplex Dowling-Meara (MIM# 1317600) is the most severe of the three common epidermolysis bullosa simplex subtypes.", "offsetInBeginSection": 0, "offsetInEndSection": 137, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9406827", "text": "In this study we sequenced these genes in a family with epidermolysis bullosa simplex Dowling-Meara.", "offsetInBeginSection": 570, "offsetInEndSection": 670, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9406827", "text": "The keratin 5 and keratin 14 genes encode proteins that form the primary structural components of the basal epidermal keratinocytes, mutations in either of these genes can cause epidermolysis bullosa simplex.", "offsetInBeginSection": 361, "offsetInEndSection": 569, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12655565", "text": "Epidermolysis bullosa simplex is a group of blistering skin disorders caused by defects in one of the keratin genes, KRT5 and KRT14.", "offsetInBeginSection": 0, "offsetInEndSection": 132, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23894602", "text": "Dowling-Meara, the major subtype of epidermolysis bullosa simplex, is inherited in an autosomal dominant manner and can be caused by mutations in either the keratin-5 (K5) or the keratin-14 (K14) gene.", "offsetInBeginSection": 159, "offsetInEndSection": 360, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19797037", "text": "Epidermolysis bullosa simplex is an autosomal dominant inherited skin blistering disorder caused by mutations in the genes KRT5 or KRT14 coding for the basal epidermal keratins 5 and 14, respectively.", "offsetInBeginSection": 0, "offsetInEndSection": 200, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11851893", "text": "Mutations in its gene cause junctional epidermolysis bullosa.", "offsetInBeginSection": 97, "offsetInEndSection": 158, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11851893", "text": "Here, we report a patient with mutations in the gene for BP180/collagen XVII, COL17A1, but predominant phenotypic features of epidermolysis bullosa simplex.", "offsetInBeginSection": 159, "offsetInEndSection": 315, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10494094", "text": "Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP) is a rare dermatologic disorder of autosomal dominant inheritance with intraepidermal blistering after minor trauma, reticular hyperpigmentation unrelated to the blistering, nail dystrophy, and mild palmoplantar keratosis.", "offsetInBeginSection": 0, "offsetInEndSection": 287, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20199538", "text": "BACKGROUND Basal epidermolysis bullosa simplex (EBS) is a hereditary skin blistering disorder resulting in most cases from missense mutations in the keratin 5 (KRT5) or keratin 14 (KRT14) genes.", "offsetInBeginSection": 0, "offsetInEndSection": 194, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aafc37afcf4565872000010", "body": "What is the function of HDAC  proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20072728", "http://www.ncbi.nlm.nih.gov/pubmed/35709754", "http://www.ncbi.nlm.nih.gov/pubmed/30421914", "http://www.ncbi.nlm.nih.gov/pubmed/32303277", "http://www.ncbi.nlm.nih.gov/pubmed/27345839", "http://www.ncbi.nlm.nih.gov/pubmed/28337317", "http://www.ncbi.nlm.nih.gov/pubmed/17767915", "http://www.ncbi.nlm.nih.gov/pubmed/31351464", "http://www.ncbi.nlm.nih.gov/pubmed/32683534", "http://www.ncbi.nlm.nih.gov/pubmed/31879846"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26927903", "text": "Rpd3, the Drosophila HDAC1 homolog, is a class I lysine deacetylase and a member of a large family of HDAC proteins.", "offsetInBeginSection": 780, "offsetInEndSection": 896, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26927903", "text": "Histone deacetylase (HDAC) proteins have a major role in epigenetic regulation of chromatin structure.", "offsetInBeginSection": 291, "offsetInEndSection": 393, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17786239", "text": "We show that class II histone deacetylase (HDAC) proteins, which function as transcriptional repressors of the myocyte enhancer factor 2 (MEF2) transcription factor, fail to accumulate in the soleus, a slow muscle, compared with fast muscles (e.g., white vastus lateralis).", "offsetInBeginSection": 147, "offsetInEndSection": 420, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17786239", "text": "Accordingly, pharmacological blockade of proteasome function specifically increases expression of class II HDAC proteins in the soleus in vivo.", "offsetInBeginSection": 421, "offsetInEndSection": 564, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17786239", "text": "Using gain- and loss-of-function approaches in mice, we discovered that class II HDAC proteins suppress the formation of slow twitch, oxidative myofibers through the repression of MEF2 activity.", "offsetInBeginSection": 565, "offsetInEndSection": 759, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26232305", "text": "Histone deacetylase (HDAC) proteins are promising targets for cancer treatment, with several HDAC inhibitors used clinically as anticancer drugs.", "offsetInBeginSection": 0, "offsetInEndSection": 145, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22621256", "text": "HDAC is a family of enzymes involved in deacetylation of lysine residues on histone and non-histone proteins.", "offsetInBeginSection": 177, "offsetInEndSection": 286, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15050820", "text": "Phylogenetic analysis of bacterial HDAC relatives suggests that all three HDAC classes precede the evolution of histone proteins and raises the possibility that the primary activity of some \"histone deacetylase\" enzymes is directed against non-histone substrates.", "offsetInBeginSection": 1530, "offsetInEndSection": 1793, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28337317", "text": "Histone deacetylase (HDAC) proteins are epigenetic regulators that deacetylate protein substrates, leading to subsequent changes in cell function.", "offsetInBeginSection": 0, "offsetInEndSection": 146, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28337317", "text": "HDAC proteins are implicated in cancers, and several HDAC inhibitors have been approved by the FDA as anticancer drugs, including SAHA (suberoylanilide hydroxamic acid; Vorinostat and Zolinza).", "offsetInBeginSection": 147, "offsetInEndSection": 340, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aacd487fcf4565872000007", "body": "Which human gene encode for DNA polymerase \u03b8?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34573292", "http://www.ncbi.nlm.nih.gov/pubmed/33723002", "http://www.ncbi.nlm.nih.gov/pubmed/28668117", "http://www.ncbi.nlm.nih.gov/pubmed/27264557", "http://www.ncbi.nlm.nih.gov/pubmed/27657134", "http://www.ncbi.nlm.nih.gov/pubmed/24375106", "http://www.ncbi.nlm.nih.gov/pubmed/11356150", "http://www.ncbi.nlm.nih.gov/pubmed/10215605", "http://www.ncbi.nlm.nih.gov/pubmed/28570559", "http://www.ncbi.nlm.nih.gov/pubmed/26484154"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28668117", "text": "DNA polymerase theta (pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ gene in mammalian genomes.", "offsetInBeginSection": 0, "offsetInEndSection": 115, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557", "text": "DNA polymerase theta (pol \u03b8) is encoded in the genomes of many eukaryotes, though not in fungi.", "offsetInBeginSection": 0, "offsetInEndSection": 96, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557", "text": "Pol \u03b8 is encoded by the POLQ gene in mammalian cells.", "offsetInBeginSection": 97, "offsetInEndSection": 151, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27657134", "text": "The gene encoding DNA polymerase \u03b8 (Pol\u03b8) was discovered over ten years ago as having a role in suppressing genome instability in mammalian cells.", "offsetInBeginSection": 0, "offsetInEndSection": 148, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28695890", "text": "Here we show that DNA polymerase \u03b8, despite its minor role in chromosomal DNA repair, substantially contributes to random integration, and that cells lacking both DNA polymerase \u03b8 and DNA ligase IV, which is essential for non-homologous end joining (NHEJ), exhibit 100% efficiency of spontaneous gene targeting by virtue of undetectable levels of random integration.", "offsetInBeginSection": 267, "offsetInEndSection": 635, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28570559", "text": "DNA polymerase \u03bd (pol \u03bd), encoded by the POLN gene, is an A-family DNA polymerase in vertebrates and some other animal lineages.", "offsetInBeginSection": 0, "offsetInEndSection": 130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28570559", "text": "Pol \u03bd-defective mice had no alteration in DNA end-joining during immunoglobulin class-switching, in contrast to animals defective in the related DNA polymerase \u03b8 (pol \u03b8).", "offsetInBeginSection": 836, "offsetInEndSection": 1009, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28687761", "text": "Here, we show that the A-family DNA polymerase \u03b8 (Pol \u03b8) promotes random integration, while canonical non-homologous DNA end joining plays a secondary role; cells double deficient for polymerase \u03b8 and canonical non-homologous DNA end joining are devoid of any integration events, demonstrating that these two mechanisms define random integration.", "offsetInBeginSection": 221, "offsetInEndSection": 570, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25775267", "text": "DNA polymerase \u03b8 protects against genomic instability via an alternative end-joining repair pathway for DNA double-strand breaks.", "offsetInBeginSection": 0, "offsetInEndSection": 130, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24375106", "text": "It encodes the \u03b8 subunit of the DNA polymerase III core complex.", "offsetInBeginSection": 131, "offsetInEndSection": 196, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ace3e3f0340b9f058000012", "body": "What is the biological role of Neddylation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32779270", "http://www.ncbi.nlm.nih.gov/pubmed/23148618", "http://www.ncbi.nlm.nih.gov/pubmed/18793140", "http://www.ncbi.nlm.nih.gov/pubmed/25628956", "http://www.ncbi.nlm.nih.gov/pubmed/33025631", "http://www.ncbi.nlm.nih.gov/pubmed/31941714", "http://www.ncbi.nlm.nih.gov/pubmed/33807046", "http://www.ncbi.nlm.nih.gov/pubmed/31111756", "http://www.ncbi.nlm.nih.gov/pubmed/31293590", "http://www.ncbi.nlm.nih.gov/pubmed/33097763"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25628956", "text": "Similar to ubiquitination, neddylation is mediated by a cascade of three NEDD8 specific enzymes, an E1 activating enzyme, an E2 conjugating enzyme and one of the several E3 ligases.", "offsetInBeginSection": 124, "offsetInEndSection": 305, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25918018", "text": "Therefore, this mutation completely inhibits global protein neddylation, including neddylation of cullin family proteins, resulting in decreased activity of cullin-RING E3 ligases.", "offsetInBeginSection": 1014, "offsetInEndSection": 1194, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25742093", "text": "Recently, accumulating evidences indicate that neddylation pathway also plays a pivotal role in the regulation of multiple processes of tumor microenvironment (TME), such as tumor angiogenesis and the function of immune cells.", "offsetInBeginSection": 606, "offsetInEndSection": 832, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25742093", "text": "Inhibition of neddylation pathway has emerged as a promising anticancer strategy, as evidenced by development of the NEDD8-activating enzyme (NAE) inhibitor MLN4924.", "offsetInBeginSection": 262, "offsetInEndSection": 427, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25742093", "text": "Protein neddylation, a newly characterized posttranslational modification that adds the ubiquitin-like molecule NEDD8 to substrates, modulates important biological processes, whereas dysfunction of neddylation may cause several serious diseases, such as cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 261, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29074978", "text": "Cullin neddylation is modulated by a scaffolding DCN protein through interactions with both the cullin protein and an E2 enzyme such as UBC12.", "offsetInBeginSection": 160, "offsetInEndSection": 302, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29074978", "text": "The Cullin-RING E3 ubiquitin ligases (CRLs) regulate homeostasis of ~20% of cellular proteins and their activation require neddylation of their cullin subunit.", "offsetInBeginSection": 0, "offsetInEndSection": 159, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23148618", "text": "The neddylation conjugation pathway has a pivotal role in mediating ubiquitination of proteins and regulation of numerous biological processes.", "offsetInBeginSection": 0, "offsetInEndSection": 143, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23148618", "text": "Neddylation, a process mediated by the protein NEDD8, is required for conformational changes of cullins, a scaffolding protein situated in the core of cullin-RING ligases, and regulation of E3 ligase activity.", "offsetInBeginSection": 518, "offsetInEndSection": 727, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27591266", "text": "However, it is unknown whether and how UBE2F, a less characterized neddylation E2, regulates lung cancer cell survival, and whether and how NOXA, a proapoptotic protein, is ubiquitylated and degraded by which E3 and via which ubiquitin linkage.Experimental Design: Methods of immunohistochemistry and immunoblotting were utilized to examine UBE2F protein expression.", "offsetInBeginSection": 126, "offsetInEndSection": 492, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ab144fefcf4565872000012", "body": "The TRPM2 gene is associated with development of spontaneous thromboembolism?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27616276", "http://www.ncbi.nlm.nih.gov/pubmed/18503142", "http://www.ncbi.nlm.nih.gov/pubmed/33784097", "http://www.ncbi.nlm.nih.gov/pubmed/11380448", "http://www.ncbi.nlm.nih.gov/pubmed/34416664", "http://www.ncbi.nlm.nih.gov/pubmed/31655312", "http://www.ncbi.nlm.nih.gov/pubmed/17550854", "http://www.ncbi.nlm.nih.gov/pubmed/23935822", "http://www.ncbi.nlm.nih.gov/pubmed/22475739", "http://www.ncbi.nlm.nih.gov/pubmed/34997907"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28970008", "text": "Using a gene elimination approach, we show that these effects correlate with Trpm2 gene copy number, supporting the notion that Trpm2 might promote hyperinflammation in DS.", "offsetInBeginSection": 1530, "offsetInEndSection": 1702, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24931166", "text": "Here, we report that one such long non-coding RNA, TRPM2-AS, an antisense transcript of TRPM2, which encodes an oxidative stress-activated ion channel, is overexpressed in prostate cancer (PCa).", "offsetInBeginSection": 316, "offsetInEndSection": 510, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21140288", "text": "Genetic variants of the TRPM2 gene confer a risk of developing Western Pacific amyotropic lateral sclerosis and parkinsonism-dementia complex and bipolar disorders.", "offsetInBeginSection": 869, "offsetInEndSection": 1033, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18503142", "text": "Genetic polymorphisms in plasminogen activator inhibitor-1 gene-675 4G/5G (PAI-1 4G/5G) are claimed to contribute to an increased risk of venous thromboembolism.", "offsetInBeginSection": 0, "offsetInEndSection": 161, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18503142", "text": "We conclude from these data, that the occurrence of PAI-1 4G/4G or 4G/5G genotypes, respectively, is clinically significant for the pathogenesis of venous thromboembolism in pregnancy but not for early abortion.", "offsetInBeginSection": 1117, "offsetInEndSection": 1328, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27919223", "text": "CONCLUSIONS This work demonstrates that SNPs in TRPM2 are associated with differences in gene expression, suggesting that modulation of expression of this innate immune gene contributes to susceptibility to R. equi pneumonia.", "offsetInBeginSection": 1131, "offsetInEndSection": 1356, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16252251", "text": "These findings suggest genetic variants of the TRPM2 gene increase risk for BD and support the notion that TRPM2 may be involved in the pathophysiology of BD.", "offsetInBeginSection": 1395, "offsetInEndSection": 1553, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15708008", "text": "We found that the 5.5-kb shorter transcript is transcribed from the intron 4 of the TRPM2 gene and encodes the striatum short form protein (SSF-TRPM2) with 1289 amino acid residues as compared to the long form protein (LF-TRPM2), in which the N-terminal 214 amino acid residues are removed.", "offsetInBeginSection": 309, "offsetInEndSection": 599, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8800739", "text": "The temporal relationship between the conversion of atrial flutter to junctional bradycardia and two episodes of thromboembolism strongly suggest a role of the lack of atrial contraction during junctional rhythm for the development of spontaneous echocardiographic contrast and thromboembolism.", "offsetInBeginSection": 212, "offsetInEndSection": 506, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11380448", "text": "The G20210A mutation in the prothrombin gene is associated with an increased risk of a first venous thromboembolic episode; few data are available about the long-term risk for recurrent venous thromboembolism and it is not known whether or not carriers of the mutation should be recommended lifelong anticoagulant treatment after the first thrombosis.", "offsetInBeginSection": 0, "offsetInEndSection": 351, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abd2ce0fcf456587200002a", "body": "Which are the two main bacterial phyla in human gut?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27900395", "http://www.ncbi.nlm.nih.gov/pubmed/19321416", "http://www.ncbi.nlm.nih.gov/pubmed/31616902", "http://www.ncbi.nlm.nih.gov/pubmed/35744604", "http://www.ncbi.nlm.nih.gov/pubmed/23294932", "http://www.ncbi.nlm.nih.gov/pubmed/36287917", "http://www.ncbi.nlm.nih.gov/pubmed/23982459", "http://www.ncbi.nlm.nih.gov/pubmed/27638955", "http://www.ncbi.nlm.nih.gov/pubmed/20941585", "http://www.ncbi.nlm.nih.gov/pubmed/18338233"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19321416", "text": "The adult human distal gut microbial community is typically dominated by 2 bacterial phyla (divisions), the Firmicutes and the Bacteroidetes.", "offsetInBeginSection": 0, "offsetInEndSection": 141, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19321416", "text": "This simplified model of the human gut microbiota illustrates niche specialization and functional redundancy within members of its major bacterial phyla, and the importance of host glycans as a nutrient foundation that ensures ecosystem stability.", "offsetInBeginSection": 1517, "offsetInEndSection": 1764, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19553672", "text": "Here, we review how members of the Bacteroidetes, one of two dominant gut-associated bacterial phyla, process complex glycans using a series of similarly patterned, cell envelope-associated multiprotein systems.", "offsetInBeginSection": 290, "offsetInEndSection": 501, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23982459", "text": "Here we reconstructed GEMs for three key species, (Bacteroides thetaiotamicron, Eubacterium rectale and Methanobrevibacter smithii) as relevant representatives of three main phyla in the human gut (Bacteroidetes, Firmicutes and Euryarchaeota).", "offsetInBeginSection": 334, "offsetInEndSection": 577, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24324923", "text": "Our data show a high bacterial diversity in P. americana gut, with communities composed mostly by the phyla Bacteroidetes, Firmicutes, Proteobacteria and Synergistetes.", "offsetInBeginSection": 1120, "offsetInEndSection": 1288, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24324923", "text": "CONCLUSION/SIGNIFICANCE Our data show a high bacterial diversity in P. americana gut, with communities composed mostly by the phyla Bacteroidetes, Firmicutes, Proteobacteria and Synergistetes.", "offsetInBeginSection": 3223, "offsetInEndSection": 3415, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24522631", "text": "In humans, obesity is associated with the relative abundance of two dominant bacterial phyla: an increase in the proportion of Firmicutes and a decrease in the proportion of Bacteroidetes.", "offsetInBeginSection": 181, "offsetInEndSection": 369, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25873372", "text": "Analyses of sequenced bacterial genomes revealed that the cut cluster is present in many human gut bacteria, is predictive of choline utilization in sequenced isolates, and is widely but discontinuously distributed across multiple bacterial phyla.", "offsetInBeginSection": 961, "offsetInEndSection": 1208, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22205877", "text": "The Bacteroidetes, one of two dominant bacterial phyla in the adult gut, possess broad glycan-degrading abilities.", "offsetInBeginSection": 292, "offsetInEndSection": 406, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22205877", "text": "Here we show that two closely related human gut Bacteroides, B. thetaiotaomicron and B. ovatus, are capable of utilizing nearly all of the major plant and host glycans, including rhamnogalacturonan II, a highly complex polymer thought to be recalcitrant to microbial degradation.", "offsetInBeginSection": 662, "offsetInEndSection": 941, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ad6e431133db5eb7800000e", "body": "Which test is used for the definition of colour-blindness?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1447573", "http://www.ncbi.nlm.nih.gov/pubmed/2973033", "http://www.ncbi.nlm.nih.gov/pubmed/301964", "http://www.ncbi.nlm.nih.gov/pubmed/9581449", "http://www.ncbi.nlm.nih.gov/pubmed/31528187", "http://www.ncbi.nlm.nih.gov/pubmed/19829027", "http://www.ncbi.nlm.nih.gov/pubmed/9468757", "http://www.ncbi.nlm.nih.gov/pubmed/24600648", "http://www.ncbi.nlm.nih.gov/pubmed/1308523", "http://www.ncbi.nlm.nih.gov/pubmed/29291080"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25452008", "text": "To test for colour-blindness, we used a cognitive approach involving a harbour seal trained to use a concept of same and different.", "offsetInBeginSection": 965, "offsetInEndSection": 1096, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26591383", "text": "The definition of five distinct colour intensities of the \"test window\" enabled a clear differentiation of unprotected individuals from those with a protective immunity.", "offsetInBeginSection": 920, "offsetInEndSection": 1089, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16431664", "text": "211 Hadza (Tanzania) males, including members of both western and eastern groups, were tested for red-green colour blindness with the Ishihara non-numeral plates.", "offsetInBeginSection": 0, "offsetInEndSection": 162, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22076482", "text": "This study presents procedures and normative data for a rapid, comprehensive seven-test battery aimed at assessing colour perception, colour naming and object colour knowledge.", "offsetInBeginSection": 184, "offsetInEndSection": 360, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/306798", "text": "Among 126 Valmiki, 128 Bagatha, 129 Konda Dora and 73 Samanta tribals of Andhra Pradesh, the incidence of red-green colour-blindness in the males ranges from zero to 2.27 per cent.", "offsetInBeginSection": 0, "offsetInEndSection": 180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/306798", "text": "Post's (1962) hypothesis of relaxation of selection against colour-blindness is also supported by our Andhra Pradesh data.", "offsetInBeginSection": 471, "offsetInEndSection": 593, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28274040", "text": "Percentage was used to calculate the prevalence of colour vision handicap and its effect on matching of shades of teeth as compared to normal vision, which was evaluated using Chi square test.", "offsetInBeginSection": 996, "offsetInEndSection": 1188, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28274040", "text": "Then, the Ishihara's colour charts were used to test the operators for colour vision handicap.", "offsetInBeginSection": 733, "offsetInEndSection": 827, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28274040", "text": "RESULTS Nineteen operators had colour vision anomalies out of hundred operators and only two operators presented with colour blindness.", "offsetInBeginSection": 1191, "offsetInEndSection": 1326, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9893853", "text": "Alleles causing colour-blindness are present in humans at non-negligible levels, and it is not yet understood how colour-blindness is maintained, since colour-vision probably provides a selective advantage, e.g.", "offsetInBeginSection": 0, "offsetInEndSection": 211, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ab1483bfcf4565872000014", "body": "The common house cat, Felis silvestris catus and the domestic dog, Canis familiaris both belong to what taxonomic order?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8759144", "http://www.ncbi.nlm.nih.gov/pubmed/33391133", "http://www.ncbi.nlm.nih.gov/pubmed/29382052", "http://www.ncbi.nlm.nih.gov/pubmed/30948740", "http://www.ncbi.nlm.nih.gov/pubmed/31550468", "http://www.ncbi.nlm.nih.gov/pubmed/31823859", "http://www.ncbi.nlm.nih.gov/pubmed/26154131", "http://www.ncbi.nlm.nih.gov/pubmed/16772461", "http://www.ncbi.nlm.nih.gov/pubmed/20980625", "http://www.ncbi.nlm.nih.gov/pubmed/21846752"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26154131", "text": "The domestic cat (Felis silvestris catus) has shared an intertwined existence with humans for thousands of years, living on our city streets and in our homes.", "offsetInBeginSection": 0, "offsetInEndSection": 158, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17727851", "text": "The present study explored the feasibility of a hair cortisol assay in domestic cats (Felis silvestris catus) and dogs (Canis familiaris) as a valid and reliable alternative to existing non-invasive techniques for monitoring the hypothalamic-pituitary-adrenal (HPA) axis activity.", "offsetInBeginSection": 0, "offsetInEndSection": 280, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15474307", "text": "A new determination of the house cat (Felis catus) prion protein gene sequence (fPrnp), which has so far been subject of controversy, is reported.", "offsetInBeginSection": 0, "offsetInEndSection": 146, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15474307", "text": "The newly determined fPrnp sequence is similar to dog (Canis familiaris) and mink (Mustela putorius) Prnp, but differs significantly from both fPrnp sequences that were previously deposited in the GenBank.", "offsetInBeginSection": 147, "offsetInEndSection": 352, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21846752", "text": "The wildcat (Felis silvestris ssp.)", "offsetInBeginSection": 0, "offsetInEndSection": 35, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7777329", "text": "A serosurvey of rabies antibodies among domestic dogs (Canis familiaris, n = 178), spotted hyaenas (Crocuta crocuta, n = 72) and African wild dogs (Lycaon pictus, n = 18) of the Masai Mara, Kenya, was carried out.", "offsetInBeginSection": 0, "offsetInEndSection": 213, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10640803", "text": "Application of the CFA 5 paint probe to metaphase spreads of the domestic cat (Felis catus, FCA) demonstrated hybridisation to cat chromosomes C1, D1, E1, and E2.", "offsetInBeginSection": 521, "offsetInEndSection": 683, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25162450", "text": "The European wildcat, Felis s. silvestris, is subject to intensive conservation measures, including captive breeding and reintroduction.", "offsetInBeginSection": 129, "offsetInEndSection": 265, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25162450", "text": "Although native haplotypes were also found in the captive population, the majority (68%) of captive individuals shared a common mtDNA haplotype with the domestic cat (Felis s. catus).", "offsetInBeginSection": 1030, "offsetInEndSection": 1213, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28341144", "text": "The study of personality or temperament is well developed in many species, but in domestic cats (Felis silvestris catus) it has lagged behind.", "offsetInBeginSection": 0, "offsetInEndSection": 142, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abd31e0fcf456587200002c", "body": "What is ATAC-seq?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32312703", "http://www.ncbi.nlm.nih.gov/pubmed/34647036", "http://www.ncbi.nlm.nih.gov/pubmed/35127984", "http://www.ncbi.nlm.nih.gov/pubmed/33659905", "http://www.ncbi.nlm.nih.gov/pubmed/32543102", "http://www.ncbi.nlm.nih.gov/pubmed/34382186", "http://www.ncbi.nlm.nih.gov/pubmed/28550296", "http://www.ncbi.nlm.nih.gov/pubmed/29181276", "http://www.ncbi.nlm.nih.gov/pubmed/30808370", "http://www.ncbi.nlm.nih.gov/pubmed/35464805"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28550296", "text": "ATAC-seq is a high-throughput sequencing technique that identifies open chromatin.", "offsetInBeginSection": 0, "offsetInEndSection": 82, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27903897", "text": "Assay for Transposase Accessible Chromatin sequencing (ATAC-seq) is a recently developed technique used to map open chromatin zones in animal genomes.", "offsetInBeginSection": 405, "offsetInEndSection": 555, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27903897", "text": "FANS-ATAC-seq compares favorably with published DNaseI sequencing (DNase-seq) results and it requires less than 50 000 nuclei for accurate identification of accessible genomic regions.", "offsetInBeginSection": 886, "offsetInEndSection": 1070, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29155775", "text": "ATAC-seq is a robust and sensitive alternative to DNase I hypersensitivity analysis coupled with next-generation sequencing (DNase-seq) and formaldehyde-assisted isolation of regulatory elements (FAIRE-seq) for genome-wide analysis of chromatin accessibility and to the sequencing of micrococcal nuclease-sensitive sites (MNase-seq) to determine nucleosome positioning.", "offsetInBeginSection": 631, "offsetInEndSection": 1000, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29155775", "text": "Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) is a method used for the identification of open (accessible) regions of chromatin.", "offsetInBeginSection": 0, "offsetInEndSection": 168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27832532", "text": "Assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) is a useful method to map genome-wide chromatin accessibility and nucleosome positioning.", "offsetInBeginSection": 0, "offsetInEndSection": 175, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29030848", "text": "To investigate the role of Piwi in heterochromatin formation around transposable element loci, we have used ATAC-seq to examine chromatin accessibility at target transposable elements in a Drosophila cultured cell line, ovarian somatic cells (OSCs).", "offsetInBeginSection": 227, "offsetInEndSection": 476, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28723572", "text": "Thus, FANS-assisted ATAC-seq using transgenic zebrafish embryos provides a robust approach for genome-wide identification of active tissue-specific enhancer elements.", "offsetInBeginSection": 1090, "offsetInEndSection": 1256, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28723572", "text": "ATAC-seq of nuclei from Tg(fli1a:egfp)y1 transgenic embryos revealed expected patterns of nucleosomal positioning at transcriptional start sites throughout the genome and association with active histone modifications.", "offsetInBeginSection": 505, "offsetInEndSection": 722, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25559105", "text": "This unit describes Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq), a method for mapping chromatin accessibility genome-wide.", "offsetInBeginSection": 0, "offsetInEndSection": 164, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abce6acfcf4565872000022", "body": "Please list 7 classes of drugs that interact with Warfarin.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19587643", "http://www.ncbi.nlm.nih.gov/pubmed/23045839", "http://www.ncbi.nlm.nih.gov/pubmed/23089199", "http://www.ncbi.nlm.nih.gov/pubmed/9669190", "http://www.ncbi.nlm.nih.gov/pubmed/8792056", "http://www.ncbi.nlm.nih.gov/pubmed/30463993", "http://www.ncbi.nlm.nih.gov/pubmed/30504330", "http://www.ncbi.nlm.nih.gov/pubmed/6347619", "http://www.ncbi.nlm.nih.gov/pubmed/11089724", "http://www.ncbi.nlm.nih.gov/pubmed/21397772"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19587643", "text": "The types of substances listed as interacting with warfarin were entire classes of drugs, individual drugs, and combinations; biologics; dietary supplements; foods; alcohol; and tobacco.", "offsetInBeginSection": 611, "offsetInEndSection": 797, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23194153", "text": "OBJECTIVES The rate of potential warfarin drug-drug interactions among long-term care (LTC) residents with atrial fibrillation (AFib) is evaluated.", "offsetInBeginSection": 0, "offsetInEndSection": 147, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22717419", "text": "CONCLUSIONS Warfarin-potentiating drugs were commonly used among AF patients on warfarin.", "offsetInBeginSection": 1956, "offsetInEndSection": 2045, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22717419", "text": "OBJECTIVES To assess the usage patterns of drugs that potentiate warfarin's anticoagulant activity and discuss their associated relationship with both risk of hemorrhage and treatment costs among warfarin users with atrial fibrillation (AF).", "offsetInBeginSection": 132, "offsetInEndSection": 373, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21359645", "text": "The objective of this paper is to give an update on drug and dietary interactions with warfarin and the novel oral anticoagulants, dabigatran, rivaroxaban, apixaban, and edoxaban.", "offsetInBeginSection": 1377, "offsetInEndSection": 1556, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21359645", "text": "The recently approved oral direct thrombin inhibitor dabigatran, along with the emerging oral anti-factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have been developed to address many of the shortcomings of warfarin therapy.", "offsetInBeginSection": 253, "offsetInEndSection": 487, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21359645", "text": "As the list of drugs and supplements that interact with warfarin is continuously expanding, and the knowledge on drug interactions with the novel oral anticoagulants is still in its infancy, clinicians need to be vigilant when initiating any of these agents or when any changes in the patient's medication profile occur and perform a close screening for potential drug and dietary interactions.", "offsetInBeginSection": 982, "offsetInEndSection": 1376, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15585436", "text": "CONCLUSION Many patients receiving warfarin therapy are treated with concomitant drugs that may interact with the warfarin.", "offsetInBeginSection": 1574, "offsetInEndSection": 1697, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16268469", "text": "We conclude that concurrent use of potentially interacting drugs with warfarin is associated with a 3 to 4.5-fold increased risk of serious bleeding in long-term warfarin users.", "offsetInBeginSection": 1387, "offsetInEndSection": 1564, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22198820", "text": "This study sought to systematically investigate the effects of VKORC1, STX4A, CYP2C9, CYP4F2, CYP3A4, and GGCX gene polymorphisms and interacting drugs on warfarin maintenance dose.", "offsetInBeginSection": 110, "offsetInEndSection": 291, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac0aee419833b0d7b000004", "body": "Is a mutation of the  ZIKV's membrane protein prM responsible for the microcephaly in new-born infants?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30769824", "http://www.ncbi.nlm.nih.gov/pubmed/28049830", "http://www.ncbi.nlm.nih.gov/pubmed/27228275", "http://www.ncbi.nlm.nih.gov/pubmed/28383800", "http://www.ncbi.nlm.nih.gov/pubmed/27355570", "http://www.ncbi.nlm.nih.gov/pubmed/32842538", "http://www.ncbi.nlm.nih.gov/pubmed/12593464", "http://www.ncbi.nlm.nih.gov/pubmed/33505863", "http://www.ncbi.nlm.nih.gov/pubmed/31662457", "http://www.ncbi.nlm.nih.gov/pubmed/31683628"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28916391", "text": "Several forms of ZIKV VLPs have been reported featuring the co-expression of the prM-E, prM-E-NS1, C-prM-E, and NS2B/NS3 viral genes in human cells.", "offsetInBeginSection": 1974, "offsetInEndSection": 2122, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28916391", "text": "Candidate ZIKV vaccines that are currently in phase I/II clinical trials include inactivated whole viruses, recombinant measles viral vector-based vaccines, DNA and mRNA vaccines, and a mosquito salivary peptide vaccine.", "offsetInBeginSection": 1387, "offsetInEndSection": 1607, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28049830", "text": "The expression of premembrane protein (prM) resulted in cell-cycle G1 accumulation, whereas membrane-anchored capsid (anaC), membrane protein (M), envelope protein (E), and nonstructural protein 4A (NS4A) caused cell-cycle G2/M accumulation.", "offsetInBeginSection": 972, "offsetInEndSection": 1213, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28049830", "text": "The Zika virus (ZIKV) causes microcephaly and the Guillain-Barr\u00e9 syndrome.", "offsetInBeginSection": 0, "offsetInEndSection": 75, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28239447", "text": "Accumulating evidence implicates Zika virus (ZIKV) in pathogenesis of microcephaly in newborns and Guillain-Barr\u00e9 syndrome in adults.", "offsetInBeginSection": 0, "offsetInEndSection": 134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28239447", "text": "They demonstrated cytopathogenic activity for seven ZIKV proteins, anaC, C, prM, M, E, NS2B and NS4A.", "offsetInBeginSection": 448, "offsetInEndSection": 549, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27355570", "text": "This ZIKV strain has recently been shown to cross the placenta and to induce fetal microcephaly and other congenital malformations in mice.", "offsetInBeginSection": 672, "offsetInEndSection": 811, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28383800", "text": "A recent outbreak of Zika virus (ZIKV) in Brazil is associated with microcephaly in infants born of infected mothers.", "offsetInBeginSection": 0, "offsetInEndSection": 117, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28931684", "text": "Zika virus (ZIKV), a mosquito-transmitted flavivirus, responsible for sporadic outbreaks of mild and febrile illness in Africa and Asia, re-emerged in the last decade causing serious human diseases including microcephaly, congenital malformations, and Guillain-Barr\u00e9 syndrome.", "offsetInBeginSection": 0, "offsetInEndSection": 277, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28198446", "text": "ZIKV nonstructural protein 1 (NS1) plays an essential role in viral replication and immune evasion.", "offsetInBeginSection": 379, "offsetInEndSection": 478, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5abcf0b0fcf4565872000024", "body": "What causes leishmaniasis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25116660", "http://www.ncbi.nlm.nih.gov/pubmed/2670376", "http://www.ncbi.nlm.nih.gov/pubmed/24707415", "http://www.ncbi.nlm.nih.gov/pubmed/23286822", "http://www.ncbi.nlm.nih.gov/pubmed/28686398", "http://www.ncbi.nlm.nih.gov/pubmed/25287721", "http://www.ncbi.nlm.nih.gov/pubmed/25988048", "http://www.ncbi.nlm.nih.gov/pubmed/33799892", "http://www.ncbi.nlm.nih.gov/pubmed/26081889", "http://www.ncbi.nlm.nih.gov/pubmed/32845368"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18457726", "text": "Culture of the offending organism in NNN medium and isoenzymatic characterization resulted in identification of MON-80 Leishmania infantum leishmaniasis.", "offsetInBeginSection": 819, "offsetInEndSection": 972, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23219435", "text": "However, in Sri Lanka, L. donovani causes mainly cutaneous leishmaniasis, while visceral leishmaniasis is rare.", "offsetInBeginSection": 409, "offsetInEndSection": 520, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23219435", "text": "Leishmania donovani is a causative agent of visceral leishmaniasis in South East Asia and Eastern Africa.", "offsetInBeginSection": 303, "offsetInEndSection": 408, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23219435", "text": "Leishmaniasis is a neglected tropical disease caused by Leishmania protozoa and associated with three main clinical presentations: cutaneous, mucocutaneous and visceral leishmaniasis.", "offsetInBeginSection": 0, "offsetInEndSection": 183, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15071036", "text": "Leishmania donovani in India causes visceral infection (kala-azar) and dermal infection (post-kala-azar dermal leishmaniasis).", "offsetInBeginSection": 0, "offsetInEndSection": 126, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25228325", "text": "L. (L.)\u00a0donovani usually causes visceral leishmaniasis, but in this case, the patient manifested cutaneous leishmaniasis.", "offsetInBeginSection": 492, "offsetInEndSection": 614, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25988048", "text": "The protozoa is obliged intracellularly and causes a wide spectrum of clinical syndromes: VL ('kala azar'), cutaneous leishmaniasis and mucocutaneous leishmaniasis (espundia).", "offsetInBeginSection": 156, "offsetInEndSection": 331, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25988048", "text": "Visceral leishmaniasis (VL) is caused by the protozoan parasite Leishmania donovani and transmitted by the bite of infected sandfly Phlebotomus argentipes.", "offsetInBeginSection": 0, "offsetInEndSection": 155, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2670376", "text": "Leishmaniasis is a parasitic infection caused by many species of the protozoa Leishmania.", "offsetInBeginSection": 0, "offsetInEndSection": 89, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25116660", "text": "Leishmaniasis is a clinically heterogeneous syndrome caused by intracellular protozoan parasites of the genus Leishmania.", "offsetInBeginSection": 0, "offsetInEndSection": 121, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ac138aa95d0062724000001", "body": "Which is the enzymatic activity of nardilysin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15544571", "http://www.ncbi.nlm.nih.gov/pubmed/19234765", "http://www.ncbi.nlm.nih.gov/pubmed/17442499", "http://www.ncbi.nlm.nih.gov/pubmed/12095415", "http://www.ncbi.nlm.nih.gov/pubmed/15809022", "http://www.ncbi.nlm.nih.gov/pubmed/23604405", "http://www.ncbi.nlm.nih.gov/pubmed/21801775", "http://www.ncbi.nlm.nih.gov/pubmed/19935654", "http://www.ncbi.nlm.nih.gov/pubmed/27051521", "http://www.ncbi.nlm.nih.gov/pubmed/16923819"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15544571", "text": "Since for those processes its enzymatic activity is not required, it is now evident that nardilysin fulfills at least two distinct functions, i.e.", "offsetInBeginSection": 353, "offsetInEndSection": 499, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21801775", "text": "The mainly neuronally expressed protein p42(IP4) (centaurin \u03b11; ADAP1), which interacts with the metalloendopeptidase nardilysin (NRD) was found to be localized in neuritic plaques in Alzheimer disease (AD) brains.", "offsetInBeginSection": 0, "offsetInEndSection": 215, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19234765", "text": "Nardilysin enhances the alpha-secretase activity of the disintegrin and metalloproteases (ADAMs) 10 and 17, thereby possibly contributing to reduced generation of amyloidogenic fragments from the amyloid precursor protein.", "offsetInBeginSection": 208, "offsetInEndSection": 430, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19234765", "text": "A prerequisite for the alpha-secretase-stimulating effect of nardilysin on the activity of ADAMs in vivo is cellular co-expression of nardilysin with ADAM10 and/or ADAM17.", "offsetInBeginSection": 431, "offsetInEndSection": 602, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19234765", "text": "The peptidase nardilysin is involved in degradation of neuropeptides and limited intracellular proteolysis.", "offsetInBeginSection": 0, "offsetInEndSection": 107, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19234765", "text": "Our data are consistent with the notion that the proposed alpha-secretase-enhancing activity of nardilysin might play a role in human brain pathology.", "offsetInBeginSection": 1136, "offsetInEndSection": 1286, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15809022", "text": "Mitochondrial MDH increased nardilysin activity about 50%, while nardilysin stabilized mMDH towards heat inactivation.", "offsetInBeginSection": 818, "offsetInEndSection": 936, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21151101", "text": "Nardilysin and TOP were required, either together or alone, for the generation of a tumor-specific CTL epitope from PRAME, an immunodominant CTL epitope from Epstein-Barr virus protein EBNA3C, and a clinically important epitope from the melanoma protein MART-1.", "offsetInBeginSection": 322, "offsetInEndSection": 583, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16923819", "text": "We have recently identified nardilysin (N-arginine dibasic convertase (NRDc)), a metalloendopeptidase of the M16 family, as a protein that specifically binds HB-EGF (Nishi, E., Prat, A., Hospital, V., Elenius, K., and Klagsbrun, M. (2001) EMBO J.", "offsetInBeginSection": 399, "offsetInEndSection": 645, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15629122", "text": "Cilostamide, a phosphodiesterase 3A inhibitor that inhibits meiosis, blocks accumulation of nuclear nardilysin.", "offsetInBeginSection": 670, "offsetInEndSection": 781, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5aaef38dfcf456587200000f", "body": "Please list 10 conditions which play a role in causing atrial fibrillation.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12693508", "http://www.ncbi.nlm.nih.gov/pubmed/17383682", "http://www.ncbi.nlm.nih.gov/pubmed/28734850", "http://www.ncbi.nlm.nih.gov/pubmed/19562528", "http://www.ncbi.nlm.nih.gov/pubmed/16793213", "http://www.ncbi.nlm.nih.gov/pubmed/31801224", "http://www.ncbi.nlm.nih.gov/pubmed/28169950", "http://www.ncbi.nlm.nih.gov/pubmed/10646954", "http://www.ncbi.nlm.nih.gov/pubmed/24388634", "http://www.ncbi.nlm.nih.gov/pubmed/9809896"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19151857", "text": "Of the long list of various cardiac conditions associated with an increased risk of cardioembolic strokes, non-valvular atrial fibrillation is the most common cause.", "offsetInBeginSection": 288, "offsetInEndSection": 453, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7759722", "text": "BACKGROUND Substantial animal data indicate that vagally induced dispersion of atrial refractoriness plays a central role in the induction and maintenance of atrial fibrillation.", "offsetInBeginSection": 212, "offsetInEndSection": 390, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10646954", "text": "Atrial fibrillation was found in 74 (2.3%).", "offsetInBeginSection": 274, "offsetInEndSection": 317, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10646954", "text": "In conclusion, in patients with coronary disease, systolic heart failure may be more important than atrial ischemia in causing atrial fibrillation.", "offsetInBeginSection": 1193, "offsetInEndSection": 1340, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16793213", "text": "Persistent atrial fibrillation patients had a higher CRP level than paroxysmal atrial fibrillation patients.", "offsetInBeginSection": 543, "offsetInEndSection": 651, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16793213", "text": "Most of these cytokines play a crucial role in inflammation response that associate with the initiating and maintenance of atrial fibrillation.", "offsetInBeginSection": 1291, "offsetInEndSection": 1434, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16793213", "text": "Hypertension, myocardial infarction and reduced lung function are predictors of atrial fibrillation.", "offsetInBeginSection": 1821, "offsetInEndSection": 1921, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16793213", "text": "Some evidences showed that C. pneumoniae was the most likely pathogen of atrial fibrillation.", "offsetInBeginSection": 1494, "offsetInEndSection": 1587, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16793213", "text": "Patients undergoing coronary artery bypass graft are at high risk for developing postoperative atrial fibrillation.", "offsetInBeginSection": 208, "offsetInEndSection": 323, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10409531", "text": "CONCLUSIONS Class 1C drugs are effective at restoring sinus rhythm by increasing the MFF to a much greater extent than observed in self terminating atrial fibrillation episodes, and reversing the spontaneous atrial fibrillation behaviour (progressive shortening of MFF and self perpetuation of atrial fibrillation).", "offsetInBeginSection": 1762, "offsetInEndSection": 2077, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ad3aa47133db5eb78000004", "body": "Which organ express and secretes the hormone FGF21?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24697521", "http://www.ncbi.nlm.nih.gov/pubmed/28844867", "http://www.ncbi.nlm.nih.gov/pubmed/26441837", "http://www.ncbi.nlm.nih.gov/pubmed/30879171", "http://www.ncbi.nlm.nih.gov/pubmed/20332535", "http://www.ncbi.nlm.nih.gov/pubmed/22917661", "http://www.ncbi.nlm.nih.gov/pubmed/28039838", "http://www.ncbi.nlm.nih.gov/pubmed/24432989", "http://www.ncbi.nlm.nih.gov/pubmed/23066506", "http://www.ncbi.nlm.nih.gov/pubmed/32421369"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26993043", "text": "The FGF21-adiponectin axis protects against a cluster of cardio-metabolic disorders via mediating multi-organ communications, and is a promising target for therapeutic interventions of these chronic diseases.", "offsetInBeginSection": 1383, "offsetInEndSection": 1591, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26654352", "text": "Fibroblast growth factor 21 (FGF21) is a peptide hormone that is synthesized by several organs and regulates energy homeostasis.", "offsetInBeginSection": 0, "offsetInEndSection": 128, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26654352", "text": "FGF21 also regulates fatty acid metabolism in mice consuming a diet that promotes hepatic lipotoxicity.", "offsetInBeginSection": 679, "offsetInEndSection": 782, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24432989", "text": "The absence of FGF21 in fetal cord blood suggests that neither placental FGF21 nor maternal circulating FGF21 is secreted into the fetal circulation.", "offsetInBeginSection": 1567, "offsetInEndSection": 1716, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28089565", "text": "Like the classical post-prandial secretagogue, cholecystokinin (CCK), FGF21 triggers intracellular calcium release via PLC-IP3R signaling.", "offsetInBeginSection": 767, "offsetInEndSection": 905, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28089565", "text": "Here, we show that FGF21 stimulates digestive enzyme secretion from pancreatic acinar cells through an autocrine/paracrine mechanism that requires signaling through a tyrosine kinase receptor complex composed of an FGF receptor and \u03b2-Klotho.", "offsetInBeginSection": 222, "offsetInEndSection": 464, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25215270", "text": "Fibroblast growth factor 21 (FGF21) is an endocrine hormone that is primarily expressed in the liver and exerts beneficial effects on obesity and related metabolic diseases.", "offsetInBeginSection": 0, "offsetInEndSection": 173, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17623664", "text": "The fibroblast growth factor (FGF) 19 subfamily of ligands, FGF19, FGF21, and FGF23, function as hormones that regulate bile acid, fatty acid, glucose, and phosphate metabolism in target organs through activating FGF receptors (FGFR1-4).", "offsetInBeginSection": 0, "offsetInEndSection": 237, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17623664", "text": "Accordingly, FGF19, but not FGF21, activates FGF signaling in hepatocytes that primarily express FGFR4 and reduces transcription of CYP7A1 that encodes the rate-limiting enzyme for bile acid synthesis.", "offsetInBeginSection": 737, "offsetInEndSection": 938, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17623664", "text": "Both FGF19 and FGF21 can signal through FGFR1-3 bound by betaKlotho and increase glucose uptake in adipocytes expressing FGFR1.", "offsetInBeginSection": 481, "offsetInEndSection": 608, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ad4f4f5133db5eb7800000a", "body": "What is the aim of the PhenCode database?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17326095", "http://www.ncbi.nlm.nih.gov/pubmed/25385275", "http://www.ncbi.nlm.nih.gov/pubmed/23575186", "http://www.ncbi.nlm.nih.gov/pubmed/25240948", "http://www.ncbi.nlm.nih.gov/pubmed/29154448", "http://www.ncbi.nlm.nih.gov/pubmed/30980206", "http://www.ncbi.nlm.nih.gov/pubmed/31394752", "http://www.ncbi.nlm.nih.gov/pubmed/11160576", "http://www.ncbi.nlm.nih.gov/pubmed/15314948", "http://www.ncbi.nlm.nih.gov/pubmed/23386187"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25385275", "text": "These subsets were filtered against disease-related variants in the ClinVar, UniProtKB/Swiss-Prot, and PhenCode databases, to identify neutral or nonpathogenic cases.", "offsetInBeginSection": 307, "offsetInEndSection": 473, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17326095", "text": "PhenCode (Phenotypes for ENCODE; http://www.bx.psu.edu/phencode) is a collaborative, exploratory project to help understand phenotypes of human mutations in the context of sequence and functional data from genome projects.", "offsetInBeginSection": 0, "offsetInEndSection": 222, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8360667", "text": "The aim of the Database is to provide the up-to-date clinical and pathological information relating to the material supplied by the Brain Bank.", "offsetInBeginSection": 416, "offsetInEndSection": 559, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27822088", "text": "AIM The aim of this study is to set up a database in order to monitor the detection rates and false-positive rates of first-trimester screening for chromosomal abnormalities and prenatal detection rates of fetal malformations in Denmark.", "offsetInBeginSection": 0, "offsetInEndSection": 237, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27822120", "text": "AIM OF DATABASE The aim of the National Database of Geriatrics is to monitor the quality of interdisciplinary diagnostics and treatment of patients admitted to a geriatric hospital unit.", "offsetInBeginSection": 0, "offsetInEndSection": 186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12527516", "text": "We aim to construct a online medical parasites database from which information can be retrieved through key words, ASP program and SQL language.", "offsetInBeginSection": 0, "offsetInEndSection": 144, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12527516", "text": "A method for online searching through the database is elaborated in this paper by introducing the construction of the medical parasites database.", "offsetInBeginSection": 331, "offsetInEndSection": 476, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20674843", "text": "OBJECTIVE The aim of the present report is to provide an overview of the first database on clinical research in veterinary homeopathy.", "offsetInBeginSection": 0, "offsetInEndSection": 134, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27822083", "text": "AIM OF DATABASE The Danish Cardiac Rehabilitation Database (DHRD) aims to improve the quality of cardiac rehabilitation (CR) to the benefit of patients with coronary heart disease (CHD).", "offsetInBeginSection": 0, "offsetInEndSection": 186, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19883199", "text": "METHODS We performed systematic database searches on four topics (ADHD prevalence, schizotypal personality, brain MRI studies in schizophrenia, recovery in schizophrenia) in three databases (PubMed, Web of Science and PsycINFO).", "offsetInBeginSection": 473, "offsetInEndSection": 701, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5a9d99ac4e03427e73000002", "body": "What is measured with the Proseek panels?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29051715", "http://www.ncbi.nlm.nih.gov/pubmed/34933097", "http://www.ncbi.nlm.nih.gov/pubmed/30709840", "http://www.ncbi.nlm.nih.gov/pubmed/34128078", "http://www.ncbi.nlm.nih.gov/pubmed/29665127", "http://www.ncbi.nlm.nih.gov/pubmed/29876303", "http://www.ncbi.nlm.nih.gov/pubmed/33549556", "http://www.ncbi.nlm.nih.gov/pubmed/25987887", "http://www.ncbi.nlm.nih.gov/pubmed/33667475", "http://www.ncbi.nlm.nih.gov/pubmed/19040730"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28936257", "text": "Among 92 proteins in the Proseek Multiplex Oncology Iv2 panel, 87 were above the limit of detection (LOD) in liquid plasma and 56 among 92 above LOD in plasma applied to FTA cards.", "offsetInBeginSection": 478, "offsetInEndSection": 658, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28586402", "text": "A total of 92 biomarkers were measured before a standardized meal as well as 30 and 120 minutes afterwards with the Proseek Multiplex CVD III kit.", "offsetInBeginSection": 217, "offsetInEndSection": 363, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25987887", "text": "RESULTS Similar quantitative expression patterns for 13 plasma antigens common to both platforms endorsed the potential efficacy of Proseek as an immune-based multiplex assay for proteomic biomarker research.", "offsetInBeginSection": 1286, "offsetInEndSection": 1494, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25987887", "text": "EDTA plasma samples (1\u00a0\u03bcL) obtained from 75 patients with Dukes' staged CRC or unaffected controls (age and sex matched with stringent inclusion/exclusion criteria) were assayed for expression of 92 human proteins employing the Proseek\u00ae Multiplex Oncology I proximity extension assay.", "offsetInBeginSection": 881, "offsetInEndSection": 1168, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19040730", "text": "ProSeeK will become a useful tool for all laboratories that are currently using MLPA in their research projects for CNV studies.", "offsetInBeginSection": 1548, "offsetInEndSection": 1676, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28694499", "text": "Using the Proseek Multiplex Inflammation assay, we measured in patients that had suffered mild TBI (n\u2009=\u200910) or severe TBI (n\u2009=\u200910) with extra-cranial injury or extracranial injury only (EC) (n\u2009=\u200910), 92 inflammation-associated proteins in serum obtained: <1\u2009hr (within 1-hour), 4-12\u2009hr and 48-72\u2009hr post injury.", "offsetInBeginSection": 503, "offsetInEndSection": 832, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28948068", "text": "A total of 92 biomarkers were measured before a standardized meal as well as 30 and 120\u00a0min afterward with the Proseek Multiplex Neurology\u00a0I kit.", "offsetInBeginSection": 308, "offsetInEndSection": 455, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28734077", "text": "METHODS AND RESULTS Plasma concentrations of MMP12 were measured at baseline in 3394 subjects with high-risk for cardiovascular disease (CVD) using the Olink ProSeek CVD I array.", "offsetInBeginSection": 524, "offsetInEndSection": 702, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28083617", "text": "Serum concentrations of 92 inflammation-associated proteins were measured in samples obtained from 80 aHSCT patients 14\u00a0days after transplantation and from 23 healthy control subjects by a novel sensitive proximity extension assay technology using Proseek Multiplex Inflammation I kit.", "offsetInBeginSection": 543, "offsetInEndSection": 829, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28930774", "text": "The samples were analyzed with a multiplex proximity extension assay in which 92 inflammation-related proteins were measured simultaneously (Proseek Multiplex Inflammation I; Olink Bioscience, Uppsala, Sweden).", "offsetInBeginSection": 738, "offsetInEndSection": 948, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ad247720340b9f058000017", "body": "What is a fibrocyte?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29653588", "http://www.ncbi.nlm.nih.gov/pubmed/36241617", "http://www.ncbi.nlm.nih.gov/pubmed/16543402", "http://www.ncbi.nlm.nih.gov/pubmed/17556364", "http://www.ncbi.nlm.nih.gov/pubmed/8731191", "http://www.ncbi.nlm.nih.gov/pubmed/22796709", "http://www.ncbi.nlm.nih.gov/pubmed/31160533", "http://www.ncbi.nlm.nih.gov/pubmed/34428284", "http://www.ncbi.nlm.nih.gov/pubmed/21801908", "http://www.ncbi.nlm.nih.gov/pubmed/21469145"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22043022", "text": "Spiral ligament fibrocytes function in cochlear homeostasis, maintaining the endocochlear potential by participating in potassium recycling, and fibrocyte degeneration contributes to hearing loss.", "offsetInBeginSection": 0, "offsetInEndSection": 196, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022512", "text": "Digestion of HMWHA with hyaluronidase produces small hyaluronic acid fragments, and these fragments inhibit fibrocyte differentiation.", "offsetInBeginSection": 563, "offsetInEndSection": 697, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022512", "text": "The addition of anti-CD44 antibodies potentiates fibrocyte differentiation, suggesting that CD44 mediates at least some of the effect of hyaluronic acid on fibrocyte differentiation.", "offsetInBeginSection": 1019, "offsetInEndSection": 1201, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022512", "text": "The fibrocyte differentiation-inhibiting factor serum amyloid P (SAP) inhibits HMWHA-induced fibrocyte differentiation and potentiates LMWHA-induced inhibition.", "offsetInBeginSection": 1202, "offsetInEndSection": 1362, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22022512", "text": "CONCLUSIONS We hypothesize that hyaluronic acid signals at least in part through CD44 to regulate fibrocyte differentiation, with a dominance hierarchy of SAP>LMWHA\u2265HMWHA>IL-4 or IL-13.", "offsetInBeginSection": 1500, "offsetInEndSection": 1687, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28915889", "text": "BACKGROUND Nintedanib, a tyrosine kinase inhibitor that is specific for platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and vascular endothelial growth factor receptors (VEGFR), has recently been approved for idiopathic pulmonary fibrosis.", "offsetInBeginSection": 0, "offsetInEndSection": 284, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28915889", "text": "CONCLUSIONS These results support the role of fibrocytes as producers of and responders to growth factors, and suggest that the anti-fibrotic effects of nintedanib are at least partly mediated by suppression of fibrocyte function.", "offsetInBeginSection": 1557, "offsetInEndSection": 1787, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24507087", "text": "Fibrocyte inhibition is considered a mechanism of anti-fibrotic action of pirfenidone.", "offsetInBeginSection": 2531, "offsetInEndSection": 2617, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24822215", "text": "IL-33 might partially reduce the therapeutic effects of glucocorticoid and cysteinyl leukotriene receptor antagonist on fibrocyte-mediated Th2 responses.", "offsetInBeginSection": 1215, "offsetInEndSection": 1368, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24822215", "text": "These findings suggest that IL-33 is involved in the airway remodeling process through its modulation of fibrocyte function independent of antigen stimulation.", "offsetInBeginSection": 1055, "offsetInEndSection": 1214, "beginSection": "abstract", "endSection": "abstract"}]}, {"id": "5ad255210340b9f058000018", "body": "Is lumican a secreted protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22266188", "http://www.ncbi.nlm.nih.gov/pubmed/30283082", "http://www.ncbi.nlm.nih.gov/pubmed/36077426", "http://www.ncbi.nlm.nih.gov/pubmed/34215697", "http://www.ncbi.nlm.nih.gov/pubmed/15466200", "http://www.ncbi.nlm.nih.gov/pubmed/20138170", "http://www.ncbi.nlm.nih.gov/pubmed/15613083", "http://www.ncbi.nlm.nih.gov/pubmed/12645630", "http://www.ncbi.nlm.nih.gov/pubmed/19394140", "http://www.ncbi.nlm.nih.gov/pubmed/32705211"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22266188", "text": "Lumican-transfected PANC-1 cells secreted a 70-kDa lumican protein and had an active ERK pathway.", "offsetInBeginSection": 267, "offsetInEndSection": 364, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15466200", "text": "The small leucine-rich proteoglycan lumican was identified from a human placenta cDNA library by the expression cloning method as a gene product that interacts with membrane-type matrix metalloproteinase-1 (MT1-MMP).", "offsetInBeginSection": 0, "offsetInEndSection": 216, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23480731", "text": "Lumican is an ECM-localized proteoglycan associated with inflammatory conditions and known to bind collagens.", "offsetInBeginSection": 129, "offsetInEndSection": 238, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23480731", "text": "In\u00a0vitro, mechanical stretch and the proinflammatory cytokine interleukin-1\u03b2 increased lumican mRNA as well as secreted lumican protein from cardiac fibroblasts.", "offsetInBeginSection": 970, "offsetInEndSection": 1133, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23480731", "text": "Stimulation with recombinant glycosylated lumican increased collagen type\u00a0I alpha\u00a02, lysyl oxidase and transforming growth factor-\u03b21 mRNA, which was attenuated by costimulation with an inhibitor of the proinflammatory transcription factor NF\u03baB.", "offsetInBeginSection": 1134, "offsetInEndSection": 1382, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20138170", "text": "Lumican is a member of a small leucine-rich proteoglycan (SLRP) family and it regulates the assembly and diameter of collagen fibers in the extracellular matrix of various tissues.", "offsetInBeginSection": 0, "offsetInEndSection": 180, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27126993", "text": "Lumican is a secreted proteoglycan that regulates collagen fibril assembly.", "offsetInBeginSection": 374, "offsetInEndSection": 449, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21421073", "text": "In conclusion, this study demonstrates a novel out-in signaling circuit in human osteosarcoma cells: secreted to extracellular matrix lumican is an endogenous inhibitor of TGF-\u03b22 activity, resulting in downstream effector modulation including pSmad 2, integrin \u03b21 and pFAK to regulate osteosarcoma adhesion.", "offsetInBeginSection": 1225, "offsetInEndSection": 1534, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16259954", "text": "The most enriched genes in a subtracted cDNA library are primarily genes for extracellular matrix components, types I and III collagen, lumican, periostin, and asporin, among others, whose expression conveys unique mechanical properties to the PDL.", "offsetInBeginSection": 206, "offsetInEndSection": 454, "beginSection": "abstract", "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12128073", "text": "Our data suggest that lumican is a significant proteoglycan component of bone matrix, which is secreted by differentiating and mature osteoblasts only and therefore it can be used as a marker to distinguish proliferating pre-osteoblasts from the differentiating osteoblasts.", "offsetInBeginSection": 1332, "offsetInEndSection": 1606, "beginSection": "abstract", "endSection": "abstract"}]}]}